ClinicalTrials.gg
Active, not recruitingNCT02951052Updated Nov 10, 2026Results posted

Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults

A Phase 3 interventional study of Cabotegravir (CAB) tablet and Rilpivirine (RPV) tablet in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Active, not recruiting at 113 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Updated Nov 10, 20267 sites added7 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
618
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies testing cabotegravir in HIV Infections — 4 open to participants now, 13 under way, 8 of them phase 3. cabotegravir · HIV Infections.

Enrollment
9th of 36
618 · median 200
Started
2016
with 2 others
Phase 3
12 of 36
2 open now
Primary completion
2018-05
later than 0 of 12 live
Registered
11th of 36
by date
Lead sponsor
24 of 36
ViiV Healthcare

Among the 36 studies testing cabotegravir in HIV Infections, this one is the 9th largest by enrollment, is one of 3 that started in 2016, is one of 12 in phase 3, reaches primary completion later than 0 of the 12 other live ones, and was the 11th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 36 studies testing cabotegravir in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About cabotegravir

cabotegravir: first FDA approval 2021 (VOCABRIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing cabotegravir in HIV Infections, or all of them as a file.
02

Study summary

The Antiretroviral Therapy as Long Acting Suppression (ATLAS) study is being conducted to establish if human immunodeficiency virus type-1 (HIV-1) infected adult subjects with current viral suppression on a regimen with 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a third agent, remain suppressed upon switching to a two-drug intramuscular (IM) long-acting (LA) regimen of cabotegravir (CAB) and rilpivirine (RPV). This is a Phase 3, multi-phase, randomized, open label, active-controlled, multicenter, parallel-group, non-inferiority study in HIV-1, antiretroviral therapy (ART)-adult subjects who are stably suppressed on a current antiretroviral (ARV) regimen. This study is designed to demonstrate the non-inferior antiviral activity of switching to a two drug CAB LA 400 mg + RPV LA 600 mg regimen every 4 weeks (Q4W: monthly) compared with maintenance of current ARV regimen containing 2 NRTIs plus an INI, NNRTI, or a PI. Eligible subjects will be randomized (1:1) into the Maintenance Phase at Day 1 to either continue current ART or switch to initiate oral therapy with CAB 30 mg + RPV 25 mg once daily for 4 Weeks followed by Q4 weekly (monthly) CAB LA + RPV LA injections. Following the Maintenance phase at Week 52, subjects who were randomized to continue their current ART regimen will be given an option to switch to CAB LA + RPV LA injections. Those subjects would transition to LA dosing, beginning with 4 weeks oral CAB + RPV therapy at Week 52, and receive the first IM CAB LA + RPV LA injections at Week 56.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Browse trials for

Keywords

  • Long-acting cabotegravir
  • Virologic failure
  • long-acting rilpivirine
  • Antiretroviral
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's enrollment of 618 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or older (or ≥19 where required by local regulatory agencies), at the time of signing the .
  • Must be on uninterrupted current regimen (either the initial or second ARV regimen) for at least 6 months prior to Screening. Any prior switch, defined as a change of a single drug or multiple drugs simultaneously, must have occurred due to tolerability/safety, access to medications, or convenience/simplification, and must NOT have been done for treatment failure (-1 RNA ≥400 c/mL).
  • Acceptable stable (initial or second) ARV regimens prior to Screening include 2 NRTIs plus: INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen);NNRTI (either the initial or second cART regimen);Boosted PI (or atazanavir [ATV] unboosted) (must be either the initial cART regimen or one historical within class switch is permitted due to safety/tolerability) The addition, removal, or switch of a drug(s) that has been used to treat HIV based on antiretroviral properties of the drug constitutes a change in ART with the following limited exceptions: Historical changes in formulations of ART drugs or booster drugs will not constitute a change in ART regimen if the data support similar exposures and efficacy, and the change must have been at least 3 months prior to Screening; Historical perinatal use of an NRTI when given in addition to an ongoing HAART will not be considered a change in ART regimen; A change in dosing scheme of the same drug from twice daily to once daily will not be considered a change in ART regimen if data support similar exposures and efficacy.
  • Documented evidence of at least two plasma HIV-1 RNA measurements \<50 c/mL in the 12 months prior to Screening: one within the 6 to 12 month window, and one within 6 months prior to Screening;
  • Plasma HIV-1 RNA \<50 c/mL at Screening;
  • A female subjects is eligible to participate if she is not pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at screen and a negative urine hCG test at Randomization), not lactating, and at least one of the following conditions applies:

    1. Non- defined as: Pre-menopausal females with one of the following: Documented tubal ligation; Documented hysteroscopic tubal occlusion procedure with follow-up; confirmation of bilateral tubal occlusion; Hysterectomy; Documented Bilateral Oophorectomy; defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) and estradiol levels consistent with menopause. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the highly effective methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrolment.
    2. Reproductive potential and agrees to the options listed in the Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential (FRP) from 30 days prior to the first dose of study medication, and until from 30 days prior to the first dose of study medication throughout the study, and for at least 30 days after discontinuation of all oral study medications and for at least 52 weeks after discontinuation of CAB LA and RPV LA. The investigator is responsible for ensuring that subjects understand how to properly use these methods of contraception.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form. Eligible subjects or their legal guardians (and next of kin when locally required), must sign a written Informed Consent Form before any protocol-specified assessments are conducted. Enrolment of subjects who are unable to provide direct informed consent is optional and will be based on local legal/regulatory requirements and site feasibility to conduct protocol procedures.
  • Subjects enrolled in France must be affiliated to, or a beneficiary of, a social security category.
  • All subjects participating in the study should be counselled on safer sexual practices including the use and benefit/risk of effective barrier methods (e.g., male condom) and on the risk of HIV transmission to an uninfected partner.

Exclusion criteria

Exclusion Criteria:

  • Within 6 months prior to Screening and after confirmed suppression to \<50 c/mL on current ART regimen, any plasma -1 RNA measurement ≥50 c/mL
  • Within the 6 to 12 month window prior to Screening and after confirmed suppression to \<50 c/mL, any plasma HIV-1 RNA measurement >200 c/mL, or 2 or more plasma HIV-1 RNA measurements ≥50 c/mL
  • Any drug holiday during the window between initiating first HIV ART and 6 months prior to Screening, except for brief periods (less than 1 month) where all ART was stopped due to tolerability and/or safety concerns
  • Any switch to a regimen, defined as change of a single drug or multiple drugs simultaneously, due to virologic failure to therapy (defined as a confirmed plasma HIV-1 RNA measurement ≥400 c/mL after initial suppression to \<50 c/mL while on first line HIV therapy regimen)
  • Abacavir/dolutegravir/lamivudine, (ABC/DTG/3TC) as current ART regimen
  • A history of use of any regimen consisting of only single NNRTI therapy (even if only for peri-partum treatment), or only single or dual NRTI therapy prior to starting cART
  • Subjects who are currently participating in or anticipate to be selected for any other interventional study
  • Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during the study
  • Any evidence of an active Center for Disease Control and Prevention (CDC) Stage 3 disease [CDC, 2014], except cutaneous Kaposi's sarcoma not requiring systemic therapy and historical or current less than 200 cells/mm\^3
  • Subjects with moderate to severe hepatic impairment
  • Any pre-existing physical or mental condition (including substance use disorder) which, in the opinion of the Investigator, may interfere with the subjects ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the subject.
  • Subjects determined by the Investigator to have a high risk of seizures, including subjects with an unstable or poorly controlled seizure disorder. A subject with a prior history of seizure may be considered for enrolment if the Investigator believes the risk of seizure recurrence is low. All cases of prior seizure history should be discussed with the Medical Monitor prior to enrolment
  • All subjects will be screened for syphilis (rapid plasma reagin [RPR]). Subjects with untreated syphilis infection, defined as a positive RPR without clear documentation of treatment, are excluded. Subjects with a serofast RPR result (persistence of a reactive nontreponemal syphilis test) despite history of adequate therapy and no evidence of re-exposure may enrol after consultation with the Medical Monitor. Subjects with a positive RPR test who have not been treated may be rescreened at least 30 days after completion of antibiotic treatment for syphilis
  • Subjects who, in the investigator's judgment, pose a significant suicide risk. Subject's recent history of suicidal behavior and/or suicidal ideation should be considered when evaluating for suicide risk
  • The subject has a tattoo or other dermatological condition overlying the gluteus region which may interfere with interpretation of injection site reactions
  • Evidence of virus (HBV) infection based on the results of testing at Screening for Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (anti-HBc), Hepatitis B surface antibody (anti-HBs) and HBV DNA as follows:•Subjects positive for HBsAg are excluded;
  • Subjects negative for anti-HBs but positive for anti-HBc (negative HBsAg status) and positive for HBV DNA are excluded
  • Asymptomatic individuals with chronic virus (HCV) infection will not be excluded, however Investigators must carefully assess if therapy specific for HCV infection is required; subjects who are anticipated to require HCV treatment within 12 months must be excluded. (HCV treatment on study may be permitted post Week 48, following consultation with the medical monitor) Subjects with HCV co-infection will be allowed entry into phase 3 studies if: Liver enzymes meet entry criteria; HCV Disease has undergone appropriate work-up, and is not advanced, and will not require treatment prior to the Week 48 visit. Additional information (where available) on subjects with HCV co-infection at screening should include results from any liver , Fibroscan, ultrasound, or other fibrosis evaluation, history of cirrhosis or other decompensated liver disease, prior treatment, and timing/plan for HCV treatment. In the event that recent biopsy or imaging data is not available or inconclusive, the Fib-4 score will be used to verify eligibility: Fib-4 score > 3.25 is exclusionary; Fib-4 scores 1.45 - 3.25 requires Medical Monitor consultation Fibrosis 4 Score Formula:( Age x ) / ( x ( sqr [ ALT ])
  • Unstable liver disease (as defined by any of the following: presence of ascites,encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices,or persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver disease per investigator assessment)
  • History of liver cirrhosis with or without hepatitis viral co-infection.
  • Ongoing or pancreatitis
  • Clinically significant cardiovascular disease, as defined by history/evidence of congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty (PTCA) or any clinically significant cardiac disease
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial neoplasia; other localized malignancies require agreement between the investigator and the Study medical monitor for inclusion of the subject prior to randomization
  • Any condition which, in the opinion of the Investigator, may interfere with the absorption, distribution, metabolism or excretion of the study drugs or render the subject unable to receive study medication
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia must not be enrolled
  • Current or anticipated need for chronic anti-coagulation with the exception of the use of low dose acetylsalicylic acid (≤325mg).
  • Any evidence of primary resistance based on the presence of any major known INI or NNRTI resistance-associated mutation, except for K103N, (International AIDS Society [IAS]-USA, 2015) by any historical resistance test result.
  • Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening phase to verify a result
  • Any acute laboratory abnormality at Screening, which, in the opinion of the investigator, would preclude the subject's participation in the study of an compound
  • Subject has estimated creatine clearance \<50mL/min per 1.73m\^2 via CKDEPI Method
  • Alanine aminotransferase (ALT) ≥3 × Exposure to an experimental drug or experimental vaccine within either 30 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to Day 1 of this study;
  • Treatment with any of the following agents within 28 days of Screening: radiation therapy; cytotoxic chemotherapeutic agents; tuberculosis therapy with the exception of isoniazid (isonicotinylhydrazid,INH); anti-coagulation agents; Immunomodulators that alter immune responses such as chronic systemic , interleukins, or interferons. Note: Subjects using short term (e.g. ≤21 days) systemic corticosteroid treatment; topical, inhaled and intranasal corticosteroids are eligible for enrolment.
  • Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening
  • Treatment with any agent, except recognized ART as allowed above, with documented activity against HIV-1 within 28 days of study Day 1
  • Use of medications which are associated with Torsade de Pointes.
  • Current or prior history of etravirine (ETR)
  • Current use of tipranavir/ritonavir or fosamprenavir/ritonavir
  • Subjects receiving any prohibited medication and who are unwilling or unable to switch to an alternate medication.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
618 participants (actual)

Study arms

  • Experimental
    CAB LA + RPV LA every 4 weeks

    Eligible subjects receive Oral CAB 30 mg + RPV 25 mg once daily for four weeks, IM CAB LA 600 mg and RPV LA 900 mg for the first injection, and Week 4 onwards subjects will receive CAB LA (400 mg) + RPV LA (600 mg) injections every 4 weeks until withdrawal.

    Drug: Cabotegravir (CAB) tablet · Drug: Rilpivirine (RPV) tablet · Drug: Cabotegravir - Injectable Suspension (CAB LA) · Drug: Rilpivirine - Injectable Suspension (RPV LA)

  • Active comparator
    Current antiretroviral regimen

    Eligible subjects will continue their current anti-retroviral regimen (2 NRTIs plus an INI, NNRTI, or a PI) for 52 weeks. After 52 weeks subjects have the option to continue study participation by switching to CAB LA + RPV LA in the Extension Phase where they will follow the procedure of CAB LA + RPV LA arm.

    Drug: 2 NRTIs plus an INI, NNRTI, or PI

Interventions

  • It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat

  • It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with "TMC" and the other side with "25". Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose

  • It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection

  • It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.

  • Drug2 NRTIs plus an INI, NNRTI, or PI

    Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus: * INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen) * NNRTI (either the initial or second cART regimen) * Boosted PI (or atazanavir \[ATV\] unboosted) (either the initial or second PI-based cART regimen)

07

What researchers measure

Primary outcomes

  1. Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48

    Number of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the non-inferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.

    Time frame: Week 48

Secondary outcomes

  1. Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48

    Plasma samples were collected for quantitative analysis of HIV-1 RNA. Number of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.

    Time frame: Week 48

  2. Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48

    Number of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART.

    Time frame: Week 48

  3. Number of Participants With Confirmed Virologic Failure (CVF)

    The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL. The outcome displays only visits during which at least one new CVF occurs. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

    Time frame: Weeks 8, 12, 20, 24, 32 and 40

  4. Absolute Values for Plasma HIV-1 RNA at Week 48

    Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.

    Time frame: Week 48

  5. Change From Baseline Values for Plasma HIV-1 RNA

    Plasma for quantitative HIV-1 RNA were collected at indicated time points. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 - HIV-1 RNA(log 10) at Baseline.

    Time frame: Baseline and Week 48

  6. Absolute Values for CD4+ Lymphocyte Count at Week 48

    Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.

    Time frame: Week 48

  7. Change From Baseline Values for CD4+ Lymphocyte Count at Week 48

    Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value at Week 48 minus Baseline value.

    Time frame: Baseline (Day 1) and Week 48

  8. Number of Participants With Disease Progression

    Disease progression was defined as HIV-associated conditions, acquired immunodeficiency syndrome (AIDS), and death through 48 Weeks. Data of participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented.

    Time frame: Up to Week 48

  9. Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety Population comprised of all randomized participants who received at least one dose of IP during the maintenance phase of the study (on or after Day 1 visit). Participants will be assessed according to actual treatment received.

    Time frame: Up to Week 48

  10. Number of Participants With Severity of Adverse Events

    Severity of adverse events (AEs) were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.

    Time frame: Up to Week 48

  11. Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

    Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  12. Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume

    Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  13. Absolute Values for Hematology Parameters: Erythrocytes

    Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  14. Absolute Values for Hematology Parameters: Hemoglobin

    Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  15. Absolute Values for Hematology Parameters: Hematocrit

    Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  16. Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

    Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  17. Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume

    Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  18. Change From Baseline for Hematology Parameters: Erythrocytes

    Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  19. Change From Baseline for Hematology Parameters: Hematocrit

    Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  20. Change From Baseline for Hematology Parameters: Hemoglobin

    Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  21. Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)

    Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  22. Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

    Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  23. Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  24. Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48

    Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  25. Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

    Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated time points.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  26. Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance

    Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  27. Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48

    The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to Division of AIDS (DAIDS) scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48.

  28. Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48

    Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  29. Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK

    Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  30. Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

    Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  31. Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  32. Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48

    Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  33. Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

    Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  34. Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.

    Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  35. Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48

    Blood samples were collected for the analysis of fasting lipid parameters- total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Week 48

  36. Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  37. Change From Baseline Values in Urine Creatinine Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  38. Change From Baseline Values in Urine Phosphate Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  39. Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Week 48

  40. Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48

    Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  41. Change From Baseline Values in Urine pH Over Time Including Week 48

    Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 24 and 48

  42. Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

    Time frame: Up to Week 48

  43. Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48

    Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Percentage change from Baseline is calculated as: value at Week 48 minus Baseline value divided by Baseline value multiplied by 100.

    Time frame: Baseline (Day 1) and at Week 48

  44. Number of Participants With Phenotypic Resistance Through Week 48

    Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.The CVF population comprised of all participants in ITT-E population who met CVF criteria.Phenotypic Resistance data for following drugs:CAB,dolutegravir(DTG),elvitegravir(EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI), atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),rito-navir(RTV),saquinavir(SQV) and tipranavir(TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance(FC\>clinical higher cutoff/biologic cutoff),partially sensitive(FC \<=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC \<= clinical lower cutoff/biologic cutoff).

    Time frame: At the time of CVF

  45. Number of Participants With Genotypic Resistance Through Week 48

    Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.

    Time frame: At the time of CVF

  46. Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

    Time frame: Up to Week 48

  47. Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK

    Blood samples were collected for the analysis of clinical chemistry parameters to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  48. Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin

    Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  49. Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  50. Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance

    Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  51. Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase

    Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  52. Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48

    Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  53. Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48

    Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

    Time frame: Baseline (Day 1) and at Week 48

  54. Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

    Time frame: Up to Week 48

  55. Plasma Trough Concentration (Ctrough) for CAB LA Evaluable

    Blood samples will be collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. PK population includes all participants who received CAB and / or RPV and underwent PK sampling during the study, and provided CAB and /or RPV plasma concentration data.

    Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  56. Ctrough for RPV LA Evaluable

    Blood samples will be collected at indicated time points for PK analysis of RPV LA.

    Time frame: Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  57. Area Under the Curve (AUC) for CAB LA

    AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for CAB LA.

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41

  58. AUC for RPV LA

    AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for RPV LA.

    Time frame: Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41

  59. Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41

    Blood samples will be collected at indicated time points for PK analysis of CAB LA.

    Time frame: Week 41- 1 Week post dose

  60. Cmax in Plasma for RPV LA Evaluable at Week 41

    Blood samples will be collected at indicated time points for PK analysis of RPV LA.

    Time frame: Week 41- 1 Week post dose

  61. Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent

    Percentage of participants with virologic failure endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \>=50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.

    Time frame: Week 48

  62. Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent

    Percentage of participants with HIV-1 RNA \< 50copies/mL endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \<50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.

    Time frame: Week 48

  63. Number of Participants With Severity of Adverse Events by Baseline Third Agents

    Severity of AEs were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.

    Time frame: Up to Week 48

  64. Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK

    Blood samples were collected for the analysis of clinical chemistry parameters: ALT, ALP, AST and CK to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  65. Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin

    Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  66. Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

    Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  67. Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance

    Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  68. Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase

    Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  69. Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48

    Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

  70. Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48

    Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Week 48

  71. Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48

    Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.

    Time frame: At the time of CVF

  72. Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48

    Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Phenotypic Resistance data for the following drugs: CAB, DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. Phenotypic resistance, partially sensitive, and Sensitive were defined based on FC value from Monogram as: resistance (FC\>clinical higher cutoff/biologic cutoff), partially sensitive (FC \<=clinical higher cutoff and \> clinical lower cutoff), sensitive (FC \<= clinical lower cutoff/biologic cutoff).

    Time frame: At the time of CVF

  73. Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm

    The PIN questionnaire explores the bother of pain at the injection site and injection site reactions (ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCFwas used as primary method of analysis

    Time frame: Week 5 and at Weeks 41 and 48

  74. Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm

    The PIN questionnaire explores the bother of pain at the injection site and injection site reactions(ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCF was used as primary method of analysis

    Time frame: Weeks 5, 41 and 48

  75. Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire

    The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for LISAT is calculated on a 0-100 scale using the formula: LISAT 100=\[100 divided by (20 minus 4)\]\*(LISAT minus 4). A response of 5 in LISAT score shows satisfaction all of the time and 1 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% confidence interval (CI).Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline (Day 1) and at Weeks 24 and 48

  76. Change From Baseline in HIV Medication, MEDWO Using HATQoL

    The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for MEDWO is calculated on a 0-100 scale using the formula: MEDWO 100=\[100 divided by (20 minus 5)\]\*(MEDWO minus 5). A response of 1 in MEDWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Weeks 24 and 48

  77. Change From Baseline in DISWO Using HATQoL

    The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for DISWO is calculated on a 0-100 scale using the formula: DISWO 100=\[100 divided by (20 minus 5)\]\*(DISWO minus 5). A response of 1 in DISWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Weeks 24 and 48

  78. Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)

    The SF-12 questionnaire consists of 7 questions which measures the degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. The HRQoL using SF-12 for the total score, physical component summary (PCS) and the mental component summary (MCS) were assessed for the two treatment groups. Missing Total or the component scores was imputed using LOCF. The PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com). The higher the score, the better will be the health status. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and at Weeks 24 and 48

  79. Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44

    The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants

    Time frame: Baseline and at Weeks 4b, 24 and 44

  80. Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm

    The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants

    Time frame: Week 48

  81. Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire

    The ACCEPT questionnaire is a generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication.The questionnaire consists of 25 items that capture six dimensions.3 questions that focus on general acceptance of study medication will be analyzed.Items on the scale are rated as 1-5 scores:1:totally disagree,2:somewhat disagree,3:somewhat agree, 4:totally agree and 5:I don't know.Total score of the dimension is calculated as the mean of the recoded items of the dimension and then linearly transformed to be on a scale from 0 to 100:score:Total Score=(mean of the recoded items in the dimension minus1)divided by2\*100.LOCF was used as primary method of analysis.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI.Baseline value is defined as the latest pre-treatment assessment with a non-missing value.Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value

    Time frame: Baseline and at Weeks 8, 24 and 48

  82. Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm

    The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.

    Time frame: Weeks 4b, 5, 40 and 41

  83. Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44

    HIVTSQc is a 12 item questionnaire. The individual treatment change item scores on HIVTSQc scale are rated as +3 ('much more satisfied', 'much more convenient', 'much more flexible',etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). The higher the score, the greater the improvement in satisfaction with each aspect of treatment and the lower the score, the greater the deterioration in satisfaction with each aspect of treatment. LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

    Time frame: Baseline and Weeks 4b, 24 and 44

Other outcomes

  1. Number of Participants With Different Demographic Parameters for Inter-subject Variability

    Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.

    Time frame: Upto Week 48

08

Results

Posted Jun 13, 2019

Participant flow

This was a phase III, randomized, open-label, active-controlled, multi-center, parallel-group, non-inferiority study to evaluate the antiviral activity and safety of two long-acting (LA) injectable drugs, cabotegravir (CAB) plus rilpivirine (RPV) when compared to current standard of care conducted in virologically suppressed human immunodeficiency.

Participant flow — Overall Study
MilestoneCAB LA+RPV LA (Q4W)Current ART
Started308308
Completed281290
Not completed2718
Withdrew: Adverse event135
Withdrew: Withdrawal by subject15
Withdrew: Physician decision20
Withdrew: Lost to follow-up11
Withdrew: Protocol-specified withdrawal criterion10
Withdrew: Protocol violation53
Withdrew: Lack of efficacy34
Withdrew: Ongoing10

Outcome measures

PrimaryNumber of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48

Number of participants with virologic failure endpoint (HIV-1 RNA\>=50 c/mL) as per Food and Drug Administration (FDA) snapshot algorithm at Week 48 was assessed to demonstrate the non-inferior antiviral activity of switching to intramuscular (IM) CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-1 RNA \>=50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Number of Participants With Virologic Failure (HIV-1 Ribonucleic Acid [RNA] >=50 Copies Per Millilter [mL]) Using Snapshot Algorithm at Week 4853
Statistical analysis
  • CAB LA+RPV LA (Q4W) vs Current ART · Adjusted difference in proportion: 0.6 · 95% CI -1.2 to 2.5Adjusted difference in proportion was based on Cochran-Mantel Haenszel stratified analysis adjusting for the following baseline stratification factors: sex at birth (Male, Female) and Baseline third agent (PI, NNRTI, INI).
SecondaryNumber of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48

Plasma samples were collected for quantitative analysis of HIV-1 RNA. Number of participants with plasma HIV-1 RNA \<50 copies/mL at Week 48 using FDA snapshot algorithm was assessed to demonstrate antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART. The HIV-1 RNA \<50 copies/mL per snapshot algorithm was determined by the last available on-treatment HIV-1 RNA measurement within the analysis visit window of interest.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Number of Participants With HIV-1 RNA <50 Copies/mL Using Snapshot Algorithm at Week 48285294
Statistical analysis
  • CAB LA+RPV LA (Q4W) vs Current ART · Adjusted difference in proportion: -3.0 · 95% CI -6.7 to 0.7Adjusted difference in proportion was based on Cochran-Mantel Haenszel stratified analysis adjusting for the following baseline stratification factors: sex at birth (Male, Female) and Baseline third agent (PI, NNRTI, INI).
SecondaryNumber of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48

Number of participants with plasma HIV-1 RNA \<200 copies/mL at Week 48 using the snapshot algorithm was assessed based on the antiviral and immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Number of Participants With HIV-1 RNA <200 Copies/mL Using Snapshot Algorithm at Week 48286295
SecondaryNumber of Participants With Confirmed Virologic Failure (CVF)

The CVF is defined as rebound as indicated by two consecutive plasma HIV-1-RNA levels \>=200 copies/mL after prior suppression to \<200 copies/mL. The outcome displays only visits during which at least one new CVF occurs. Plasma samples were collected for quantitative analysis of HIV-1 RNA.

Time frame:
Weeks 8, 12, 20, 24, 32 and 40
Reported as:
Count of participants · Participants
Number of Participants With Confirmed Virologic Failure (CVF)
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Week 810
Week 1220
Week 2022
Week 2432
Week 3233
Week 4034
SecondaryAbsolute Values for Plasma HIV-1 RNA at Week 48

Logarithm to base 10 (log10) values for plasma HIV-1 RNA has been presented.

Time frame:
Week 48
Reported as:
Mean · log10 copies/mL
Absolute Values for Plasma HIV-1 RNA at Week 48
log10 copies/mLCAB LA+RPV LA (Q4W)Current ART
Absolute Values for Plasma HIV-1 RNA at Week 481.505 ± 0.04701.518 ± 0.1123
SecondaryChange From Baseline Values for Plasma HIV-1 RNA

Plasma for quantitative HIV-1 RNA were collected at indicated time points. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as: HIV-1 RNA(log 10) at Week 48 - HIV-1 RNA(log 10) at Baseline.

Time frame:
Baseline and Week 48
Reported as:
Mean · log10 copies/mL
Change From Baseline Values for Plasma HIV-1 RNA
log10 copies/mLCAB LA+RPV LA (Q4W)Current ART
Change From Baseline Values for Plasma HIV-1 RNA-0.013 ± 0.19400.012 ± 0.1201
SecondaryAbsolute Values for CD4+ Lymphocyte Count at Week 48

Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.

Time frame:
Week 48
Reported as:
Mean · Cells per cubic millimeter
Absolute Values for CD4+ Lymphocyte Count at Week 48
Cells per cubic millimeterCAB LA+RPV LA (Q4W)Current ART
Absolute Values for CD4+ Lymphocyte Count at Week 48685.3 ± 262.97716.7 ± 292.85
SecondaryChange From Baseline Values for CD4+ Lymphocyte Count at Week 48

Blood samples were collected and CD4+ cell count assessment by flow cyclometry was carried out to evaluate the immunologic activity of switching to IM CAB LA+RPV LA every 4 weeks compared to current ART.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value at Week 48 minus Baseline value.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Cells per cubic millimeter
Change From Baseline Values for CD4+ Lymphocyte Count at Week 48
Cells per cubic millimeterCAB LA+RPV LA (Q4W)Current ART
Change From Baseline Values for CD4+ Lymphocyte Count at Week 489.9 ± 187.2419.4 ± 168.80
SecondaryNumber of Participants With Disease Progression

Disease progression was defined as HIV-associated conditions, acquired immunodeficiency syndrome (AIDS), and death through 48 Weeks. Data of participants who experienced disease progression to Centers for Disease Control and Prevention (CDC) Stage III or death has been presented.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Disease Progression
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Number of Participants With Disease Progression88
SecondaryNumber of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect, associated with liver injury and impaired liver function or any other situations as per medical or scientific judgement. Safety Population comprised of all randomized participants who received at least one dose of IP during the maintenance phase of the study (on or after Day 1 visit). Participants will be assessed according to actual treatment received.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs)
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Any non-SAE263117
Any SAE1314
SecondaryNumber of Participants With Severity of Adverse Events

Severity of adverse events (AEs) were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table) Version 2.0, November 2014. Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Grade 1101115
Grade 215881
Grade 32719
Grade 484
Grade 501
SecondaryAbsolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^9 cells per liter
Absolute Values for Hematology Parameters Over Time Including Week 48: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
10^9 cells per literCAB LA+RPV LA (Q4W)Current ART
Basophils, Baseline, n=308, 3070.021 ± 0.01470.021 ± 0.0148
Basophils, Week 4, n=299, 2910.024 ± 0.01530.023 ± 0.0161
Basophils, Week 8, n=216, 2940.023 ± 0.01880.022 ± 0.0155
Basophils, Week 12, n=293, 2900.022 ± 0.01540.022 ± 0.0157
Basophils, Week 16, n=274, 2920.022 ± 0.01470.022 ± 0.0140
Basophils, Week 20, n=273, 2920.023 ± 0.01820.024 ± 0.0195
Basophils, Week 24, n=277, 2920.023 ± 0.01390.024 ± 0.0133
Basophils, Week 28, n=266, 2950.024 ± 0.01500.023 ± 0.0138
Basophils, Week 32, n=262, 2830.025 ± 0.01710.024 ± 0.0159
Basophils, Week 36, n=260, 2820.029 ± 0.02110.028 ± 0.0190
Basophils, Week 40, n=258, 2800.035 ± 0.02660.031 ± 0.0206
Basophils, Week 44, n=258, 2680.037 ± 0.02750.033 ± 0.0222
Basophils, Week 48, n=246, 2740.040 ± 0.02530.039 ± 0.0249
Eosinophils, Baseline, n=308, 3070.142 ± 0.14090.140 ± 0.1538
Eosinophils, Week 4, n=299, 2910.168 ± 0.15870.145 ± 0.1422
Eosinophils, Week 8, n=216, 2940.154 ± 0.13790.131 ± 0.1333
Eosinophils, Week 12, n=293, 2900.142 ± 0.11720.132 ± 0.1471
Eosinophils, Week 16, n=274, 2920.153 ± 0.13950.131 ± 0.1584
Eosinophils, Week 20, n=273, 2920.152 ± 0.14800.116 ± 0.1094
Eosinophils, Week 24, n=277, 2920.143 ± 0.13230.121 ± 0.1337
Eosinophils, Week 28, n=266, 2950.144 ± 0.12660.129 ± 0.1320
Eosinophils, Week 32, n=262, 2830.170 ± 0.16430.131 ± 0.1319
Eosinophils, Week 36, n=260, 2820.150 ± 0.14030.132 ± 0.1162
Eosinophils, Week 40, n=258, 2800.161 ± 0.12060.132 ± 0.1124
Eosinophils, Week 44, n=258, 2680.175 ± 0.14710.136 ± 0.1126
Eosinophils, Week 48, n=246, 2740.174 ± 0.14120.140 ± 0.1265
Leukocytes, Baseline, n=308, 3075.87 ± 1.9285.65 ± 1.897
Leukocytes, Week 4, n=300, 2986.43 ± 2.1545.81 ± 1.733
Leukocytes, Week 8, n=217, 3016.14 ± 1.8755.64 ± 1.663
Leukocytes, Week 12, n=294, 2936.24 ± 1.8765.77 ± 1.751
Leukocytes, Week 16, n=279, 2956.27 ± 1.9205.82 ± 1.756
Leukocytes, Week 20, n=276, 2986.27 ± 1.9475.70 ± 1.721
Leukocytes, Week 24, n=279, 2946.18 ± 1.9315.78 ± 1.756
Leukocytes, Week 28, n=268, 2976.08 ± 1.9495.73 ± 1.637
Leukocytes, Week 32, n=267, 2886.30 ± 1.9145.73 ± 1.666
Leukocytes, Week 36, n=264, 2856.14 ± 1.8315.80 ± 1.968
Leukocytes, Week 40, n=264, 2866.24 ± 2.0465.74 ± 1.713
Leukocytes, Week 44, n=269, 2796.15 ± 1.8845.66 ± 1.745
Leukocytes, Week 48, n=252, 2826.01 ± 1.9435.62 ± 1.679
Lymphocytes, Baseline, n=308, 3071.943 ± 0.60731.940 ± 0.6880
Lymphocytes, Week 4, n=299, 2912.127 ± 0.69422.059 ± 0.6929
Lymphocytes, Week 8, n=216, 2941.995 ± 0.63471.975 ± 0.6549
Lymphocytes, Week 12, n=293, 2901.984 ± 0.64282.026 ± 0.6996
Lymphocytes, Week 16, n=274, 2922.057 ± 0.68402.029 ± 0.6584
Lymphocytes, Week 20, n=273, 2922.035 ± 0.61402.030 ± 0.6906
Lymphocytes, Week 24, n=277, 2922.016 ± 0.65231.980 ± 0.6047
Lymphocytes, Week 28, n=266, 2952.049 ± 0.69602.016 ± 0.6476
Lymphocytes, Week 32, n=262, 2832.020 ± 0.61572.007 ± 0.6511
Lymphocytes, Week 36, n=260, 2821.960 ± 0.60091.984 ± 0.6444
Lymphocytes, Week 40, n=258, 2801.994 ± 0.61491.957 ± 0.6305
Lymphocytes, Week 44, n=258, 2682.016 ± 0.64571.970 ± 0.6219
Lymphocytes, Week 48, n=246, 2741.900 ± 0.57251.915 ± 0.6204
Neutrophils, Baseline, n=308, 3073.437 ± 1.61063.209 ± 1.5748
Neutrophils, Week 4, n=299, 2913.708 ± 1.87633.244 ± 1.3931
Neutrophils, Week 8, n=216, 2943.597 ± 1.61283.190 ± 1.3370
Neutrophils, Week 12, n=293, 2903.724 ± 1.57513.268 ± 1.4153
Neutrophils, Week 16, n=274, 2923.670 ± 1.67773.308 ± 1.3870
Neutrophils, Week 20, n=273, 2923.707 ± 1.65323.188 ± 1.3345
Neutrophils, Week 24, n=277, 2923.613 ± 1.59783.289 ± 1.4381
Neutrophils, Week 28, n=266, 2953.528 ± 1.54643.221 ± 1.2962
Neutrophils, Week 32, n=262, 2833.704 ± 1.61963.228 ± 1.2909
Neutrophils, Week 36, n=260, 2823.629 ± 1.56883.314 ± 1.6341
Neutrophils, Week 40, n=258, 2803.688 ± 1.76853.280 ± 1.4190
Neutrophils, Week 44, n=258, 2683.571 ± 1.54253.169 ± 1.4140
Neutrophils, Week 48, n=246, 2743.450 ± 1.56493.172 ± 1.3627
Monocytes, Baseline, n=308, 3070.353 ± 0.17450.339 ± 0.1596
Monocytes, Week 4, n=299, 2910.404 ± 0.19510.367 ± 0.1694
Monocytes, Week 8, n=216, 2940.369 ± 0.16280.358 ± 0.1875
Monocytes, Week 12, n=293, 2900.375 ± 0.15630.342 ± 0.1693
Monocytes, Week 16, n=274, 2920.364 ± 0.15370.345 ± 0.1645
Monocytes, Week 20, n=273, 2920.356 ± 0.15260.342 ± 0.1632
Monocytes, Week 24, n=277, 2920.370 ± 0.16320.341 ± 0.1632
Monocytes, Week 28, n=266, 2950.354 ± 0.16310.333 ± 0.1592
Monocytes, Week 32, n=262, 2830.378 ± 0.16290.351 ± 0.1801
Monocytes, Week 36, n=260, 2820.376 ± 0.15930.366 ± 0.1824
Monocytes, Week 40, n=258, 2800.402 ± 0.16120.359 ± 0.1823
Monocytes, Week 44, n=258, 2680.409 ± 0.16430.388 ± 0.1795
Monocytes, Week 48, n=246, 2740.407 ± 0.16000.384 ± 0.1742
Platelets, Baseline, n=308, 308231.1 ± 56.75232.9 ± 59.28
Platelets, Week 4, n=300, 298233.5 ± 55.09238.1 ± 61.98
Platelets, Week 8, n=216, 298227.4 ± 47.04234.0 ± 61.84
Platelets, Week 12, n=294, 290230.2 ± 57.32237.8 ± 64.42
Platelets, Week 16, n=279, 294226.1 ± 56.82236.4 ± 61.63
Platelets, Week 20, n=274, 297226.5 ± 58.11237.7 ± 61.51
Platelets, Week 24, n=279, 292224.9 ± 53.19239.8 ± 64.11
Platelets, Week 28, n=268, 295224.7 ± 54.15239.0 ± 62.32
Platelets, Week 32, n=267, 289226.5 ± 50.84239.3 ± 59.53
Platelets, Week 36, n=267, 284229.0 ± 53.90242.9 ± 66.12
Platelets, Week 40, n=263, 288230.1 ± 53.48240.8 ± 61.92
Platelets, Week 44, n=270, 286235.5 ± 55.80241.4 ± 61.73
Platelets, Week 48, n=253, 281230.5 ± 54.33240.2 ± 62.95
SecondaryAbsolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume

Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Femtoliters
Absolute Values for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
FemtolitersCAB LA+RPV LA (Q4W)Current ART
Baseline, n=308, 30895.7 ± 7.9796.6 ± 9.35
Week 4, n=300, 30094.6 ± 6.8896.9 ± 9.31
Week 8, n=218, 30192.7 ± 5.7696.8 ± 9.25
Week 12, n=294, 29391.7 ± 5.6996.9 ± 9.34
Week 16, n=280, 29690.6 ± 5.4896.8 ± 9.64
Week 20, n=276, 29890.3 ± 5.3797.0 ± 9.63
Week 24, n=279, 29490.2 ± 5.4496.9 ± 9.75
Week 28, n=268, 29790.2 ± 5.6897.2 ± 9.77
Week 32, n=268, 29190.1 ± 5.5596.7 ± 9.36
Week 36, n=267, 28889.8 ± 5.6496.5 ± 9.08
Week 40, n=264, 28989.9 ± 5.5796.5 ± 9.05
Week 44, n=273, 28689.9 ± 5.5296.2 ± 9.08
Week 48, n=255, 28489.9 ± 5.5896.2 ± 9.38
SecondaryAbsolute Values for Hematology Parameters: Erythrocytes

Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^12 cells per liter
Absolute Values for Hematology Parameters: Erythrocytes
10^12 cells per literCAB LA+RPV LA (Q4W)Current ART
Baseline, n=308, 3084.55 ± 0.5634.49 ± 0.570
Week 4, n=300, 3004.59 ± 0.5034.45 ± 0.567
Week 8, n=218, 3014.68 ± 0.4794.49 ± 0.566
Week 12, n=294, 2934.79 ± 0.4644.51 ± 0.580
Week 16, n=280, 2964.84 ± 0.4754.48 ± 0.549
Week 20, n=276, 2984.86 ± 0.4594.48 ± 0.586
Week 24, n=279, 2944.86 ± 0.4714.48 ± 0.572
Week 28, n=268, 2974.85 ± 0.4564.47 ± 0.565
Week 32, n=268, 2914.84 ± 0.4524.48 ± 0.550
Week 36, n=267, 2884.81 ± 0.4624.49 ± 0.561
Week 40, n=264, 2894.84 ± 0.4564.49 ± 0.572
Week 44, n=273, 2864.86 ± 0.4484.49 ± 0.572
Week 48, n=255, 2844.81 ± 0.4484.50 ± 0.600
SecondaryAbsolute Values for Hematology Parameters: Hemoglobin

Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Absolute Values for Hematology Parameters: Hemoglobin
Grams per literCAB LA+RPV LA (Q4W)Current ART
Baseline, n=308, 308142.2 ± 17.24141.4 ± 16.29
Week 4, n=300, 300141.7 ± 16.30140.5 ± 16.44
Week 8, n=218, 301141.5 ± 16.08141.2 ± 16.51
Week 12, n=294, 293142.4 ± 15.90141.6 ± 16.62
Week 16, n=280, 296142.5 ± 16.19140.5 ± 15.81
Week 20, n=276, 298142.6 ± 15.52141.2 ± 16.62
Week 24, n=279, 294143.3 ± 15.66141.6 ± 16.18
Week 28, n=268, 297142.8 ± 16.05140.9 ± 15.89
Week 32, n=268, 291143.0 ± 15.42141.8 ± 15.81
Week 36, n=267, 288142.7 ± 16.31142.3 ± 15.72
Week 40, n=264, 289143.5 ± 15.80142.4 ± 15.90
Week 44, n=273, 286143.6 ± 15.66142.1 ± 16.38
Week 48, n=255, 284142.7 ± 15.93142.8 ± 16.34
SecondaryAbsolute Values for Hematology Parameters: Hematocrit

Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Proportion of red blood cells in blood
Absolute Values for Hematology Parameters: Hematocrit
Proportion of red blood cells in bloodCAB LA+RPV LA (Q4W)Current ART
Baseline, n=308, 3080.4333 ± 0.048040.4305 ± 0.04454
Week 4, n=300, 3000.4325 ± 0.045700.4283 ± 0.04548
Week 8, n=218, 3010.4327 ± 0.045700.4310 ± 0.04580
Week 12, n=294, 2930.4379 ± 0.044830.4338 ± 0.04640
Week 16, n=280, 2960.4369 ± 0.046260.4304 ± 0.04418
Week 20, n=276, 2980.4378 ± 0.044760.4312 ± 0.04755
Week 24, n=279, 2940.4376 ± 0.045890.4312 ± 0.04595
Week 28, n=268, 2970.4364 ± 0.046070.4308 ± 0.04555
Week 32, n=268, 2910.4350 ± 0.043110.4299 ± 0.04431
Week 36, n=267, 2880.4311 ± 0.044620.4295 ± 0.04348
Week 40, n=264, 2890.4342 ± 0.043810.4300 ± 0.04449
Week 44, n=273, 2860.4357 ± 0.042880.4282 ± 0.04472
Week 48, n=255, 2840.4318 ± 0.044380.4286 ± 0.04465
SecondaryChange From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets

Blood samples were collected for the analysis of hematology parameters including basophil, eosinophils, leukocytes, lymphocytes, neutrophils, monocytes, and platelets at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^9 cells per liters
Change From Baseline for Hematology Parameters: Basophil, Eosinophils, Leukocytes, Lymphocytes, Neutrophils, Monocytes, and Platelets
10^9 cells per litersCAB LA+RPV LA (Q4W)Current ART
Basophils, Week 4, n=299, 2900.003 ± 0.02020.003 ± 0.0185
Basophils, Week 8, n=216, 2930.003 ± 0.02040.000 ± 0.0181
Basophils, Week 12, n=293, 2890.002 ± 0.02050.001 ± 0.0197
Basophils, Week 16, n=274, 2910.001 ± 0.01860.001 ± 0.0181
Basophils, Week 20, n=273, 2910.002 ± 0.02250.002 ± 0.0212
Basophils, Week 24, n=277, 2910.002 ± 0.01690.003 ± 0.0167
Basophils, Week 28, n=266, 2940.003 ± 0.02000.002 ± 0.0181
Basophils, Week 32, n=262, 2820.005 ± 0.01990.003 ± 0.0189
Basophils, Week 36, n=260, 2810.009 ± 0.02310.007 ± 0.0217
Basophils, Week 40, n=258, 2790.014 ± 0.02920.011 ± 0.0233
Basophils, Week 44, n=258, 2670.017 ± 0.02830.012 ± 0.0239
Basophils, Week 48, n=246, 2730.019 ± 0.02730.018 ± 0.0263
Eosinophils, Week 4, n=299, 2900.026 ± 0.13940.009 ± 0.1409
Eosinophils, Week 8, n=216, 2930.015 ± 0.1278-0.008 ± 0.1319
Eosinophils, Week 12, n=293, 289-0.003 ± 0.1155-0.010 ± 0.1533
Eosinophils, Week 16, n=274, 2910.009 ± 0.1246-0.011 ± 0.1759
Eosinophils, Week 20, n=273, 2910.009 ± 0.1410-0.027 ± 0.1352
Eosinophils, Week 24, n=277, 2910.002 ± 0.1228-0.021 ± 0.1490
Eosinophils, Week 28, n=266, 294-0.002 ± 0.1298-0.011 ± 0.1387
Eosinophils, Week 32, n=262, 2820.022 ± 0.1629-0.012 ± 0.1511
Eosinophils, Week 36, n=260, 2810.002 ± 0.1413-0.012 ± 0.1382
Eosinophils, Week 40, n=258, 2790.019 ± 0.1319-0.006 ± 0.1283
Eosinophils, Week 44, n=258, 2670.032 ± 0.1388-0.004 ± 0.1061
Eosinophils, Week 48, n=246, 2730.032 ± 0.13210.002 ± 0.1253
Leukocytes, Week 4, n=300, 2970.54 ± 1.5990.13 ± 1.544
Leukocytes, Week 8, n=217, 3000.19 ± 1.579-0.02 ± 1.548
Leukocytes, Week 12, n=294, 2920.35 ± 1.7430.10 ± 1.571
Leukocytes, Week 16, n=279, 2940.34 ± 1.6530.17 ± 1.558
Leukocytes, Week 20, n=276, 2970.46 ± 1.5650.04 ± 1.529
Leukocytes, Week 24, n=279, 2930.32 ± 1.7200.10 ± 1.661
Leukocytes, Week 28, n=268, 2960.25 ± 1.6510.07 ± 1.471
Leukocytes, Week 32, n=267, 2870.43 ± 1.6020.07 ± 1.631
Leukocytes, Week 36, n=264, 2840.33 ± 1.6990.13 ± 1.821
Leukocytes, Week 40, n=264, 2850.35 ± 1.8080.12 ± 1.675
Leukocytes, Week 44, n=269, 2780.22 ± 1.581-0.03 ± 1.561
Leukocytes, Week 48, n=252, 2810.09 ± 1.646-0.06 ± 1.538
Lymphocytes, Week 4, n=299, 2900.174 ± 0.51850.128 ± 0.5618
Lymphocytes, Week 8, n=216, 2930.068 ± 0.53190.023 ± 0.5250
Lymphocytes, Week 12, n=293, 2890.033 ± 0.50730.079 ± 0.5844
Lymphocytes, Week 16, n=274, 2910.114 ± 0.55960.095 ± 0.5389
Lymphocytes, Week 20, n=273, 2910.071 ± 0.52740.086 ± 0.5411
Lymphocytes, Week 24, n=277, 2910.079 ± 0.54080.049 ± 0.4863
Lymphocytes, Week 28, n=266, 2940.101 ± 0.61330.069 ± 0.6005
Lymphocytes, Week 32, n=262, 2820.063 ± 0.53920.064 ± 0.5757
Lymphocytes, Week 36, n=260, 2810.008 ± 0.53330.036 ± 0.5525
Lymphocytes, Week 40, n=258, 2790.020 ± 0.51710.035 ± 0.5280
Lymphocytes, Week 44, n=258, 2670.045 ± 0.54300.045 ± 0.5472
Lymphocytes, Week 48, n=246, 273-0.063 ± 0.5528-0.035 ± 0.5115
Neutrophils, Week 4, n=299, 2900.258 ± 1.54450.004 ± 1.3601
Neutrophils, Week 8, n=216, 2930.080 ± 1.4401-0.031 ± 1.3599
Neutrophils, Week 12, n=293, 2890.283 ± 1.62270.028 ± 1.3884
Neutrophils, Week 16, n=274, 2910.181 ± 1.54150.080 ± 1.4451
Neutrophils, Week 20, n=273, 2910.341 ± 1.4475-0.019 ± 1.4228
Neutrophils, Week 24, n=277, 2910.175 ± 1.58830.056 ± 1.5091
Neutrophils, Week 28, n=266, 2940.129 ± 1.4052-0.001 ± 1.3377
Neutrophils, Week 32, n=262, 2820.291 ± 1.60150.008 ± 1.4430
Neutrophils, Week 36, n=260, 2810.289 ± 1.57020.077 ± 1.6758
Neutrophils, Week 40, n=258, 2790.245 ± 1.66210.075 ± 1.5336
Neutrophils, Week 44, n=258, 2670.063 ± 1.4874-0.105 ± 1.4587
Neutrophils, Week 48, n=246, 2730.009 ± 1.5413-0.066 ± 1.3969
Monocytes, Week 4, n=299, 2900.049 ± 0.16630.030 ± 0.1270
Monocytes Week 8, n=216, 2930.014 ± 0.14330.018 ± 0.1591
Monocytes, Week 12, n=293, 2890.018 ± 0.15530.001 ± 0.1367
Monocytes, Week 16, n=274, 2910.005 ± 0.15880.003 ± 0.1403
Monocytes, Week 20, n=273, 2910.003 ± 0.15270.004 ± 0.1328
Monocytes, Week 24, n=277, 2910.012 ± 0.14840.002 ± 0.1331
Monocytes, Week 28, n=266, 2940.001 ± 0.1548-0.004 ± 0.1343
Monocytes, Week 32, n=262, 2820.019 ± 0.15350.011 ± 0.1585
Monocytes, Week 36, n=260, 2810.016 ± 0.15010.024 ± 0.1551
Monocytes, Week 40, n=258, 2790.039 ± 0.15070.020 ± 0.1550
Monocytes, Week 44, n=258, 2670.045 ± 0.16730.045 ± 0.1539
Monocytes, Week 48, n=246, 2730.047 ± 0.15020.039 ± 0.1499
Platelets, Week 4, n=300, 2981.8 ± 38.024.3 ± 36.15
Platelets, Week 8, n=216, 298-5.5 ± 31.980.7 ± 35.15
Platelets, Week 12, n=294, 290-0.8 ± 40.835.5 ± 36.76
Platelets, Week 16, n=279, 294-5.2 ± 40.674.3 ± 34.61
Platelets, Week 20, n=274, 297-3.7 ± 36.875.5 ± 38.86
Platelets, Week 24, n=279, 292-4.7 ± 35.226.7 ± 41.78
Platelets, Week 28, n=268, 295-5.3 ± 35.225.4 ± 38.41
Platelets, Week 32, n=267, 289-2.6 ± 36.516.5 ± 35.99
Platelets, Week 36, n=267, 284-1.2 ± 37.269.8 ± 44.52
Platelets, Week 40, n=263, 2880.0 ± 40.749.7 ± 39.91
Platelets, Week 44, n=270, 2864.5 ± 38.319.2 ± 42.82
Platelets, Week 48, n=253, 2810.0 ± 38.6310.4 ± 41.75
SecondaryChange From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume

Blood samples were collected for the analysis of hematology parameter including erythrocyte mean corpuscular volume at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Femtoliters
Change From Baseline for Hematology Parameters: Erythrocyte Mean Corpuscular Volume
FemtolitersCAB LA+RPV LA (Q4W)Current ART
Week 4, n=300, 300-1.1 ± 2.710.2 ± 1.82
Week 8, n=218, 301-3.0 ± 4.300.1 ± 1.76
Week 12, n=294, 293-3.9 ± 5.230.2 ± 2.08
Week 16, n=280, 296-4.9 ± 5.860.2 ± 2.42
Week 20, n=276, 298-5.3 ± 5.980.3 ± 2.88
Week 24, n=279, 294-5.4 ± 5.970.3 ± 3.24
Week 28, n=268, 297-5.5 ± 6.110.4 ± 3.46
Week 32, n=268, 291-5.5 ± 6.100.1 ± 3.47
Week 36, n=267, 288-5.8 ± 6.24-0.0 ± 3.69
Week 40, n=264, 289-5.6 ± 6.21-0.1 ± 3.62
Week 44, n=273, 286-5.8 ± 6.33-0.3 ± 3.68
Week 48, n=255, 284-5.7 ± 6.76-0.4 ± 3.57
SecondaryChange From Baseline for Hematology Parameters: Erythrocytes

Blood samples were collected for the analysis of hematology parameters including erythrocytes at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · 10^12 cells per liter
Change From Baseline for Hematology Parameters: Erythrocytes
10^12 cells per literCAB LA+RPV LA (Q4W)Current ART
Week 4, n=300, 3000.04 ± 0.255-0.03 ± 0.226
Week 8, n=218, 3010.14 ± 0.331-0.01 ± 0.249
Week 12, n=294, 2930.23 ± 0.3740.01 ± 0.252
Week 16, n=280, 2960.28 ± 0.380-0.01 ± 0.256
Week 20, n=276, 2980.30 ± 0.408-0.01 ± 0.273
Week 24, n=279, 2940.32 ± 0.397-0.01 ± 0.246
Week 28, n=268, 2970.28 ± 0.386-0.01 ± 0.246
Week 32, n=268, 2910.29 ± 0.393-0.01 ± 0.261
Week 36, n=267, 2880.26 ± 0.401-0.01 ± 0.259
Week 40, n=264, 2890.27 ± 0.396-0.01 ± 0.260
Week 44, n=273, 2860.31 ± 0.391-0.01 ± 0.264
Week 48, n=255, 2840.25 ± 0.394-0.01 ± 0.262
SecondaryChange From Baseline for Hematology Parameters: Hematocrit

Blood samples were collected for the analysis of hematology parameters including hematocrit at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline for Hematology Parameters: Hematocrit
Proportion of red blood cells in bloodCAB LA+RPV LA (Q4W)Current ART
Week 4, n=300, 300-0.0003 ± 0.02236-0.0023 ± 0.02194
Week 8, n=218, 3010.0007 ± 0.02613-0.0005 ± 0.02330
Week 12, n=294, 2930.0042 ± 0.026070.0020 ± 0.02408
Week 16, n=280, 2960.0038 ± 0.02509-0.0007 ± 0.02513
Week 20, n=276, 2980.0043 ± 0.027420.0002 ± 0.02613
Week 24, n=279, 2940.0052 ± 0.027900.0002 ± 0.02576
Week 28, n=268, 2970.0023 ± 0.026990.0002 ± 0.02603
Week 32, n=268, 2910.0022 ± 0.02872-0.0011 ± 0.02916
Week 36, n=267, 288-0.0012 ± 0.02793-0.0011 ± 0.02797
Week 40, n=264, 289-0.0001 ± 0.02741-0.0011 ± 0.02781
Week 44, n=273, 2860.0031 ± 0.02896-0.0025 ± 0.02814
Week 48, n=255, 284-0.0021 ± 0.02717-0.0031 ± 0.02700
SecondaryChange From Baseline for Hematology Parameters: Hemoglobin

Blood samples were collected for the analysis of hematology parameter including hemoglobin at indicated timepoints. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline was defined as post-dose visit value minus Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Change From Baseline for Hematology Parameters: Hemoglobin
Grams per literCAB LA+RPV LA (Q4W)Current ART
Week 4, n=300, 300-0.4 ± 6.91-1.0 ± 6.73
Week 8, n=218, 301-0.4 ± 8.18-0.6 ± 7.33
Week 12, n=294, 2930.0 ± 8.14-0.3 ± 7.52
Week 16, n=280, 2960.4 ± 8.22-1.2 ± 7.75
Week 20, n=276, 2980.3 ± 8.60-0.5 ± 8.55
Week 24, n=279, 2941.2 ± 8.78-0.0 ± 8.46
Week 28, n=268, 2970.3 ± 8.49-0.6 ± 8.68
Week 32, n=268, 2910.9 ± 8.940.2 ± 9.45
Week 36, n=267, 2880.7 ± 9.030.8 ± 9.32
Week 40, n=264, 2890.8 ± 8.960.7 ± 9.29
Week 44, n=273, 2861.7 ± 9.490.6 ± 9.53
Week 48, n=255, 2840.2 ± 9.260.9 ± 9.07
SecondaryAbsolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)

Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · International units per liter
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST) and Creatinine Kinase (CK)
International units per literCAB LA+RPV LA (Q4W)Current ART
ALT, Baseline (Day 1), n=308, 30823.8 ± 13.4722.4 ± 12.90
ALT, Week 4, n=301, 30324.4 ± 15.6022.3 ± 11.10
ALT, Week 8, n=229, 30324.0 ± 16.8524.0 ± 29.86
ALT, Week 12, n=295, 29929.0 ± 114.2522.7 ± 13.48
ALT, Week 16, n=284, 29823.7 ± 22.3221.8 ± 11.31
ALT, Week 20, n=277, 30223.1 ± 22.4921.2 ± 10.50
ALT, Week 24, n=284, 29926.3 ± 62.0521.6 ± 12.64
ALT, Week 28, n=267, 29621.1 ± 12.1322.1 ± 14.62
ALT, Week 32, n=275, 29421.8 ± 12.5621.8 ± 12.09
ALT, Week 36, n=273, 29223.2 ± 24.9422.3 ± 12.17
ALT, Week 40, n=270, 29324.5 ± 37.3922.1 ± 12.78
ALT, Week 44, n=275, 29321.6 ± 13.1022.1 ± 13.67
ALT, Week 48, n=265, 29221.8 ± 13.5421.7 ± 11.08
ALP, Baseline (Day 1), n=308, 30876.6 ± 28.2077.5 ± 26.77
ALP, Week 4, n=301, 30370.4 ± 22.7575.7 ± 25.58
ALP, Week 8, n=229, 30368.9 ± 21.9878.8 ± 32.40
ALP, Week 12, n=295, 29968.9 ± 24.7978.6 ± 28.87
ALP, Week 16, n=284, 29867.9 ± 19.7677.3 ± 27.21
ALP, Week 20, n=277, 30267.6 ± 18.7276.7 ± 25.48
ALP, Week 24, n=284, 29968.1 ± 19.1577.5 ± 26.36
ALP, Week 28, n=267, 29667.6 ± 18.8977.2 ± 26.72
ALP, Week 32, n=275, 29466.6 ± 19.1475.8 ± 25.56
ALP, Week 36, n=273, 29266.8 ± 20.6876.4 ± 25.93
ALP, Week 40, n=270, 29366.2 ± 17.5876.2 ± 26.08
ALP, Week 44, n=275, 29366.1 ± 18.3476.8 ± 25.82
ALP, Week 48, n=265, 29266.5 ± 18.8477.1 ± 26.39
AST, Baseline (Day 1), n=308, 30823.9 ± 11.3122.5 ± 10.21
AST, Week 4, n=301, 30323.2 ± 11.7722.7 ± 10.93
AST, Week 8, n=229, 30324.3 ± 19.4922.5 ± 12.31
AST, Week 12, n=295, 29926.1 ± 64.6923.2 ± 10.61
AST, Week 16, n=284, 29824.1 ± 18.2022.5 ± 8.59
AST, Week 20, n=277, 30223.5 ± 15.2322.0 ± 6.83
AST, Week 24, n=284, 29824.2 ± 22.8922.5 ± 9.30
AST, Week 28, n=267, 29622.2 ± 8.7222.9 ± 9.61
AST, Week 32, n=275, 29422.8 ± 13.7123.2 ± 12.32
AST, Week 36, n=273, 29223.0 ± 11.2722.6 ± 7.18
AST, Week 40, n=270, 29323.8 ± 14.9622.5 ± 7.79
AST, Week 44, n=275, 29322.9 ± 14.8222.6 ± 10.26
AST Week 48, n=265, 29222.9 ± 10.3523.2 ± 9.30
CK, Baseline (Day 1), n=308, 308196.6 ± 367.30160.8 ± 367.57
CK, Week 4, n=301, 303192.9 ± 437.09190.6 ± 472.57
CK, Week 8, n=229, 303275.9 ± 1064.72145.4 ± 141.19
CK, Week 12, n=295, 299200.7 ± 484.08177.0 ± 321.29
CK, Week 16, n=284, 298253.5 ± 849.45167.5 ± 286.90
CK, Week 20, n=277, 302228.4 ± 570.80144.5 ± 133.32
CK, Week 24, n=284, 299193.1 ± 444.27161.2 ± 241.73
CK, Week 28, n=267, 296168.8 ± 163.54182.7 ± 420.44
CK, Week 32, n=275, 294216.5 ± 593.10195.9 ± 489.99
CK, Week 36, n=273, 292186.4 ± 325.64150.7 ± 134.40
CK, Week 40, n=270, 293235.1 ± 624.03160.7 ± 179.64
CK, Week 44, n=275, 293245.5 ± 1189.35149.9 ± 148.23
CK, Week 48, n=265, 292198.8 ± 398.14179.0 ± 331.51
SecondaryAbsolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

Blood samples were collected for the analysis of clinical chemistry parameter-albumin at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Grams per literCAB LA+RPV LA (Q4W)Current ART
Baseline (Day 1), n=308, 30844.2 ± 3.1244.3 ± 3.19
Week 4, n=301, 30343.7 ± 2.8843.8 ± 2.87
Week 8, n=229, 30343.8 ± 3.0643.7 ± 3.17
Week 12, n=295, 29943.6 ± 2.9943.9 ± 3.12
Week 16, n=284, 29843.5 ± 2.7743.5 ± 3.12
Week 20, n=277, 30243.4 ± 2.7243.5 ± 3.07
Week 24, n=284, 29943.4 ± 2.7443.5 ± 3.02
Week 28, n=267, 29643.6 ± 2.8543.3 ± 3.07
Week 32, n=275, 29443.5 ± 2.8343.4 ± 3.25
Week 36, n=273, 29243.3 ± 2.8243.4 ± 3.07
Week 40, n=270, 29343.7 ± 2.7243.4 ± 3.04
Week 44, n=275, 29343.7 ± 2.7843.5 ± 3.02
Week 48, n=265, 29243.8 ± 2.7444.0 ± 2.92
SecondaryAbsolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Micromoles per liter
Absolute Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per literCAB LA+RPV LA (Q4W)Current ART
Bilirubin, Baseline (Day 1), n=308, 3089.9 ± 9.719.2 ± 6.39
Bilirubin, Week 4, n=301, 3039.1 ± 3.988.9 ± 6.14
Bilirubin, Week 8, n=229, 3039.3 ± 4.059.4 ± 9.06
Bilirubin, Week 12, n=295, 2999.3 ± 4.459.3 ± 6.62
Bilirubin, Week 16, n=284, 29810.0 ± 10.719.1 ± 6.28
Bilirubin, Week 20, n=277, 3029.7 ± 4.289.3 ± 7.56
Bilirubin, Week 24, n=284, 2989.3 ± 3.909.4 ± 8.38
Bilirubin, Week 28, n=267, 2969.8 ± 3.999.1 ± 7.05
Bilirubin, Week 32, n=275, 2949.8 ± 4.369.3 ± 7.05
Bilirubin, Week 36, n=273, 2929.3 ± 3.799.2 ± 7.34
Bilirubin, Week 40, n=270, 2939.6 ± 4.079.5 ± 9.04
Bilirubin, Week 44, n=275, 2939.6 ± 4.199.7 ± 8.49
Bilirubin, Week 48, n=265, 2929.7 ± 4.249.5 ± 6.36
Direct bilirubin, Baseline (Day 1), n=308, 3082.4 ± 1.352.2 ± 1.25
Direct bilirubin, Week 4, n=301, 3032.3 ± 1.042.3 ± 1.27
Direct bilirubin, Week 8, n=229, 3032.3 ± 1.082.4 ± 3.96
Direct bilirubin, Week 12, n=295, 2992.2 ± 1.032.3 ± 1.30
Direct bilirubin, Week 16, n=284, 2982.5 ± 4.982.1 ± 1.08
Direct bilirubin, Week 20, n=277, 3022.2 ± 0.952.0 ± 1.31
Direct bilirubin, Week 24, n=284, 2982.2 ± 0.992.1 ± 1.26
Direct bilirubin, Week 28, n=267, 2962.1 ± 0.942.0 ± 1.28
Direct bilirubin, Week 32, n=275, 2942.1 ± 1.002.0 ± 1.22
Direct bilirubin, Week 36, n=273, 2922.1 ± 1.112.1 ± 1.27
Direct bilirubin, Week 40, n=270, 2932.1 ± 1.082.1 ± 1.37
Direct bilirubin, Week 44, n=275, 2932.2 ± 0.952.2 ± 1.30
Direct bilirubin, Week 48, n=265, 2922.2 ± 0.922.2 ± 1.23
Creatinine, Baseline (Day 1), n=308, 30879.05 ± 16.38077.83 ± 16.497
Creatinine, Week 4, n=301, 30180.17 ± 15.46479.47 ± 16.284
Creatinine, Week 8, n=229, 30378.79 ± 16.12279.22 ± 16.824
Creatinine, Week 12, n=295, 29978.65 ± 16.53479.50 ± 17.191
Creatinine, Week 16, n=284, 29878.72 ± 15.60679.51 ± 17.171
Creatinine, Week 20, n=277, 30279.75 ± 15.69579.62 ± 16.909
Creatinine, Week 24, n=284, 29880.15 ± 18.47879.05 ± 16.673
Creatinine, Week 28, n=267, 29680.42 ± 16.33579.35 ± 16.574
Creatinine, Week 32, n=275, 29479.65 ± 15.04479.69 ± 16.634
Creatinine, Week 36, n=273, 29279.73 ± 15.99479.34 ± 16.527
Creatinine, Week 40, n=270, 29380.28 ± 15.85679.42 ± 16.856
Creatinine, Week 44, n=275, 29379.98 ± 15.77579.16 ± 16.583
Creatinine, Week 48, n=265, 29280.77 ± 16.45678.65 ± 16.204
SecondaryAbsolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48

Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Millimoles per liter
Absolute Values for Clinical Chemistry Parameters: Total Carbon-dioxide (CO2), Chloride, Glucose, Phosphate, Potassium, Sodium and Urea Over Time Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
CO2, Baseline (Day 1), n=308, 30822.7 ± 2.3322.6 ± 2.24
CO2, Week 4, n=301, 30323.7 ± 2.4923.3 ± 2.27
CO2, Week 8, n=229, 30323.1 ± 2.1723.2 ± 2.47
CO2, Week 12, n=295, 29923.2 ± 2.1423.0 ± 2.36
CO2, Week 16, n=284, 29822.9 ± 2.1623.0 ± 2.31
CO2, Week 20, n=277, 30222.9 ± 2.1622.9 ± 2.29
CO2, Week 24, n=284, 29822.9 ± 2.3122.8 ± 2.41
CO2, Week 28, n=267, 29622.7 ± 2.4222.7 ± 2.27
CO2, Week 32, n=275, 29422.6 ± 2.1522.8 ± 2.34
CO2, Week 36, n=273, 29222.8 ± 2.1923.0 ± 2.26
CO2, Week 40, n=270, 29323.1 ± 2.2723.0 ± 2.45
CO2, Week 44, n=275, 29323.0 ± 2.1923.2 ± 2.31
CO2, Week 48, n=265, 29222.7 ± 2.2922.9 ± 2.29
Chloride, Baseline (Day 1), n=308, 308103.8 ± 2.03103.8 ± 2.39
Chloride, Week 4, n=301, 303104.3 ± 2.13104.3 ± 2.22
Chloride, Week 8, n=229, 303104.3 ± 2.26104.2 ± 2.40
Chloride, Week 12, n=295, 299104.2 ± 2.27104.3 ± 2.24
Chloride, Week 16, n=284, 298104.5 ± 2.21104.5 ± 2.28
Chloride, Week 20, n=277, 302104.7 ± 2.41104.5 ± 2.38
Chloride, Week 24, n=284, 299104.5 ± 2.36104.7 ± 2.30
Chloride, Week 28, n=267, 296104.8 ± 2.19104.8 ± 2.36
Chloride, Week 32, n=275, 294104.7 ± 2.50104.7 ± 2.31
Chloride, Week 36, n=273, 292104.8 ± 2.18104.6 ± 2.36
Chloride, Week 40, n=270, 293104.7 ± 2.22104.6 ± 2.61
Chloride, Week 44, n=275, 293104.6 ± 2.10104.6 ± 2.27
Chloride, Week 48, n=265, 292104.4 ± 2.38104.1 ± 2.37
Glucose, Baseline (Day 1), n=301, 2995.00 ± 0.7145.17 ± 0.988
Glucose, Week 4, n=216, 2265.17 ± 0.7475.42 ± 1.250
Glucose, Week 8, n=153, 2185.16 ± 0.9905.35 ± 1.037
Glucose, Week 12, n=206, 2215.19 ± 0.9655.35 ± 1.091
Glucose, Week 16, n=209, 2165.22 ± 1.1635.36 ± 1.317
Glucose, Week 20, n=194, 2215.20 ± 0.7365.37 ± 1.209
Glucose, Week 24, n=215, 2295.24 ± 0.8105.35 ± 0.840
Glucose, Week 28, n=190, 2265.16 ± 0.6975.36 ± 0.876
Glucose, Week 32, n=194, 2195.33 ± 1.0425.45 ± 1.102
Glucose, Week 36, n=191, 2205.19 ± 0.7775.40 ± 1.507
Glucose, Week 40, n=195, 2185.30 ± 0.7975.44 ± 1.227
Glucose, Week 44, n=193, 2135.22 ± 0.8875.44 ± 1.317
Glucose, Week 48, n=242, 2775.08 ± 0.6145.22 ± 0.963
Phosphate, Baseline (Day 1), n=308, 3081.042 ± 0.17711.051 ± 0.1722
Phosphate, Week 4, n=301, 3031.110 ± 0.17931.066 ± 0.1773
Phosphate, Week 8, n=229, 3031.097 ± 0.19441.042 ± 0.1843
Phosphate, Week 12, n=295, 2991.080 ± 0.18721.062 ± 0.1922
Phosphate, Week 16, n=284, 2981.081 ± 0.17961.052 ± 0.1724
Phosphate, Week 20, n=277, 3021.073 ± 0.17461.061 ± 0.1873
Phosphate, Week 24, n=284, 2991.082 ± 0.17881.057 ± 0.1849
Phosphate, Week 28, n=267, 2961.072 ± 0.17141.053 ± 0.1741
Phosphate, Week 32, n=275, 2941.061 ± 0.17301.054 ± 0.1761
Phosphate, Week 36, n=273, 2921.052 ± 0.17001.049 ± 0.1798
Phosphate, Week 40, n=270, 2931.065 ± 0.17891.046 ± 0.1763
Phosphate, Week 44, n=275, 2931.066 ± 0.17981.052 ± 0.1902
Phosphate, Week 48, n=265, 2921.077 ± 0.18161.052 ± 0.1834
Potassium, Baseline (Day 1), n=308, 3084.16 ± 0.2814.17 ± 0.314
Potassium, Week 4, n=301, 3034.21 ± 0.3074.28 ± 0.352
Potassium, Week 8, n=229, 3034.16 ± 0.2964.22 ± 0.393
Potassium, Week 12, n=295, 2994.19 ± 0.3304.24 ± 0.332
Potassium, Week 16, n=284, 2984.18 ± 0.3164.23 ± 0.321
Potassium, Week 20, n=277, 3024.19 ± 0.3114.21 ± 0.320
Potassium, Week 24, n=284, 2984.18 ± 0.2874.23 ± 0.337
Potassium, Week 28, n=267, 2964.19 ± 0.3464.24 ± 0.391
Potassium, Week 32, n=275, 2944.18 ± 0.3684.21 ± 0.341
Potassium, Week 36, n=273, 2924.19 ± 0.3264.23 ± 0.345
Potassium, Week 40, n=270, 2934.20 ± 0.3014.23 ± 0.322
Potassium, Week 44, n=275, 2934.21 ± 0.3234.23 ± 0.359
Potassium, Week 48, n=265, 2924.15 ± 0.2714.16 ± 0.331
Sodium, Baseline (Day 1), n=308, 308139.0 ± 1.91139.0 ± 1.76
Sodium, Week 4, n=301, 303139.3 ± 1.70139.1 ± 1.87
Sodium, Week 8, n=229, 303139.1 ± 1.98139.0 ± 1.80
Sodium, Week 12, n=295, 299139.2 ± 1.84139.2 ± 1.85
Sodium, Week 16, n=284, 298139.1 ± 1.98139.1 ± 1.96
Sodium, Week 20, n=277, 302139.2 ± 1.87139.3 ± 1.81
Sodium, Week 24, n=284, 299139.3 ± 1.88139.3 ± 1.96
Sodium, Week 28, n=267, 296139.5 ± 1.77139.2 ± 2.01
Sodium, Week 32, n=275, 294139.3 ± 1.75139.5 ± 1.84
Sodium, Week 36, n=273, 292139.4 ± 1.79139.5 ± 2.15
Sodium, Week 40, n=270, 293139.4 ± 1.93139.5 ± 1.97
Sodium, Week 44, n=275, 293139.4 ± 1.80139.5 ± 1.93
Sodium, Week 48, n=265, 292139.4 ± 1.94139.4 ± 1.83
Urea, Baseline (Day 1), n=308, 3085.23 ± 1.5465.22 ± 1.632
Urea, Week 4, n=301, 3035.24 ± 1.4955.28 ± 1.549
Urea, Week 8, n=229, 3035.32 ± 1.6405.22 ± 1.529
Urea, Week 12, n=295, 2995.38 ± 1.6125.30 ± 1.649
Urea, Week 16, n=284, 2985.30 ± 1.6625.41 ± 1.659
Urea, Week 20, n=277, 3025.37 ± 1.6315.33 ± 1.662
Urea, Week 24, n=284, 2995.49 ± 1.7495.36 ± 1.639
Urea, Week 28, n=267, 2965.39 ± 1.7565.24 ± 1.527
Urea, Week 32, n=275, 2945.44 ± 1.6245.29 ± 1.599
Urea, Week 36, n=273, 2925.26 ± 1.6645.20 ± 1.485
Urea, Week 40, n=270, 2935.47 ± 1.5935.30 ± 1.537
Urea, Week 44, n=275, 2935.37 ± 1.5315.26 ± 1.524
Urea, Week 48, n=265, 2925.48 ± 1.6485.21 ± 1.437
SecondaryAbsolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

Blood samples were collected for the analysis of clinical chemistry parameter-lipase at indicated time points.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Units per liter
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Units per literCAB LA+RPV LA (Q4W)Current ART
Baseline, n=308, 30830.5 ± 22.8830.8 ± 19.12
Week 4, n=301, 30335.3 ± 52.7332.3 ± 23.30
Week 8, n=227, 30330.6 ± 22.7031.9 ± 20.71
Week 12, n=294, 29733.2 ± 27.9230.0 ± 18.06
Week 16, n=285, 29933.8 ± 30.4933.9 ± 34.69
Week 20, n=278, 30231.0 ± 21.7331.6 ± 28.88
Week 24, n=283, 29933.1 ± 24.0933.8 ± 29.69
Week 28, n=267, 29732.9 ± 27.4233.1 ± 19.69
Week 32, n=274, 29435.7 ± 60.6333.8 ± 21.64
Week 36, n=273, 29236.2 ± 51.5831.6 ± 18.46
Week 40, n=269, 29335.7 ± 36.0631.4 ± 15.80
Week 44, n=274, 29333.3 ± 26.2933.3 ± 20.44
Week 48, n=264, 29034.3 ± 30.9732.4 ± 20.40
SecondaryAbsolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance

Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance at indicated timepoints. Glomerular filtration rate (GFR) will be estimated by the central laboratory using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI).

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Milliliter per minute per 1.73meter^2
Absolute Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance
Milliliter per minute per 1.73meter^2CAB LA+RPV LA (Q4W)Current ART
Baseline, n=308, 308100.5 ± 18.30101.1 ± 17.72
Week 4, n=301, 30198.7 ± 17.2698.9 ± 17.93
Week 8, n=227, 303100.1 ± 17.1999.5 ± 17.59
Week 12, n=295, 297100.9 ± 17.7299.2 ± 18.34
Week 16, n=284, 297100.5 ± 17.2699.0 ± 18.32
Week 20, n=277, 30299.4 ± 17.3798.7 ± 17.73
Week 24, n=283, 29898.9 ± 17.0498.9 ± 17.44
Week 28, n=267, 29698.5 ± 17.6699.0 ± 17.33
Week 32, n=274, 29499.1 ± 16.8998.4 ± 17.54
Week 36, n=273, 29299.0 ± 17.1998.6 ± 16.85
Week 40, n=268, 29398.5 ± 17.3298.5 ± 17.37
Week 44, n=274, 29398.2 ± 16.9699.0 ± 17.39
Week 48, n=264, 29197.6 ± 16.9799.3 ± 17.09
SecondaryNumber of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48

The dipstick test gives results in a semi-quantitative manner and results for urinalysis parameters (ketones, glucose, bilirubin, occult blood, nitrite and blood protein) can be read as positive, trace, 1+, 2+, 3+ and 4+ indicating proportional concentrations in the urine sample. The urine parameters were graded according to Division of AIDS (DAIDS) scale where Grade 1 indicates mild (trace to 1+), Grade 2 indicates moderate (2+) and Grade 3 indicates severe (3+ or higher). Only participants with abnormal findings for urinalysis at any visit has been presented.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48.
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Urinalysis Parameters Over Time Including Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Urine bilirubin,Baseline (Day 1),Trace, n=303, 30100
Urine bilirubin, Baseline (Day 1), 1+, n=303, 30167
Urine bilirubin, Baseline (Day 1), 2+, n=303, 30100
Urine bilirubin, Baseline (Day 1), 3+, n=303, 30100
Urine glucose, Baseline (Day 1), Trace, n=303, 30111
Urine glucose, Baseline (Day 1), 1+, n=303, 30101
Urine glucose, Baseline (Day 1), 2+, n=303, 30100
Urine glucose, Baseline (Day 1), 3+, n=303, 30101
Urine ketones, Baseline (Day 1), Trace, n=303, 3011617
Urine ketones, Baseline (Day 1), 1+, n=303, 30140
Urine ketones, Baseline (Day 1), 2+, n=303, 30121
Urine ketones, Baseline (Day 1), 3+, n=303, 30100
Urine leukocyte esterase,Baseline,Trace,n=303,3012518
Urine leukocyte esterase, Baseline, 1+, n=303, 3011416
Urine leukocyte esterase, Baseline, 2+, n=303, 301148
Urine leukocyte esterase, Baseline, 3+, n=303, 30155
Urine nitrite, Baseline, positive, n=303, 3011111
Urine occult blood, Baseline, Trace, n=303, 3011912
Urine occult blood, Baseline, 1+, n=303, 30189
Urine occult blood, Baseline, 2+, n=303, 30175
Urine occult blood, Baseline, 3+, n=303, 30153
Urine protein, Baseline, Trace, n=303, 3011420
Urine protein, Baseline, 1+, n=303, 301612
Urine protein, Baseline, 2+, n=303, 30101
Urine protein, Baseline, 3+, n=303, 30100
Urine protein, Baseline, 4+, n=303, 30100
Urine bilirubin, Week 4, Trace, n=303, 30200
Urine bilirubin, Week 4, 1+, n=303, 30295
Urine bilirubin, Week 4, 2+, n=303, 30200
Urine bilirubin, Week 4, 3+, n=303, 30200
Urine glucose, Week 4, Trace, n=303, 30232
Urine glucose, Week 4, 1+, n=303, 30212
Urine glucose, Week 4, 2+, n=303, 30220
Urine glucose, Week 4, 3+, n=303, 30201
Urine ketones, Week 4, Trace, n=303, 302915
Urine ketones, Week 4, 1+, n=303, 30202
Urine ketones, Week 4, 2+, n=303, 30211
Urine ketones, Week 4, 3+, n=303, 30200
Urine leukocyte esterase, Week 4, Trace,n=303, 3022529
Urine leukocyte esterase, Week 4, 1+, n=303, 3021415
Urine leukocyte esterase, Week 4, 2+, n=303, 302149
Urine leukocyte esterase, Week 4, 3+, n=303, 30234
Urine nitrite, Week 4, positive, n=303, 3021012
Urine occult blood, Week 4, Trace, n=303, 3021518
Urine occult blood, Week 4, 1+, n=303, 302910
Urine occult blood, Week 4, 2+, n=303, 30255
Urine occult blood, Week 4, 3+, n=303, 30243
Urine protein, Week 4, Trace, n=303, 3021013
Urine protein, Week 4, 1+, n=303, 30287
Urine protein, Week 4, 2+, n=303, 30224
Urine protein, Week 4, 3+, n=303, 30200
Urine protein, Week 4, 4+, n=303, 30200
Urine bilirubin, Week 24, Trace, n=279, 29800
Urine bilirubin, Week 24, 1+, n=279, 2981013
Urine bilirubin, Week 24, 2+, n=279, 29800
Urine bilirubin, Week 24, 3+, n=279, 29800
Urine glucose, Week 24, Trace, n=279, 29801
Urine glucose, Week 24, 1+, n=279, 29820
Urine glucose, Week 24, 2+, n=279, 29801
Urine glucose, Week 24, 3+, n=279, 29811
Urine ketones, Week 24, Trace, n=279, 2981613
Urine ketones, Week 24, 1+, n=279, 29811
Urine ketones, Week 24, 2+, n=279, 29800
Urine ketones, Week 24, 3+, n=279, 29800
Urine leukocyte esterase,Week 24, Trace, n=279,2982217
Urine leukocyte esterase, Week 24, 1+, n=279, 2981414
Urine leukocyte esterase, Week 24, 2+, n=279, 298614
Urine leukocyte esterase, Week 24, 3+, n=279, 29837
Urine nitrite, Week 24, positive, n=279, 298910
Urine occult blood, Week 24, Trace, n=279, 2981310
Urine occult blood, Week 24, 1+, n=279, 29856
Urine occult blood, Week 24, 2+, n=279, 29864
Urine occult blood, Week 24, 3+, n=279, 29806
Urine protein, Week 24, Trace, n=279, 2981021
Urine protein, Week 24, 1+, n=279, 298412
Urine protein, Week 24, 2+, n=279, 29813
Urine protein, Week 24, 3+, n=279, 29800
Urine protein, Week 24, 4+, n=279, 29800
Urine bilirubin, Week 48, Trace, n=279, 29000
Urine bilirubin, Week 48, 1+, n=279, 29098
Urine bilirubin, Week 48, 2+, n=279, 29010
Urine bilirubin, Week 48, 3+, n=279, 29000
Urine glucose, Week 48, Trace, n=279, 29001
Urine glucose, Week 48, 1+, n=279, 29002
Urine glucose, Week 48, 2+, n=279, 29010
Urine glucose, Week 48, 3+, n=279, 29002
Urine ketones, Week 48, Trace, n=279, 290139
Urine ketones, Week 48, 1+, n=279, 29000
Urine ketones, Week 48, 2+, n=279, 29000
Urine ketones, Week 48, 3+, n=279, 29000
Urine leukocyte esterase, Week 48, Trace,n=279,2902427
Urine leukocyte esterase, Week 48, 1+, n=279, 2901315
Urine leukocyte esterase, Week 48, 2+, n=279, 29077
Urine leukocyte esterase, Week 48, 3+, n=279, 29056
Urine nitrite, Week 48, positive, n=279, 290106
Urine occult blood, Week 48, Trace, n=279, 2901112
Urine occult blood, Week 48, 1+, n=279, 29055
Urine occult blood, Week 48, 2+, n=279, 29044
Urine occult blood, Week 48, 3+, n=279, 29060
Urine protein, Week 48, Trace, n=279, 2901015
Urine protein, Week 48, 1+, n=279, 29046
Urine protein, Week 48, 2+, n=279, 29033
Urine protein, Week 48, 3+, n=279, 29000
Urine protein, Week 48, 4+, n=279, 29001
SecondaryNumber of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48

Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0).

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Count of participants · Participants
Number of Participants With Urine Potential of Hydrogen (pH) Over Time Including Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Baseline, pH=5, n=303, 3014442
Baseline, pH=5.5, n=303, 3017880
Baseline, pH=6, n=303, 3018572
Baseline, pH=6.5, n=303, 3014745
Baseline, pH=7, n=303, 3013234
Baseline, pH=7.5, n=303, 3011219
Baseline, pH=8, n=303, 30137
Baseline, pH=8.5, n=303, 30101
Baseline, pH>9.0, n=303, 30121
Week 4, pH=5, n=303, 3024153
Week 4, pH=5.5, n=303, 3027893
Week 4, pH=6, n=303, 3027367
Week 4, pH=6.5, n=303, 3024941
Week 4, pH=7, n=303, 3023828
Week 4, pH=7.5, n=303, 3021214
Week 4, pH=8, n=303, 30283
Week 4, pH=8.5, n=303, 30232
Week 4, pH>9.0, n=303, 30211
Week 24, pH=5, n=279, 2982326
Week 24, pH=5.5, n=279, 2988596
Week 24, pH=6, n=279, 2986667
Week 24, pH=6.5, n=279, 2984452
Week 24, pH=7, n=279, 2983231
Week 24, pH=7.5, n=279, 2981615
Week 24, pH=8, n=279, 29878
Week 24, pH=8.5, n=279, 29822
Week 24, pH>9.0, n=279, 29841
Week 48, pH=5, n=279, 2904543
Week 48, pH=5.5, n=279, 2906983
Week 48, pH=6, n=279, 2906158
Week 48, pH=6.5, n=279, 2904748
Week 48, pH=7, n=279, 2903130
Week 48, pH=7.5, n=279, 2901717
Week 48, pH=8, n=279, 29065
Week 48, pH=8.5, n=279, 29004
Week 48, pH>9.0, n=279, 29032
SecondaryChange From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK

Blood samples were collected for the analysis of clinical chemistry parameters including ALT, ALP, AST and CK. Baseline values is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · International units per liter
Change From Baseline in Clinical Chemistry Parameters Over Time Including Week 48: ALT, ALP, AST and CK
International units per literCAB LA+RPV LA (Q4W)Current ART
ALT, Week 4, n=301, 3030.8 ± 13.980.1 ± 9.65
ALT, Week 8, n=229, 3030.7 ± 15.351.6 ± 29.98
ALT, Week 12, n=295, 2995.2 ± 113.340.4 ± 11.60
ALT, Week 16, n=284, 298-0.1 ± 21.80-0.6 ± 10.14
ALT, Week 20, n=277, 302-0.8 ± 22.62-1.1 ± 10.86
ALT, Week 24, n=284, 2992.2 ± 61.65-0.6 ± 10.57
ALT, Week 28, n=267, 296-2.7 ± 11.14-0.2 ± 12.52
ALT, Week 32, n=275, 294-1.9 ± 14.44-0.5 ± 11.49
ALT, Week 36, n=273, 292-0.8 ± 23.510.1 ± 10.95
ALT, Week 40, n=270, 2930.6 ± 36.29-0.2 ± 11.82
ALT, Week 44, n=275, 293-2.2 ± 13.97-0.2 ± 12.37
ALT, Week 48, n=265, 292-1.9 ± 13.43-0.6 ± 10.50
ALP, Week 4, n=301, 303-6.0 ± 12.74-2.2 ± 8.85
ALP, Week 8, n=229, 303-6.7 ± 16.591.1 ± 20.99
ALP, Week 12, n=295, 299-8.0 ± 20.870.9 ± 14.45
ALP, Week 16, n=284, 298-9.7 ± 19.47-0.5 ± 10.35
ALP, Week 20, n=277, 302-9.2 ± 19.05-1.0 ± 11.65
ALP, Week 24, n=284, 299-9.0 ± 19.02-0.1 ± 10.67
ALP, Week 28, n=267, 296-10.1 ± 19.08-0.2 ± 11.44
ALP, Week 32, n=275, 294-9.9 ± 19.10-1.7 ± 11.29
ALP, Week 36, n=273, 292-10.5 ± 20.41-1.1 ± 11.44
ALP, Week 40, n=270, 293-10.4 ± 20.71-1.1 ± 11.34
ALP, Week 44, n=275, 293-11.4 ± 20.64-0.7 ± 12.02
ALP, Week 48, n=265, 292-10.9 ± 23.27-0.3 ± 12.51
AST, Week 4, n=301, 303-0.3 ± 12.520.2 ± 10.02
AST, Week 8, n=229, 3031.2 ± 19.73-0.1 ± 13.68
AST, Week 12, n=295, 2992.3 ± 65.030.6 ± 8.82
AST, Week 16, n=284, 2980.1 ± 18.49-0.1 ± 9.71
AST, Week 20, n=277, 302-0.5 ± 17.02-0.6 ± 9.80
AST, Week 24, n=284, 2980.1 ± 24.120.0 ± 9.57
AST, Week 28, n=267, 296-1.4 ± 8.770.3 ± 11.19
AST, Week 32, n=275, 294-1.2 ± 16.080.6 ± 13.40
AST, Week 36, n=273, 292-1.2 ± 12.950.1 ± 9.61
AST, Week 40, n=270, 293-0.2 ± 17.270.0 ± 10.64
AST, Week 44, n=275, 293-1.1 ± 16.510.1 ± 11.09
AST Week 48, n=265, 292-1.0 ± 12.790.7 ± 10.75
CK, Week 4, n=301, 303-0.1 ± 548.1530.8 ± 435.12
CK, Week 8, n=229, 30398.2 ± 1076.99-16.5 ± 344.96
CK, Week 12, n=295, 2996.0 ± 585.4514.9 ± 288.85
CK, Week 16, n=284, 29854.2 ± 882.235.8 ± 411.52
CK, Week 20, n=277, 30231.2 ± 653.11-16.7 ± 363.30
CK, Week 24, n=284, 299-9.2 ± 538.95-0.7 ± 353.99
CK, Week 28, n=267, 296-1.9 ± 213.9820.8 ± 538.83
CK, Week 32, n=275, 29413.3 ± 699.6034.0 ± 597.29
CK, Week 36, n=273, 292-18.2 ± 476.64-10.8 ± 358.72
CK, Week 40, n=270, 29339.7 ± 704.18-0.3 ± 373.96
CK, Week 44, n=275, 29347.4 ± 1185.55-10.9 ± 350.64
CK, Week 48, n=265, 292-0.6 ± 528.7118.1 ± 463.49
SecondaryChange From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin

Blood samples were collected for the analysis of clinical chemistry parameter-albumin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per liter
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Albumin
Grams per literCAB LA+RPV LA (Q4W)Current ART
Week 4, n=301, 303-0.5 ± 2.60-0.5 ± 2.49
Week 8, n=229, 303-0.3 ± 2.76-0.7 ± 2.70
Week 12, n=295, 299-0.6 ± 2.72-0.4 ± 2.63
Week 16, n=284, 298-0.6 ± 2.78-0.8 ± 2.70
Week 20, n=277, 302-0.8 ± 2.78-0.8 ± 2.56
Week 24, n=284, 299-0.7 ± 2.69-0.8 ± 2.59
Week 28, n=267, 296-0.7 ± 2.60-1.0 ± 2.47
Week 32, n=275, 294-0.6 ± 2.78-1.0 ± 2.56
Week 36, n=273, 292-0.9 ± 2.71-0.9 ± 2.65
Week 40, n=270, 293-0.5 ± 2.53-1.0 ± 2.61
Week 44, n=275, 293-0.4 ± 2.58-0.8 ± 2.47
Week 48, n=265, 292-0.4 ± 2.64-0.4 ± 2.55
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected for the analysis of clinical chemistry parameters including bilirubin, creatinine and direct bilirubin. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Micromoles per liter
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per literCAB LA+RPV LA (Q4W)Current ART
Bilirubin, Week 4, n=301, 303-0.8 ± 9.87-0.3 ± 4.17
Bilirubin, Week 8, n=229, 303-0.1 ± 6.920.1 ± 7.66
Bilirubin, Week 12, n=295, 299-0.6 ± 10.230.1 ± 4.56
Bilirubin, Week 16, n=284, 2980.2 ± 14.00-0.2 ± 4.12
Bilirubin, Week 20, n=277, 302-0.2 ± 10.040.0 ± 6.10
Bilirubin, Week 24, n=284, 298-0.6 ± 9.900.2 ± 5.90
Bilirubin, Week 28, n=267, 2960.0 ± 10.46-0.1 ± 4.76
Bilirubin, Week 32, n=275, 294-0.1 ± 10.360.0 ± 4.94
Bilirubin, Week 36, n=273, 292-0.6 ± 10.390.1 ± 4.55
Bilirubin, Week 40, n=270, 293-0.3 ± 10.610.2 ± 6.28
Bilirubin, Week 44, n=275, 293-0.4 ± 10.110.4 ± 5.24
Bilirubin, Week 48, n=265, 292-0.3 ± 10.570.2 ± 3.91
Direct bilirubin, Week 4, n=301, 303-0.1 ± 1.480.1 ± 1.20
Direct bilirubin, Week 8, n=229, 303-0.1 ± 1.420.2 ± 3.96
Direct bilirubin, Week 12, n=295, 299-0.2 ± 1.610.1 ± 1.21
Direct bilirubin, Week 16, n=284, 2980.1 ± 5.02-0.1 ± 1.12
Direct bilirubin, Week 20, n=277, 302-0.3 ± 1.52-0.2 ± 1.29
Direct bilirubin, Week 24, n=284, 298-0.2 ± 1.55-0.1 ± 1.24
Direct bilirubin, Week 28, n=267, 296-0.3 ± 1.55-0.2 ± 1.29
Direct bilirubin, Week 32, n=275, 294-0.3 ± 1.61-0.2 ± 1.24
Direct bilirubin, Week 36, n=273, 292-0.3 ± 1.70-0.1 ± 1.20
Direct bilirubin, Week 40, n=270, 293-0.3 ± 1.68-0.2 ± 1.18
Direct bilirubin, Week 44, n=275, 293-0.2 ± 1.55-0.1 ± 1.19
Direct bilirubin, Week 48, n=265, 292-0.2 ± 1.540.0 ± 1.23
Creatinine, Week 4, n=301, 3011.15 ± 8.2051.80 ± 8.022
Creatinine, Week 8, n=229, 303-0.66 ± 9.0421.23 ± 7.560
Creatinine, Week 12, n=295, 299-0.38 ± 9.3801.71 ± 7.638
Creatinine, Week 16, n=284, 298-0.60 ± 9.2251.62 ± 8.169
Creatinine, Week 20, n=277, 3020.53 ± 9.3901.80 ± 8.454
Creatinine, Week 24, n=284, 2980.90 ± 12.4941.36 ± 8.038
Creatinine, Week 28, n=267, 2961.14 ± 10.9981.59 ± 8.303
Creatinine, Week 32, n=275, 2940.33 ± 10.1021.95 ± 8.331
Creatinine, Week 36, n=273, 2920.34 ± 10.5851.62 ± 7.891
Creatinine, Week 40, n=270, 2930.88 ± 9.9861.64 ± 8.318
Creatinine, Week 44, n=275, 2931.03 ± 11.2531.40 ± 8.008
Creatinine, Week 48, n=265, 2921.59 ± 11.2530.82 ± 7.846
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48

Blood samples were collected for the analysis of clinical chemistry parameters which includes total CO2, chloride, glucose, phosphate, potassium, sodium and urea. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Clinical Chemistry Parameters Over Time Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
CO2, Week 4, n=301, 3031.0 ± 2.530.7 ± 2.21
CO2, Week 8, n=229, 3030.4 ± 2.310.6 ± 2.52
CO2, Week 12, n=295, 2990.5 ± 2.420.3 ± 2.39
CO2, Week 16, n=284, 2980.3 ± 2.420.5 ± 2.41
CO2, Week 20, n=277, 3020.2 ± 2.260.3 ± 2.31
CO2, Week 24, n=284, 2980.2 ± 2.460.2 ± 2.44
CO2, Week 28, n=267, 2960.1 ± 2.470.1 ± 2.39
CO2, Week 32, n=275, 2940.0 ± 2.370.2 ± 2.31
CO2, Week 36, n=273, 2920.2 ± 2.370.3 ± 2.39
CO2, Week 40, n=270, 2930.5 ± 2.490.4 ± 2.29
CO2, Week 44, n=275, 2930.5 ± 2.340.5 ± 2.19
CO2, Week 48, n=265, 2920.1 ± 2.410.2 ± 2.31
Chloride, Week 4, n=301, 3030.4 ± 2.050.5 ± 2.13
Chloride, Week 8, n=229, 3030.3 ± 2.120.5 ± 2.19
Chloride, Week 12, n=295, 2990.4 ± 2.300.5 ± 2.25
Chloride, Week 16, n=284, 2980.6 ± 2.410.8 ± 2.25
Chloride, Week 20, n=277, 3020.8 ± 2.320.8 ± 2.38
Chloride, Week 24, n=284, 2990.6 ± 2.480.9 ± 2.26
Chloride, Week 28, n=267, 2960.9 ± 2.211.0 ± 2.55
Chloride, Week 32, n=275, 2940.8 ± 2.410.9 ± 2.33
Chloride, Week 36, n=273, 2920.9 ± 2.180.9 ± 2.48
Chloride, Week 40, n=270, 2930.8 ± 2.240.8 ± 2.76
Chloride, Week 44, n=275, 2930.7 ± 2.200.8 ± 2.28
Chloride, Week 48, n=265, 2920.5 ± 2.360.3 ± 2.38
Glucose, Week 4, n=218, 2260.17 ± 0.7210.21 ± 0.900
Glucose, Week 8, n=151, 2130.22 ± 0.8410.22 ± 0.832
Glucose, Week 12, n=204, 2160.19 ± 0.8550.19 ± 0.974
Glucose, Week 16, n=207, 2110.23 ± 1.0500.27 ± 1.084
Glucose, Week 20, n=192, 2160.19 ± 0.7120.19 ± 0.961
Glucose, Week 24, n=212, 2240.23 ± 0.7100.16 ± 0.881
Glucose, Week 28, n=188, 2250.17 ± 0.7930.28 ± 0.903
Glucose, Week 32, n=192, 2130.35 ± 0.9560.27 ± 0.939
Glucose, Week 36, n=190, 2150.18 ± 0.8030.26 ± 1.070
Glucose, Week 40, n=193, 2130.27 ± 0.8330.25 ± 0.891
Glucose, Week 44, n=193, 2130.23 ± 0.8950.27 ± 0.898
Glucose, Week 48, n=238, 2740.04 ± 0.6930.02 ± 0.924
Phosphate, Week 4, n=301, 3030.066 ± 0.16660.015 ± 0.1595
Phosphate, Week 8, n=229, 3030.062 ± 0.1862-0.006 ± 0.1609
Phosphate, Week 12, n=295, 2990.041 ± 0.19780.013 ± 0.1742
Phosphate, Week 16, n=284, 2980.041 ± 0.20120.003 ± 0.1640
Phosphate, Week 20, n=277, 3020.035 ± 0.18710.010 ± 0.1839
Phosphate, Week 24, n=284, 2990.042 ± 0.19630.006 ± 0.1845
Phosphate, Week 28, n=267, 2960.037 ± 0.18220.004 ± 0.1823
Phosphate, Week 32, n=275, 2940.021 ± 0.19800.005 ± 0.1886
Phosphate, Week 36, n=273, 2920.011 ± 0.1846-0.002 ± 0.1855
Phosphate, Week 40, n=270, 2930.024 ± 0.2035-0.004 ± 0.1736
Phosphate, Week 44, n=275, 2930.027 ± 0.19820.004 ± 0.1811
Phosphate, Week 48, n=265, 2920.034 ± 0.20070.003 ± 0.1741
Potassium, Week 4, n=301, 3030.05 ± 0.3420.11 ± 0.375
Potassium, Week 8, n=229, 3030.01 ± 0.3110.06 ± 0.393
Potassium, Week 12, n=295, 2990.04 ± 0.3410.08 ± 0.356
Potassium, Week 16, n=284, 2980.01 ± 0.3410.06 ± 0.340
Potassium, Week 20, n=277, 3020.04 ± 0.3450.05 ± 0.359
Potassium, Week 24, n=284, 2980.03 ± 0.3250.07 ± 0.337
Potassium, Week 28, n=267, 2960.04 ± 0.3800.07 ± 0.389
Potassium, Week 32, n=275, 2940.02 ± 0.3900.05 ± 0.347
Potassium, Week 36, n=273, 2920.03 ± 0.3560.07 ± 0.359
Potassium, Week 40, n=270, 2930.04 ± 0.3440.07 ± 0.350
Potassium, Week 44, n=275, 2930.06 ± 0.3440.07 ± 0.372
Potassium, Week 48, n=265, 292-0.02 ± 0.2990.00 ± 0.332
Sodium, Week 4, n=301, 3030.3 ± 1.840.1 ± 1.99
Sodium, Week 8, n=229, 3030.2 ± 1.99-0.1 ± 1.92
Sodium, Week 12, n=295, 2990.2 ± 2.070.2 ± 1.91
Sodium, Week 16, n=284, 2980.1 ± 2.180.1 ± 2.06
Sodium, Week 20, n=277, 3020.3 ± 2.100.3 ± 1.95
Sodium, Week 24, n=284, 2990.3 ± 2.070.2 ± 1.95
Sodium, Week 28, n=267, 2960.5 ± 2.110.2 ± 2.24
Sodium, Week 32, n=275, 2940.3 ± 2.050.4 ± 1.89
Sodium, Week 36, n=273, 2920.5 ± 2.010.5 ± 2.19
Sodium, Week 40, n=270, 2930.4 ± 2.020.5 ± 2.07
Sodium, Week 44, n=275, 2930.5 ± 2.030.5 ± 2.05
Sodium, Week 48, n=265, 2920.4 ± 2.200.3 ± 1.95
Urea, Week 4, n=301, 3030.01 ± 1.3690.08 ± 1.334
Urea, Week 8, n=229, 3030.07 ± 1.4530.00 ± 1.363
Urea, Week 12, n=295, 2990.15 ± 1.4090.09 ± 1.381
Urea, Week 16, n=284, 2980.08 ± 1.3870.19 ± 1.496
Urea, Week 20, n=277, 3020.15 ± 1.3990.11 ± 1.461
Urea, Week 24, n=284, 2990.25 ± 1.4200.15 ± 1.311
Urea, Week 28, n=267, 2960.15 ± 1.5240.00 ± 1.439
Urea, Week 32, n=275, 2940.20 ± 1.5110.06 ± 1.415
Urea, Week 36, n=273, 2920.06 ± 1.420-0.02 ± 1.386
Urea, Week 40, n=270, 2930.19 ± 1.4000.09 ± 1.452
Urea, Week 44, n=275, 2930.13 ± 1.4260.02 ± 1.467
Urea, Week 48, n=265, 2920.24 ± 1.465-0.01 ± 1.312
SecondaryChange From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase

Blood samples were collected for the analysis of clinical chemistry parameter-lipase. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Units per liter
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Lipase
Units per literCAB LA+RPV LA (Q4W)Current ART
Week 4, n=301, 3035.2 ± 41.421.5 ± 23.88
Week 8, n=227, 3031.2 ± 19.311.0 ± 17.96
Week 12, n=294, 2972.7 ± 25.12-0.8 ± 18.59
Week 16, n=285, 2992.6 ± 24.793.5 ± 31.03
Week 20, n=278, 3020.9 ± 15.650.8 ± 28.95
Week 24, n=283, 2992.1 ± 20.793.0 ± 23.85
Week 28, n=267, 2972.2 ± 24.932.3 ± 18.96
Week 32, n=274, 2945.2 ± 57.443.1 ± 21.31
Week 36, n=273, 2925.1 ± 49.920.7 ± 17.39
Week 40, n=269, 2935.1 ± 33.580.5 ± 17.60
Week 44, n=274, 2932.0 ± 22.572.3 ± 21.13
Week 48, n=264, 2903.0 ± 28.261.5 ± 19.00
SecondaryChange From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.

Blood samples were collected for the analysis of clinical chemistry parameter-creatinine clearance. GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Milliliters per minute per 1.73meter^2
Change From Baseline Values for Clinical Chemistry Parameter Over Time Including Week 48: Creatinine Clearance.
Milliliters per minute per 1.73meter^2CAB LA+RPV LA (Q4W)Current ART
Week 4, n=301, 301-1.8 ± 9.51-2.3 ± 9.18
Week 8, n=227, 3030.4 ± 9.88-1.5 ± 8.06
Week 12, n=295, 2970.3 ± 10.28-1.9 ± 8.02
Week 16, n=284, 2970.4 ± 10.63-1.9 ± 8.69
Week 20, n=277, 302-1.0 ± 10.37-2.4 ± 8.55
Week 24, n=283, 298-1.0 ± 10.52-2.3 ± 8.76
Week 28, n=267, 296-1.8 ± 11.47-2.4 ± 8.93
Week 32, n=274, 294-1.2 ± 11.11-3.0 ± 8.94
Week 36, n=273, 292-1.2 ± 11.26-2.6 ± 8.52
Week 40, n=268, 293-1.7 ± 10.70-2.7 ± 9.10
Week 44, n=274, 293-2.1 ± 10.45-2.3 ± 8.74
Week 48, n=264, 291-2.5 ± 11.80-1.9 ± 8.50
SecondaryChange From Baseline Values for Fasting Lipid Panel Over Time Including Week 48

Blood samples were collected for the analysis of fasting lipid parameters- total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Fasting Lipid Panel Over Time Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
Total cholesterol, Week 48, n=231, 2420.08 ± 0.688-0.04 ± 0.665
HDL cholesterol, Week 48, n=231, 2420.040 ± 0.27020.002 ± 0.2682
LDL cholesterol, Week 48, n=224, 2380.098 ± 0.6105-0.017 ± 0.5314
Triglycerides, Week 48, n=231, 242-0.159 ± 0.8670-0.033 ± 0.7844
SecondaryChange From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine albumin/creatinine ratio and urine protein/creatinine ratio.Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Grams per mole
Change From Baseline Values in Urine Albumin/Creatinine Ratio and Urine Protein/Creatinine Ratio Over Time Including Week 48
Grams per moleCAB LA+RPV LA (Q4W)Current ART
Urine albumin/creatinine ratio, Week 4,n=210, 2210.32 ± 3.9480.06 ± 6.383
Urine albumin/creatinine ratio, Week 24,n=198, 208-0.08 ± 3.360-0.11 ± 8.552
Urine albumin/creatinine ratio, Week 48,n=191, 1970.15 ± 6.049-0.14 ± 5.286
Urine protein/creatinine, Week 4, n=234, 236-0.66 ± 11.8031.85 ± 31.997
Urine protein/creatinine, Week 24, n=208, 232-2.49 ± 8.0281.67 ± 20.505
Urine protein/creatinine, Week 48, n=206, 225-1.72 ± 9.5516.70 ± 112.353
SecondaryChange From Baseline Values in Urine Creatinine Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine creatinine. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Micromoles per liter
Change From Baseline Values in Urine Creatinine Over Time Including Week 48
Micromoles per literCAB LA+RPV LA (Q4W)Current ART
Week 4, n=304, 302-543.9 ± 8693.94-305.5 ± 8787.62
Week 24, n=282, 297-341.8 ± 9286.26-270.4 ± 8437.76
Week 48, n=282, 291-342.9 ± 8965.01-521.6 ± 7873.28
SecondaryChange From Baseline Values in Urine Phosphate Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine phosphate. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Millimoles per liter
Change From Baseline Values in Urine Phosphate Over Time Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
Week 4, n=302, 300-0.460 ± 15.27071.483 ± 15.0378
Week 24, n=281, 2940.286 ± 16.18870.640 ± 14.4201
Week 48, n=280, 291-0.369 ± 14.24411.254 ± 15.6532
SecondaryChange From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine retinol binding protein. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Nanomoles per liter
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48
Nanomoles per literCAB LA+RPV LA (Q4W)Current ART
Change From Baseline Values in Urine Retinol Binding Protein Over Time Including Week 48-1.8913 ± 14.101251.4289 ± 15.70559
SecondaryChange From Baseline Values in Urine Specific Gravity Over Time Including Week 48

Urine biomarker samples were collected for the analysis of urine specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. The urine specific gravity was measured as the ratio of urine density compared with water density.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · Ratio of urine density to water density
Change From Baseline Values in Urine Specific Gravity Over Time Including Week 48
Ratio of urine density to water densityCAB LA+RPV LA (Q4W)Current ART
Week 4, n=298, 295-0.0009 ± 0.00800-0.0000 ± 0.00785
Week 24, n=274, 291-0.0008 ± 0.00784-0.0000 ± 0.00770
Week 48, n=274, 283-0.0009 ± 0.00772-0.0002 ± 0.00768
SecondaryChange From Baseline Values in Urine pH Over Time Including Week 48

Urine samples were collected for analysis of urine pH. pH is calculated on a scale of 0 to 14, values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH of less than 7 is acidic and a pH of greater than 7 is basic. Normal urine has a slightly acidic pH (5.0-6.0). The dipstick test gives results in a semi-quantitative manner. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 24 and 48
Reported as:
Mean · pH
Change From Baseline Values in Urine pH Over Time Including Week 48
pHCAB LA+RPV LA (Q4W)Current ART
Week 4, n=298, 2950.08 ± 0.886-0.13 ± 0.935
Week 24, n=274, 2910.18 ± 1.0210.01 ± 0.870
Week 48, n=274, 2830.09 ± 1.036-0.02 ± 0.951
SecondaryNumber of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Number of Participants Who Discontinued or Withdrawn Due to AEs Over Time Including Week 48135
SecondaryPercentage Change From Baseline in Fasting Lipids Overtime Including Week 48

Blood samples were collected at Baseline and at Week 48 to assess fasting lipids which included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Percentage change from Baseline is calculated as: value at Week 48 minus Baseline value divided by Baseline value multiplied by 100.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Percent change
Percentage Change From Baseline in Fasting Lipids Overtime Including Week 48
Percent changeCAB LA+RPV LA (Q4W)Current ART
Cholesterol, Week 48, Overall, n=231, 2423.25 ± 15.5630.13 ± 13.379
HDL cholesterol, Week 48, Overall, n=231, 2425.059 ± 20.53682.132 ± 18.0473
LDL cholesterol, Week 48, Overall, n=224, 2386.762 ± 31.72091.029 ± 19.4719
Triglycerides, Week 48, Overall, n=231, 2420.708 ± 43.51608.203 ± 51.7632
SecondaryNumber of Participants With Phenotypic Resistance Through Week 48

Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria.The CVF population comprised of all participants in ITT-E population who met CVF criteria.Phenotypic Resistance data for following drugs:CAB,dolutegravir(DTG),elvitegravir(EVG), raltegravir(RAL),delavirdine(DLV),efavirenz(EFV),etravirine(ETR),nevirapine(NVP),RPV,lamivudine(3TC),abacavir(ABC),emtricitabine(FTC),tenofovir(TDF),zidovudine(ZDV),stavudine(d4T),didanosine(ddI), atazanavir(ATV),darunavir(DRV),fosamprenavir(FPV),indinavir(IDV),lopinavir(LPV),nelfinavir(NFV),rito-navir(RTV),saquinavir(SQV) and tipranavir(TPV) in participants meeting CVF criteria is presented.Phenotypic resistance, partially sensitive, and Sensitive were defined based on fold change(FC) value from Monogram as:resistance(FC\>clinical higher cutoff/biologic cutoff),partially sensitive(FC \<=clinical higher cutoff and \> clinical lower cutoff),sensitive(FC \<= clinical lower cutoff/biologic cutoff).

Time frame:
At the time of CVF
Reported as:
Count of participants · Participants
Number of Participants With Phenotypic Resistance Through Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
INI, CAB, resistant, n=3, 410
INI, CAB, sensitive, n=3, 424
INI, DTG, resistant, n=3, 400
INI, DTG, partially sensitive, n=3, 400
INI, DTG, sensitive, n=3, 434
INI, EVG, resistant, n=3, 410
INI, EVG, sensitive, n=3, 424
INI, RAL, resistant, n=3, 410
INI, RAL, sensitive, n=3, 424
NNRTI, DLV, resistant, n=3, 320
NNRTI, DLV, sensitive, n=3, 313
NNRTI, EFV, resistant, n=3, 320
NNRTI, EFV, sensitive, n=3, 313
NNRTI, ETR, resistant, n=3, 300
NNRTI, ETR, partially sensitive, n=3, 320
NNRTI, ETR, sensitive, n=3, 313
NNRTI, NVP, resistant, n=3, 320
NNRTI, NVP, sensitive, n=3, 313
NNRTI, RPV, resistant, n=3, 330
NNRTI, RPV, sensitive, n=3, 303
NRTI, 3TC, resistant, n=3, 301
NRTI, 3TC, sensitive, n=3, 332
NRTI, ABC, resistant, n=3, 300
NRTI, ABC, partially sensitive, n=3, 300
NRTI, ABC, sensitive, n=3, 333
NRTI, FTC, resistant, n=3, 301
NRTI, FTC, sensitive, n=3, 332
NRTI, TDF, resistant, n=3, 300
NRTI, TDF, partially sensitive, n=3, 300
NRTI, TDF, sensitive, n=3, 333
NRTI, ZDV, resistant, n=3, 310
NRTI, ZDV, sensitive, n=3, 323
NRTI, d4T, resistant, n=3, 300
NRTI, d4T, sensitive, n=3, 333
NRTI, ddI, resistant, n=3, 300
NRTI, ddI, partially sensitive, n=3, 300
NRTI, ddI, sensitive, n=3, 333
PI, ATV, resistant, n=3, 300
PI, ATV, sensitive, n=3, 333
PI, DRV, resistant, n=3, 300
PI, DRV, partially sensitive, n=3, 300
PI, DRV, sensitive, n=3, 333
PI, FPV, resistant, n=3, 300
PI, FPV, partially sensitive, n=3, 300
PI, FPV, sensitive, n=3, 333
PI, IDV, resistant, n=3, 300
PI, IDV, sensitive, n=3, 333
PI, LPV, resistant, n=3, 300
PI, LPV, partially sensitive, n=3, 300
PI, LPV, sensitive, n=3, 333
PI, NFV, resistant, n=3, 300
PI, NFV, sensitive, n=3, 333
PI, RTV, resistant, n=3, 300
PI, RTV, sensitive, n=3, 333
PI, SQV, resistant, n=3, 300
PI, SQV, partially sensitive, n=3, 300
PI, SQV, sensitive, n=3, 333
PI, TPV, resistant, n=3, 300
PI, TPV, partially sensitive, n=3, 300
PI, TPV, sensitive, n=3, 333
SecondaryNumber of Participants With Genotypic Resistance Through Week 48

Plasma samples were collected and analyzed from participants who met confirmed virologic withdrawal criteria. Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.

Time frame:
At the time of CVF
Reported as:
Count of participants · Participants
Number of Participants With Genotypic Resistance Through Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
INI, DTG, resistant00
INI, DTG, resistance possible00
INI, DTG, sensitive34
INI, EVG, resistant10
INI, EVG, resistance possible00
INI, EVG, sensitive24
INI, RAL, resistant10
INI, RAL, resistance possible00
INI, RAL, sensitive24
NNRTI, DLV, resistant00
NNRTI, DLV, resistance possible00
NNRTI, DLV, sensitive34
NNRTI, EFV, resistant11
NNRTI, EFV, resistance possible00
NNRTI, EFV, sensitive23
NNRTI, ETR, resistant00
NNRTI, ETR, resistance possible20
NNRTI, ETR, sensitive14
NNRTI, NVP, resistant11
NNRTI, NVP, resistance possible00
NNRTI, NVP, sensitive23
NNRTI, RPV, resistant31
NNRTI, RPV, resistance possible00
NNRTI, RPV, sensitive03
NRTI, 3TC, resistant02
NNRTI, 3TC, resistance possible00
NRTI, 3TC, sensitive32
NRTI, ABC, resistant00
NRTI, ABC, resistance possible00
NRTI, ABC, sensitive34
NRTI, FTC, resistant02
NRTI, FTC, resistance possible00
NRTI, FTC, sensitive32
NRTI, TDF, resistant00
NRTI, TDF, resistance possible00
NRTI, TDF, sensitive34
NRTI, ZDV, resistant00
NRTI, ZDV, resistance possible00
NRTI, ZDV, sensitive34
NRTI, d4T, resistant00
NRTI, d4T, resistance possible00
NRTI, d4T, sensitive34
NRTI, ddI, resistant00
NRTI, ddI, resistance possible02
NRTI, ddI, sensitive32
PI, ATV, resistant10
PI, ATV, resistance possible00
PI, ATV, sensitive24
PI, ATV/r, resistant00
PI, ATV/r, resistance possible10
PI, ATV/r, sensitive24
PI, DRV/r, resistant00
PI, DRV/r, resistance possible00
PI, DRV/r, sensitive34
PI, FPV/r, resistant00
PI, FPV/r, resistance possible00
PI, FPV/r, sensitive34
PI, IDV/r, resistant00
PI, IDV/r, resistance possible00
PI, IDV/r, sensitive34
PI, LPV/r, resistant00
PI, LPV/r, resistance possible00
PI, LPV/r, sensitive34
PI, NFV, resistant10
PI, NFV, resistance possible00
PI, NFV, sensitive24
PI, RTV, resistant00
PI, RTV, resistance possible00
PI, RTV, sensitive34
PI, SQV/r, resistant00
PI, SQV/r, resistance possible00
PI, SQV/r, sensitive34
PI, TPV/r, resistant00
PI, TPV/r, resistance possible00
PI, TPV/r, sensitive34
SecondaryNumber of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With AEs by Using Baseline Third Agent Treatment Class Overtime Including Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
Any AE, INI, n=102, 999968
Any AE, NNRTI, n=155, 155148116
Any AE, PI, n=51, 544736
SecondaryAbsolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK

Blood samples were collected for the analysis of clinical chemistry parameters to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · International units per liter
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK
International units per literCAB LA+RPV LA (Q4W)Current ART
PI, ALT, Baseline, n=51, 5419.3 ± 11.2318.7 ± 9.13
PI, ALT, Week 4, n=51, 5328.7 ± 20.1219.8 ± 12.29
PI, ALT, Week 8, n=34, 5325.8 ± 19.2819.6 ± 10.43
PI, ALT, Week 12, n=50, 5224.7 ± 17.0920.1 ± 14.19
PI, ALT, Week 16, n=48, 5326.3 ± 19.8920.0 ± 12.04
PI, ALT, Week 20, n=46, 5324.9 ± 18.4619.0 ± 9.52
PI, ALT, Week 24, n=47, 5324.1 ± 13.7519.1 ± 10.02
PI, ALT, Week 28, n=42, 5322.0 ± 12.4219.4 ± 10.45
PI, ALT, Week 32, n=45, 5122.7 ± 15.1818.8 ± 8.18
PI, ALT, Week 36, n=44, 5022.3 ± 15.0920.7 ± 13.18
PI, ALT, Week 40, n=42, 5124.9 ± 19.6319.5 ± 13.46
PI, ALT, Week 44, n=47, 5123.2 ± 17.0519.3 ± 14.23
PI, ALT, Week 48, n=43, 5022.5 ± 13.2819.0 ± 8.52
INI, ALT, Baseline, n=102, 9924.8 ± 15.2321.2 ± 10.93
INI, ALT, Week 4, n=99, 9726.5 ± 18.3521.7 ± 10.09
INI, ALT, Week 8, n=73, 9828.4 ± 22.7726.8 ± 49.37
INI, ALT, Week 12, n=99, 9523.8 ± 14.2122.9 ± 16.05
INI, ALT, Week 16, n=93, 9623.2 ± 13.6221.2 ± 11.24
INI, ALT, Week 20, n=93, 9723.0 ± 15.2920.7 ± 9.83
INI, ALT, Week 24, n=94, 9525.7 ± 20.0921.0 ± 13.40
INI, ALT, Week 28, n=89, 9321.5 ± 13.0620.9 ± 14.10
INI, ALT, Week 32, n=93, 9522.5 ± 10.9521.1 ± 12.32
INI, ALT, Week 36, n=94, 9526.5 ± 38.4120.5 ± 9.38
INI, ALT, Week 40, n=90, 9530.2 ± 61.8020.6 ± 9.20
INI, ALT, Week 44, n=91, 9423.2 ± 15.0320.7 ± 10.01
INI, ALT, Week 48, n=91, 9524.4 ± 17.5820.3 ± 9.79
NNRTI, ALT, Baseline, n=155, 15524.6 ± 12.6724.4 ± 14.74
NNRTI, ALT, Week 4, n=151, 15321.6 ± 10.7223.7 ± 11.16
NNRTI, ALT, Week 8, n=122, 15220.8 ± 10.1323.7 ± 12.94
NNRTI, ALT, Week 12, n=146, 15233.9 ± 161.8123.6 ± 11.27
NNRTI, ALT, Week 16, n=143, 14923.2 ± 27.1822.8 ± 11.06
NNRTI, ALT, Week 20, n=138, 15222.6 ± 27.3622.3 ± 11.15
NNRTI, ALT, Week 24, n=143, 15127.4 ± 85.7022.9 ± 12.88
NNRTI, ALT, Week 28, n=136, 15020.6 ± 11.4523.8 ± 16.00
NNRTI, ALT, Week 32, n=137, 14821.1 ± 12.6923.4 ± 12.86
NNRTI, ALT, Week 36, n=135, 14721.2 ± 12.3824.1 ± 13.19
NNRTI, ALT, Week 40, n=138, 14720.8 ± 10.6323.9 ± 14.24
NNRTI, ALT, Week 44, n=137, 14820.0 ± 9.6123.9 ± 15.22
NNRTI, ALT, Week 48, n=131, 14719.8 ± 9.6223.5 ± 12.32
PI, ALP, Baseline, n=51, 5473.8 ± 24.9070.2 ± 19.56
PI, ALP, Week 4, n=51, 5370.4 ± 20.0367.7 ± 19.24
PI, ALP, Week 8, n=34, 5372.4 ± 34.8670.9 ± 23.18
PI, ALP, Week 12, n=50, 5268.2 ± 17.4971.6 ± 23.60
PI, ALP, Week 16, n=48, 5366.9 ± 15.7071.2 ± 21.50
PI, ALP, Week 20, n=46, 5367.7 ± 16.3670.8 ± 20.96
PI, ALP, Week 24, n=47, 5367.6 ± 16.1470.3 ± 19.23
PI, ALP, Week 28, n=42, 5367.3 ± 17.7173.7 ± 21.89
PI, ALP, Week 32, n=45, 5163.8 ± 16.0969.8 ± 21.44
PI, ALP, Week 36, n=44, 5064.3 ± 16.5071.7 ± 23.57
PI, ALP, Week 40, n=42, 5165.5 ± 13.6368.5 ± 19.55
PI, ALP, Week 44, n=47, 5163.0 ± 15.7669.1 ± 20.67
PI, ALP, Week 48, n=43, 5063.6 ± 14.2269.9 ± 18.94
INI, ALP, Baseline, n=102, 9966.3 ± 17.3164.9 ± 19.05
INI, ALP, Week 4, n=99, 9765.9 ± 17.2564.4 ± 18.77
INI, ALP, Week 8, n=73, 9864.0 ± 16.2169.7 ± 38.92
INI, ALP, Week 12, n=99, 9564.7 ± 16.3367.7 ± 27.73
INI, ALP, Week 16, n=93, 9665.3 ± 17.0164.4 ± 20.89
INI, ALP, Week 20, n=93, 9764.9 ± 16.8064.2 ± 19.58
INI, ALP, Week 24, n=94, 9565.0 ± 17.0864.4 ± 19.46
INI, ALP, Week 28, n=89, 9365.0 ± 15.8163.3 ± 18.76
INI, ALP, Week 32, n=93, 9564.4 ± 16.1262.3 ± 17.96
INI, ALP, Week 36, n=94, 9564.3 ± 18.1562.2 ± 18.12
INI, ALP, Week 40, n=90, 9565.1 ± 17.0762.2 ± 18.22
INI, ALP, Week 44, n=91, 9464.0 ± 16.7164.1 ± 19.31
INI, ALP, Week 48, n=91, 9565.1 ± 15.9863.0 ± 18.76
NNRTI, ALP, Baseline, n=155, 15584.4 ± 32.4788.1 ± 28.83
NNRTI, ALP, Week 4, n=151, 15373.4 ± 26.1685.6 ± 27.39
NNRTI, ALP, Week 8, n=122, 15270.9 ± 20.0087.4 ± 28.15
NNRTI, ALP, Week 12, n=146, 15272.0 ± 30.6887.8 ± 28.30
NNRTI, ALP, Week 16, n=143, 14969.9 ± 22.3787.7 ± 28.55
NNRTI, ALP, Week 20, n=138, 15269.3 ± 20.5186.7 ± 26.18
NNRTI, ALP, Week 24, n=143, 15170.2 ± 21.0888.3 ± 27.77
NNRTI, ALP, Week 28, n=136, 15069.3 ± 20.9187.0 ± 28.40
NNRTI, ALP, Week 32, n=137, 14869.1 ± 21.6086.5 ± 26.32
NNRTI, ALP, Week 36, n=135, 14769.3 ± 23.2287.1 ± 26.24
NNRTI, ALP, Week 40, n=138, 14767.1 ± 18.9887.8 ± 27.07
NNRTI, ALP, Week 44, n=137, 14868.4 ± 19.9487.5 ± 26.53
NNRTI, ALP, Week 48, n=131, 14768.5 ± 21.6988.6 ± 27.61
PI, AST, Baseline, n=51, 5419.7 ± 6.9720.1 ± 5.66
PI, AST, Week 4, n=51, 5323.5 ± 9.7622.5 ± 17.53
PI, AST, Week 8, n=34, 5323.4 ± 11.0420.0 ± 5.24
PI, AST, Week 12, n=50, 5222.5 ± 11.6021.8 ± 9.63
PI, AST, Week 16, n=48, 5323.7 ± 15.7722.0 ± 10.39
PI, AST, Week 20, n=46, 5324.1 ± 20.5320.6 ± 6.35
PI, AST, Week 24, n=47, 5321.5 ± 7.0221.7 ± 11.65
PI, AST, Week 28, n=42, 5322.9 ± 9.2022.0 ± 8.47
PI, AST, Week 32, n=45, 5123.0 ± 13.5120.3 ± 5.57
PI, AST, Week 36, n=44, 5021.5 ± 7.8821.8 ± 7.04
PI, AST, Week 40, n=42, 5125.1 ± 23.5120.5 ± 7.55
PI, AST, Week 44, n=47, 5121.6 ± 8.8021.4 ± 13.16
PI, AST, Week 48, n=43, 5021.6 ± 7.5922.2 ± 8.85
INI, AST, Baseline, n=102, 9924.5 ± 13.0322.2 ± 13.13
INI, AST, Week 4, n=99, 9724.5 ± 13.2222.0 ± 10.41
INI, AST, Week 8, n=73, 9826.8 ± 25.3423.6 ± 19.30
INI, AST, Week 12, n=99, 9523.2 ± 10.4723.2 ± 13.10
INI, AST, Week 16, n=93, 9622.5 ± 8.7822.5 ± 9.96
INI, AST, Week 20, n=93, 9722.8 ± 10.1121.4 ± 6.12
INI, AST, Week 24, n=94, 9524.4 ± 12.4222.0 ± 9.44
INI, AST, Week 28, n=89, 9321.3 ± 7.1421.6 ± 8.49
INI, AST, Week 32, n=93, 9522.2 ± 7.7721.6 ± 7.87
INI, AST, Week 36, n=94, 9523.9 ± 15.0621.1 ± 5.43
INI, AST, Week 40, n=90, 9525.4 ± 18.0121.8 ± 7.30
INI, AST, Week 44, n=91, 9425.6 ± 23.2921.4 ± 6.51
INI, AST, Week 48, n=91, 9524.9 ± 13.8822.4 ± 9.70
NNRTI, AST, Baseline, n=155, 15524.8 ± 10.9923.6 ± 9.16
NNRTI, AST, Week 4, n=151, 15322.2 ± 11.3523.2 ± 7.95
NNRTI, AST, Week 8, n=122, 15223.0 ± 17.1622.8 ± 7.19
NNRTI, AST, Week 12, n=146, 15229.4 ± 91.3423.6 ± 9.12
NNRTI, AST, Week 16, n=143, 14925.3 ± 22.9122.6 ± 6.80
NNRTI, AST, Week 20, n=138, 15223.8 ± 16.1222.9 ± 7.33
NNRTI, AST, Week 24, n=143, 15025.1 ± 30.4023.1 ± 8.25
NNRTI, AST, Week 28, n=136, 15022.6 ± 9.4924.0 ± 10.53
NNRTI, AST, Week 32, n=137, 14823.2 ± 16.6925.1 ± 15.63
NNRTI, AST, Week 36, n=135, 14722.8 ± 8.9023.9 ± 7.99
NNRTI, AST, Week 40, n=138, 14722.3 ± 7.6623.7 ± 8.01
NNRTI, AST, Week 44, n=137, 14821.7 ± 7.1123.8 ± 10.98
NNRTI, AST, Week 48, n=131, 14722.0 ± 7.8624.2 ± 9.16
PI, CK, Baseline, n=51, 54121.3 ± 173.52111.8 ± 66.03
PI, CK, Week 4, n=51, 53130.0 ± 94.61244.2 ± 908.06
PI, CK, Week 8, n=34, 53157.7 ± 174.37134.2 ± 179.01
PI, CK, Week 12, n=50, 52124.2 ± 71.36168.8 ± 406.86
PI, CK, Week 16, n=48, 53142.3 ± 197.96127.0 ± 82.59
PI, CK, Week 20, n=46, 53227.9 ± 689.65117.5 ± 76.83
PI, CK, Week 24, n=47, 53120.8 ± 72.63128.9 ± 85.38
PI, CK, Week 28, n=42, 53185.9 ± 237.49124.2 ± 96.15
PI, CK, Week 32, n=45, 51282.5 ± 959.49110.1 ± 58.84
PI, CK, Week 36, n=44, 50115.5 ± 81.36130.9 ± 95.59
PI, CK, Week 40, n=42, 51319.4 ± 1169.15109.9 ± 53.99
PI, CK, Week 44, n=47, 51117.2 ± 74.25114.4 ± 62.44
PI, CK, Week 48, n=43, 50123.5 ± 90.77183.1 ± 485.07
INI, CK, Baseline, n=102, 99257.9 ± 565.99214.3 ± 627.94
INI, CK, Week 4, n=99, 97225.9 ± 484.50193.6 ± 415.15
INI, CK, Week 8, n=73, 98306.8 ± 791.76158.0 ± 164.72
INI, CK, Week 12, n=99, 95242.5 ± 649.06195.3 ± 383.74
INI, CK, Week 16, n=93, 96198.6 ± 335.16216.4 ± 422.21
INI, CK, Week 20, n=93, 97200.9 ± 301.61158.8 ± 156.94
INI, CK, Week 24, n=94, 95202.1 ± 276.49178.8 ± 356.60
INI, CK, Week 28, n=89, 93151.1 ± 128.42192.6 ± 463.71
INI, CK, Week 32, n=93, 95182.2 ± 202.28175.1 ± 256.84
INI, CK, Week 36, n=94, 95190.7 ± 268.67153.8 ± 151.29
INI, CK, Week 40, n=90, 95286.9 ± 705.76178.2 ± 200.25
INI, CK, Week 44, n=91, 94457.7 ± 2054.68153.6 ± 139.48
INI, CK, Week 48, n=91, 95278.9 ± 651.96188.7 ± 339.93
NNRTI, CK, Baseline, n=155, 155180.9 ± 210.84143.8 ± 118.05
NNRTI, CK, Week 4, n=151, 153192.5 ± 472.95170.1 ± 226.58
NNRTI, CK, Week 8, n=122, 152290.4 ± 1322.89141.1 ± 106.01
NNRTI, CK, Week 12, n=146, 152198.5 ± 430.65168.5 ± 236.30
NNRTI, CK, Week 16, n=143, 149326.5 ± 1157.93150.4 ± 214.31
NNRTI, CK, Week 20, n=138, 152247.2 ± 661.97144.9 ± 131.72
NNRTI, CK, Week 24, n=143, 151210.9 ± 582.66161.5 ± 182.51
NNRTI, CK, Week 28, n=136, 150175.0 ± 156.46197.3 ± 460.97
NNRTI, CK, Week 32, n=137, 148218.0 ± 617.20238.8 ± 656.12
NNRTI, CK, Week 36, n=135, 147206.4 ± 401.19155.5 ± 134.30
NNRTI, CK, Week 40, n=138, 147175.6 ± 156.39166.9 ± 191.28
NNRTI, CK, Week 44, n=137, 148148.6 ± 94.67159.7 ± 171.66
NNRTI, CK, Week 48, n=131, 147167.8 ± 132.83171.3 ± 256.04
SecondaryAbsolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin

Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per Liter
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin
Grams per LiterCAB LA+RPV LA (Q4W)Current ART
PI, Baseline, n=51, 5443.9 ± 3.2244.2 ± 3.36
PI, Week 4, n=51, 5344.1 ± 2.9043.9 ± 2.92
PI, Week 8, n=34, 5344.6 ± 3.3644.1 ± 3.32
PI, Week 12, n=50, 5243.7 ± 3.2543.8 ± 3.56
PI, Week 16, n=48, 5343.8 ± 3.1943.4 ± 3.36
PI, Week 20, n=46, 5343.6 ± 2.7043.3 ± 3.57
PI, Week 24, n=47, 5343.5 ± 2.8043.3 ± 3.09
PI, Week 28, n=42, 5343.5 ± 2.7442.8 ± 3.43
PI, Week 32, n=45, 5143.2 ± 2.8543.7 ± 3.31
PI, Week 36, n=44, 5043.5 ± 2.8743.4 ± 3.02
PI, Week 40, n=42, 5144.2 ± 2.6443.9 ± 3.11
PI, Week 44, n=47, 5143.6 ± 2.5843.9 ± 3.03
PI, Week 48, n=43, 5043.9 ± 2.9744.5 ± 2.44
INI, Baseline, n=102, 9944.3 ± 3.0844.9 ± 3.21
INI, Week 4, n=99, 9743.9 ± 2.9143.8 ± 2.57
INI, Week 8, n=73, 9843.7 ± 3.0743.9 ± 3.10
INI, Week 12, n=99, 9544.1 ± 3.0144.3 ± 2.62
INI, Week 16, n=93, 9643.9 ± 2.7743.7 ± 2.76
INI, Week 20, n=93, 9743.6 ± 2.7044.1 ± 2.87
INI, Week 24, n=94, 9543.4 ± 3.0343.9 ± 3.00
INI, Week 28, n=89, 9344.0 ± 2.9743.9 ± 2.87
INI, Week 32, n=93, 9544.1 ± 2.8743.7 ± 2.89
INI, Week 36, n=94, 9543.6 ± 2.7443.7 ± 2.60
INI, Week 40, n=90, 9544.1 ± 2.7943.6 ± 2.70
INI, Week 44, n=91, 9443.6 ± 2.9643.8 ± 2.83
INI, Week 48, n=91, 9544.3 ± 2.5844.3 ± 2.73
NNRTI, Baseline, n=155, 15544.1 ± 3.1144.0 ± 3.10
NNRTI, Week 4, n=151, 15343.4 ± 2.8343.7 ± 3.04
NNRTI, Week 8, n=122, 15243.6 ± 2.9643.4 ± 3.16
NNRTI, Week 12, n=146, 15243.3 ± 2.8643.7 ± 3.25
NNRTI, Week 16, n=143, 14943.3 ± 2.6143.3 ± 3.27
NNRTI, Week 20, n=138, 15243.1 ± 2.7543.2 ± 2.98
NNRTI, Week 24, n=143, 15143.4 ± 2.5443.4 ± 3.01
NNRTI, Week 28, n=136, 15043.3 ± 2.7843.2 ± 3.03
NNRTI, Week 32, n=137, 14843.2 ± 2.7443.1 ± 3.43
NNRTI, Week 36, n=135, 14743.0 ± 2.8643.3 ± 3.37
NNRTI, Week 40, n=138, 14743.3 ± 2.6643.1 ± 3.20
NNRTI, Week 44, n=137, 14843.7 ± 2.7443.2 ± 3.13
NNRTI, Week 48, n=131, 14743.4 ± 2.7343.6 ± 3.14
SecondaryAbsolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Micromoles per liter
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per literCAB LA+RPV LA (Q4W)Current ART
PI, Bilirubin, Baseline, n=51, 5418.3 ± 20.5413.9 ± 11.07
PI, Bilirubin, Week 4, n=51, 539.3 ± 3.8114.4 ± 10.37
PI, Bilirubin, Week 8, n=34, 538.9 ± 3.4514.2 ± 10.79
PI, Bilirubin, Week 12, n=50, 528.1 ± 3.4415.6 ± 11.70
PI, Bilirubin, Week 16, n=48, 538.7 ± 3.9514.7 ± 10.78
PI, Bilirubin, Week 20, n=46, 539.3 ± 3.6015.6 ± 14.96
PI, Bilirubin, Week 24, n=47, 539.5 ± 3.4216.8 ± 16.15
PI, Bilirubin, Week 28, n=42, 539.4 ± 4.2915.0 ± 12.75
PI, Bilirubin, Week 32, n=45, 519.7 ± 3.6617.1 ± 12.45
PI, Bilirubin, Week 36, n=44, 508.3 ± 3.1716.0 ± 14.09
PI, Bilirubin, Week 40, n=42, 519.2 ± 3.5117.9 ± 18.08
PI, Bilirubin, Week 44, n=47, 519.5 ± 3.4118.1 ± 16.62
PI, Bilirubin, Week 48, n=43, 509.3 ± 3.7716.7 ± 10.73
INI, Bilirubin, Baseline, n=102, 999.4 ± 3.949.7 ± 5.07
INI, Bilirubin, Week 4, n=99, 979.5 ± 3.889.0 ± 4.77
INI, Bilirubin, Week 8, n=73, 9810.1 ± 4.2910.7 ± 12.28
INI, Bilirubin, Week 12, n=99, 959.9 ± 4.509.2 ± 3.91
INI, Bilirubin, Week 16, n=93, 969.8 ± 4.299.6 ± 3.80
INI, Bilirubin, Week 20, n=93, 9710.1 ± 4.059.3 ± 3.60
INI, Bilirubin, Week 24, n=94, 949.4 ± 4.119.1 ± 3.81
INI, Bilirubin, Week 28, n=89, 9310.3 ± 3.539.5 ± 4.67
INI, Bilirubin, Week 32, n=93, 959.9 ± 4.428.8 ± 3.32
INI, Bilirubin, Week 36, n=94, 959.8 ± 4.099.1 ± 3.76
INI, Bilirubin, Week 40, n=90, 959.9 ± 4.128.9 ± 3.63
INI, Bilirubin, Week 44, n=91, 9410.1 ± 4.759.0 ± 3.40
INI, Bilirubin, Week 48, n=91, 9510.3 ± 4.378.9 ± 3.76
NNRTI, Bilirubin, Baseline, n=155, 1557.4 ± 3.307.2 ± 3.30
NNRTI, Bilirubin, Week 4, n=151, 1538.7 ± 4.106.9 ± 2.98
NNRTI, Bilirubin, Week 8, n=122, 1528.9 ± 4.016.8 ± 3.40
NNRTI, Bilirubin, Week 12, n=146, 1529.3 ± 4.667.1 ± 3.50
NNRTI, Bilirubin, Week 16, n=143, 14910.5 ± 14.516.8 ± 3.52
NNRTI, Bilirubin, Week 20, n=138, 1529.6 ± 4.637.1 ± 3.15
NNRTI, Bilirubin, Week 24, n=143, 1519.1 ± 3.936.9 ± 3.75
NNRTI, Bilirubin, Week 28, n=136, 1509.7 ± 4.176.9 ± 3.29
NNRTI, Bilirubin, Week 32, n=137, 1489.7 ± 4.556.9 ± 3.52
NNRTI, Bilirubin, Week 36, n=135, 1479.3 ± 3.727.0 ± 3.33
NNRTI, Bilirubin, Week 40, n=138, 1479.6 ± 4.217.0 ± 3.43
NNRTI, Bilirubin, Week 44, n=137, 1489.4 ± 4.037.1 ± 3.25
NNRTI, Bilirubin, Week 48, n=131, 1479.4 ± 4.287.3 ± 3.19
PI, Direct bilirubin, Baseline, n=51, 543.6 ± 2.132.9 ± 1.68
PI, Direct bilirubin, Week 4, n=51, 532.4 ± 1.203.3 ± 1.67
PI, Direct bilirubin, Week 8, n=34, 532.3 ± 1.122.8 ± 1.68
PI, Direct bilirubin, Week 12, n=50, 521.9 ± 0.803.2 ± 1.95
PI, direct bilirubin, Week 16, n=48, 532.0 ± 0.872.9 ± 1.45
PI, Direct bilirubin, Week 20, n=46, 532.2 ± 0.792.9 ± 2.17
PI, Direct bilirubin, Week 24, n=47, 532.2 ± 0.753.1 ± 2.02
PI, Direct bilirubin, Week 28, n=42, 532.1 ± 1.082.7 ± 1.84
PI, Direct bilirubin, Week 32, n=45, 512.2 ± 0.883.1 ± 1.84
PI, Direct bilirubin, Week 36, n=44, 501.9 ± 0.803.1 ± 1.95
PI, Direct bilirubin, Week 40, n=42, 512.0 ± 0.773.2 ± 2.05
PI, Direct bilirubin, Week 44, n=47, 512.1 ± 0.833.3 ± 1.99
PI, Direct bilirubin, Week 48, n=43, 502.3 ± 0.933.2 ± 1.71
INI, Direct bilirubin, Baseline, n=102, 992.4 ± 0.962.3 ± 1.16
INI, Direct bilirubin, Week 4, n=99, 972.4 ± 0.902.3 ± 1.18
INI, Direct bilirubin, Week 8, n=73, 982.4 ± 1.023.0 ± 6.70
INI, Direct bilirubin, Week 12, n=99, 952.3 ± 0.982.3 ± 1.06
INI, Direct bilirubin, Week 16, n=93, 962.3 ± 1.032.1 ± 0.87
INI, Direct bilirubin, Week 20, n=93, 972.2 ± 0.852.1 ± 0.89
INI, Direct bilirubin, Week 24, n=94, 942.2 ± 1.022.0 ± 0.78
INI, Direct bilirubin, Week 28, n=89, 932.2 ± 0.742.1 ± 1.12
INI, Direct bilirubin, Week 32, n=93, 952.2 ± 0.941.9 ± 0.77
INI, Direct bilirubin, Week 36, n=94, 952.2 ± 1.252.0 ± 0.97
INI, Direct bilirubin, Week 40, n=90, 952.2 ± 1.062.0 ± 1.11
INI, Direct bilirubin. Week 44, n=91, 942.3 ± 0.992.1 ± 0.95
INI, Direct bilirubin, Week 48, n=91, 952.3 ± 0.822.2 ± 1.00
NNRTI, Direct bilirubin, Baseline, n=155, 1552.1 ± 1.001.9 ± 1.00
NNRTI, Direct bilirubin, Week 4, n=151, 1532.2 ± 1.062.0 ± 0.96
NNRTI, Direct bilirubin, Week 8, n=122, 1522.2 ± 1.101.9 ± 0.97
NNRTI, Direct bilirubin, Week 12, n=146, 1522.2 ± 1.121.9 ± 0.98
NNRTI, Direct bilirubin, Week 16, n=143, 1492.7 ± 6.951.9 ± 0.90
NNRTI, Direct bilirubin, Week 20, n=138, 1522.2 ± 1.071.7 ± 0.97
NNRTI, Week 24, Direct bilirubin, n=143, 1512.1 ± 1.041.8 ± 0.95
NNRTI, Direct bilirubin, Week 28, n=136, 1502.1 ± 1.011.7 ± 1.01
NNRTI, Direct bilirubin, Week 32, n=137, 1482.1 ± 1.081.7 ± 0.94
NNRTI, Direct bilirubin, Week 36, n=135, 1472.1 ± 1.101.7 ± 0.94
NNRTI, Direct bilirubin, Week 40, n=138, 1472.1 ± 1.181.7 ± 1.00
NNRTI, Direct bilirubin, Week 44, n=137, 1482.1 ± 0.961.8 ± 0.91
NNRTI, Direct bilirubin, Week 48, n=131, 1472.2 ± 0.981.9 ± 0.96
PI, Creatinine, Baseline, n=51, 5471.41 ± 12.31570.20 ± 13.391
PI, Creatinine, Week 4, n=51, 5372.87 ± 11.63272.53 ± 14.574
PI, Creatinine, Week 8, n=34, 5371.66 ± 13.01271.54 ± 14.362
PI, Creatinine, Week 12, n=50, 5270.05 ± 11.60973.22 ± 14.968
PI, Creatinine, Week 16, n=48, 5371.05 ± 11.77873.25 ± 15.740
PI, Creatinine, Week 20, n=46, 5373.40 ± 12.19175.37 ± 15.799
PI, Creatinine, Week 24, n=47, 5372.75 ± 11.65472.84 ± 14.549
PI, Creatinine, Week 28, n=42, 5375.18 ± 13.11873.42 ± 14.738
PI, Creatinine, Week 32, n=45, 5174.59 ± 13.73073.93 ± 15.399
PI, Creatinine, Week 36, n=44, 5074.41 ± 12.21772.37 ± 14.570
PI, Creatinine, Week 40, n=42, 5174.31 ± 11.74973.73 ± 15.726
PI, Creatinine, Week 44, n=47, 5175.38 ± 13.40573.00 ± 14.885
PI, Creatinine, Week 48, n=43, 5076.95 ± 13.02172.21 ± 15.031
INI, Creatinine, Baseline, n=102, 9988.16 ± 16.83586.34 ± 17.320
INI, Creatinine, Week 4, n=99, 9586.39 ± 14.47287.66 ± 16.208
INI, Creatinine, Week 8, n=73, 9885.52 ± 15.85188.11 ± 17.308
INI, Creatinine, Week 12, n=99, 9585.53 ± 17.53989.36 ± 17.923
INI, Creatinine, Week 16, n=93, 9684.99 ± 15.42986.85 ± 17.320
INI, Creatinine, Week 20, n=93, 9785.01 ± 14.69587.06 ± 16.987
INI, Creatinine, Week 24, n=94, 9484.21 ± 15.03987.02 ± 16.777
INI, Creatinine, Week 28, n=89, 9384.84 ± 15.67087.41 ± 17.065
INI, Creatinine, Week 32, n=93, 9585.42 ± 15.34986.91 ± 15.628
INI, Creatinine, Week 36, n=94, 9584.49 ± 15.18987.20 ± 15.835
INI, Creatinine, Week 40, n=90, 9585.92 ± 14.65187.70 ± 17.119
INI, Creatinine, Week 44, n=91, 9484.66 ± 15.70187.08 ± 16.694
INI, Creatinine, Week 48, n=91, 9585.27 ± 15.68386.64 ± 15.958
NNRTI, Creatinine, Baseline, n=155, 15575.57 ± 14.60475.06 ± 14.671
NNRTI, Creatinine, Week 4, n=151, 15378.57 ± 15.81476.79 ± 14.908
NNRTI, Creatinine, Week 8, n=122, 15276.75 ± 15.75976.17 ± 14.876
NNRTI, Creatinine, Week 12, n=146, 15276.93 ± 15.49575.50 ± 14.723
NNRTI, Creatinine, Week 16, n=143, 14977.22 ± 15.40677.00 ± 16.025
NNRTI, Creatinine, Week 20, n=138, 15278.32 ± 16.37276.36 ± 15.744
NNRTI, Creatinine, Week 24, n=143, 15179.92 ± 21.43076.26 ± 15.534
NNRTI, Creatinine, Week 28, n=136, 15079.13 ± 17.03976.45 ± 15.060
NNRTI, Creatinine, Week 32, n=137, 14877.40 ± 14.11777.05 ± 16.200
NNRTI, Creatinine, Week 36, n=135, 14778.15 ± 16.83976.64 ± 15.734
NNRTI, Creatinine, Week 40, n=138, 14778.42 ± 16.66276.04 ± 15.083
NNRTI, Creatinine, Week 44, n=137, 14878.45 ± 15.90976.25 ± 15.257
NNRTI, Creatinine, Week 48, n=131, 14778.91 ± 17.38975.67 ± 14.794
SecondaryAbsolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance

Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Milliliters per minute per 1.73meter^2
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance
Milliliters per minute per 1.73meter^2CAB LA+RPV LA (Q4W)Current ART
PI, Baseline, n=51, 54105.2 ± 15.67104.9 ± 15.22
PI, Week 4, n=51, 53103.0 ± 15.59102.1 ± 15.68
PI, Week 8, n=34, 53104.3 ± 14.52103.5 ± 15.61
PI, Week 12, n=50, 52107.1 ± 14.95101.1 ± 15.94
PI, Week 16, n=48, 53105.4 ± 15.88101.8 ± 15.99
PI, Week 20, n=46, 53102.9 ± 17.1799.8 ± 16.53
PI, Week 24, n=47, 53103.3 ± 14.64101.0 ± 15.54
PI, Week 28, n=42, 53100.6 ± 16.62100.8 ± 14.58
PI, Week 32, n=45, 51101.0 ± 17.38100.4 ± 16.04
PI, Week 36, n=44, 50100.7 ± 16.68101.7 ± 14.42
PI, Week 40, n=42, 51100.2 ± 14.54100.3 ± 15.51
PI, Week 44, n=47, 5199.8 ± 18.00101.0 ± 15.31
PI, Week 48, n=43, 5098.8 ± 17.31102.2 ± 15.45
INI, Baseline, n=102, 9992.3 ± 17.6294.9 ± 18.82
INI, Week 4, n=99, 9593.4 ± 15.0793.1 ± 18.22
INI, Week 8, n=72, 9894.4 ± 17.0593.0 ± 18.12
INI, Week 12, n=99, 9394.5 ± 16.8291.6 ± 18.81
INI, Week 16, n=93, 9694.9 ± 16.0294.4 ± 18.30
INI, Week 20, n=93, 9795.3 ± 15.9793.3 ± 17.48
INI, Week 24, n=94, 9495.6 ± 15.8893.1 ± 17.21
INI, Week 28, n=89, 9395.4 ± 17.0093.6 ± 17.89
INI, Week 32, n=92, 9594.8 ± 17.1693.1 ± 16.94
INI, Week 36, n=94, 9595.6 ± 15.8192.7 ± 15.65
INI, Week 40, n=89, 9594.8 ± 16.3292.9 ± 18.15
INI, Week 44, n=91, 9494.8 ± 15.6493.4 ± 17.94
INI, Week 48, n=90, 9495.4 ± 16.2093.5 ± 17.00
NNRTI, Baseline, n=155, 155104.4 ± 17.78103.7 ± 16.85
NNRTI, Week 4, n=151, 153100.8 ± 18.35101.5 ± 17.72
NNRTI, Week 8, n=121, 152102.3 ± 17.23102.2 ± 16.85
NNRTI, Week 12, n=146, 152103.1 ± 18.02103.2 ± 17.47
NNRTI, Week 16, n=143, 148102.5 ± 17.66101.0 ± 18.66
NNRTI, Week 20, n=138, 152101.0 ± 17.94101.8 ± 17.61
NNRTI, Week 24, n=142, 15199.6 ± 18.18101.7 ± 17.43
NNRTI, Week 28, n=136, 15099.9 ± 18.23101.7 ± 17.20
NNRTI, Week 32, n=137, 148101.3 ± 16.10101.0 ± 17.79
NNRTI, Week 36, n=135, 147100.8 ± 18.02101.4 ± 17.46
NNRTI, Week 40, n=137, 147100.5 ± 18.40101.6 ± 16.68
NNRTI, Week 44, n=136, 14899.9 ± 17.23101.8 ± 16.96
NNRTI, Week 48, n=131, 14798.7 ± 17.35102.1 ± 16.83
SecondaryAbsolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase

Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Units per liter
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase
Units per literCAB LA+RPV LA (Q4W)Current ART
PI, Baseline, n=51, 5427.6 ± 21.6933.0 ± 22.44
PI, Week 4, n=51, 5325.5 ± 14.4134.4 ± 20.77
PI, Week 8, n=34, 5323.4 ± 10.9635.7 ± 28.85
PI, Week 12, n=49, 5226.4 ± 12.0031.2 ± 15.31
PI, Week 16, n=47, 5328.1 ± 13.0134.6 ± 18.14
PI, Week 20, n=46, 5325.8 ± 11.3732.7 ± 16.37
PI, Week 24, n=47, 5325.8 ± 11.7430.5 ± 15.48
PI, Week 28, n=42, 5326.4 ± 10.8633.4 ± 15.92
PI, Week 32, n=45, 5126.9 ± 12.1836.2 ± 24.23
PI, Week 36, n=44, 5027.1 ± 13.6932.7 ± 17.14
PI, Week 40, n=42, 5130.5 ± 19.7832.0 ± 15.16
PI, Week 44, n=47, 5127.1 ± 10.7035.2 ± 18.59
PI, Week 48, n=43, 5026.3 ± 12.0232.7 ± 15.62
INI, Baseline, n=102, 9929.3 ± 20.9028.2 ± 16.64
INI, Week 4, n=99, 9736.8 ± 43.4632.1 ± 31.31
INI, Week 8, n=72, 9828.8 ± 16.8027.7 ± 12.72
INI, Week 12, n=99, 9333.1 ± 20.9829.8 ± 23.81
INI, Week 16, n=93, 9734.4 ± 33.0928.9 ± 14.77
INI, Week 20, n=94, 9732.0 ± 28.1929.1 ± 16.34
INI, Week 24, n=94, 9532.0 ± 19.1530.1 ± 21.56
INI, Week 28, n=89, 9435.1 ± 38.3232.8 ± 24.85
INI, Week 32, n=92, 9532.6 ± 23.0032.7 ± 21.75
INI, Week 36, n=94, 9535.0 ± 32.3227.6 ± 12.20
INI, Week 40, n=89, 9533.8 ± 20.1429.6 ± 14.21
INI, Week 44, n=91, 9434.6 ± 34.6632.8 ± 22.45
INI, Week 48, n=90, 9435.1 ± 36.8831.6 ± 23.18
NNRTI, Baseline, n=155, 15532.1 ± 24.4631.8 ± 19.30
NNRTI, Week 4, n=151, 15337.6 ± 64.9531.7 ± 17.60
NNRTI, Week 8, n=121, 15233.8 ± 27.2633.4 ± 21.17
NNRTI, Week 12, n=146, 15235.6 ± 34.7629.7 ± 14.64
NNRTI, Week 16, n=145, 14935.3 ± 32.6636.8 ± 46.27
NNRTI, Week 20, n=138, 15232.0 ± 19.0332.9 ± 37.34
NNRTI, Week 24, n=142, 15136.2 ± 29.0837.2 ± 36.77
NNRTI, Week 28, n=136, 15033.4 ± 21.7133.1 ± 17.20
NNRTI, Week 32, n=137, 14840.6 ± 83.2033.6 ± 20.70
NNRTI, Week 36, n=135, 14739.9 ± 67.6333.9 ± 21.66
NNRTI, Week 40, n=138, 14738.6 ± 46.3432.3 ± 16.96
NNRTI, Week 44, n=136, 14834.5 ± 23.2732.9 ± 19.81
NNRTI, Week 48, n=131, 14636.3 ± 30.6032.8 ± 20.04
SecondaryAbsolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48

Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Millimoles per liter
Absolute Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
PI, CO2, Baseline, n=51, 5422.3 ± 2.5322.7 ± 2.17
PI, CO2, Week 4, n=51, 5323.6 ± 2.3723.4 ± 2.28
PI, CO2, Week 8, n=34, 5323.0 ± 1.9523.0 ± 2.53
PI, CO2, Week 12, n=50, 5222.9 ± 2.1422.9 ± 2.41
PI, CO2, Week 16, n=48, 5323.0 ± 2.0722.9 ± 2.32
PI, CO2, Week 20, n=46, 5323.1 ± 2.0422.7 ± 2.59
PI, CO2, Week 24, n=47, 5322.7 ± 1.9522.8 ± 2.62
PI, CO2, Week 28, n=42, 5322.7 ± 2.3122.5 ± 2.48
PI, CO2, Week 32, n=45, 5122.6 ± 2.2222.6 ± 2.84
PI, CO2, Week 36, n=44, 5022.6 ± 2.2122.4 ± 2.36
PI, CO2, Week 40, n=42, 5122.8 ± 2.2423.1 ± 2.37
PI, CO2, Week 44, n=47, 5122.9 ± 1.9423.1 ± 2.37
PI, CO2, Week 48, n=43, 5023.0 ± 2.0122.7 ± 2.19
INI, CO2, Baseline, n=102, 9922.8 ± 2.0922.9 ± 2.08
INI, CO2, Week 4, n=99, 9723.7 ± 2.3623.7 ± 2.28
INI, CO2, Week 8, n=73, 9823.0 ± 2.1023.6 ± 2.20
INI, CO2, Week 12, n=99, 9523.2 ± 2.0723.3 ± 2.26
INI, CO2, Week 16, n=93, 9622.8 ± 2.1023.5 ± 2.39
INI, CO2, Week 20, n=93, 9722.8 ± 2.1123.6 ± 2.14
INI, CO2, Week 24, n=94, 9522.8 ± 2.2223.1 ± 2.21
INI, CO2, Week 28, n=89, 9322.5 ± 2.2123.1 ± 2.14
INI, CO2, Week 32, n=93, 9522.8 ± 2.1723.0 ± 2.09
INI, CO2, Week 36, n=94, 9522.8 ± 1.9023.5 ± 2.12
INI, CO2, Week 40, n=90, 9523.1 ± 2.0723.2 ± 2.09
INI, CO2, Week 44, n=91, 9423.1 ± 2.0823.7 ± 2.11
INI, CO2, Week 48, n=91, 9522.9 ± 1.9723.3 ± 2.32
NNRTI, CO2, Baseline, n=155, 15522.7 ± 2.4122.3 ± 2.35
NNRTI, CO2, Week 4, n=151, 15323.7 ± 2.6323.0 ± 2.24
NNRTI, CO2, Week 8, n=122, 15223.2 ± 2.2823.1 ± 2.61
NNRTI, CO2, Week 12, n=146, 15223.2 ± 2.1822.8 ± 2.39
NNRTI, CO2, Week 16, n=143, 14923.0 ± 2.2422.8 ± 2.23
NNRTI, CO2, Week 20, n=138, 15222.9 ± 2.2422.5 ± 2.20
NNRTI, CO2, Week 24, n=143, 15023.0 ± 2.4922.7 ± 2.45
NNRTI, CO2, Week 28, n=136, 15022.8 ± 2.5822.6 ± 2.27
NNRTI, CO2, Week 32, n=137, 14822.5 ± 2.1122.7 ± 2.29
NNRTI, CO2, Week 36, n=135, 14722.8 ± 2.3822.8 ± 2.27
NNRTI, CO2, Week 40, n=138, 14723.1 ± 2.4022.8 ± 2.68
NNRTI, CO2, Week 44, n=137, 14823.0 ± 2.3522.8 ± 2.38
NNRTI, CO2, Week 48, n=131, 14722.5 ± 2.5522.6 ± 2.29
PI, Chloride, Baseline, n=51, 54104.0 ± 1.46103.5 ± 2.61
PI, Chloride, Week 4, n=51, 53104.5 ± 1.80104.0 ± 2.10
PI, Chloride, Week 8, n=34, 53104.4 ± 2.35104.2 ± 2.28
PI, Chloride, Week 12, n=50, 52104.4 ± 2.02104.3 ± 2.13
PI, Chloride, Week 16, n=48, 53104.4 ± 2.08104.5 ± 2.10
PI, Chloride, Week 20, n=46, 53104.8 ± 1.98104.2 ± 1.97
PI, Chloride, Week 24, n=47, 53105.1 ± 1.85104.7 ± 2.02
PI, Chloride, Week 28, n=42, 53105.3 ± 1.88104.6 ± 2.47
PI, Chloride, Week 32, n=45, 51105.0 ± 2.32104.4 ± 1.92
PI, Chloride, Week 36, n=44, 50105.0 ± 2.17104.4 ± 2.27
PI, Chloride, Week 40, n=42, 51105.2 ± 2.27104.5 ± 2.31
PI, Chloride, Week 44, n=47, 51105.1 ± 1.84104.5 ± 1.88
PI, Chloride, Week 48, n=43, 50104.4 ± 1.72104.3 ± 1.88
INI, Chloride, Baseline, n=102, 99103.6 ± 2.03103.5 ± 2.26
INI, Chloride, Week 4, n=99, 97104.0 ± 2.17104.0 ± 2.15
INI, Chloride, Week 8, n=73, 98104.1 ± 2.16103.5 ± 2.58
INI, Chloride, Week 12, n=99, 95104.1 ± 2.31104.0 ± 2.32
INI, Chloride, Week 16, n=93, 96104.7 ± 2.05104.2 ± 2.26
INI, Chloride, Week 20, n=93, 97104.8 ± 2.39103.8 ± 2.36
INI, Chloride, Week 24, n=94, 95104.3 ± 2.30104.1 ± 2.50
INI, Chloride, Week 28, n=89, 93104.7 ± 1.92104.0 ± 2.16
INI, Chloride, Week 32, n=93, 95104.5 ± 2.33104.2 ± 2.47
INI, Chloride, Week 36, n=94, 95104.6 ± 2.04104.1 ± 2.40
INI, Chloride, Week 40, n=90, 95104.4 ± 1.94103.9 ± 2.48
INI, Chloride, Week 44, n=91, 94104.5 ± 2.12104.0 ± 2.27
INI, Chloride, Week 48, n=91, 95104.2 ± 2.43103.2 ± 2.26
NNRTI, Chloride, Baseline, n=155, 155103.9 ± 2.18104.0 ± 2.37
NNRTI, Chloride, Week 4, n=151, 153104.3 ± 2.21104.6 ± 2.29
NNRTI, Chloride, Week 8, n=122, 152104.4 ± 2.31104.7 ± 2.22
NNRTI, Chloride, Week 12, n=146, 152104.3 ± 2.33104.5 ± 2.23
NNRTI, Chloride, Week 16, n=143, 149104.4 ± 2.37104.8 ± 2.34
NNRTI, Chloride, Week 20, n=138, 152104.6 ± 2.55105.1 ± 2.38
NNRTI, Chloride, Week 24, n=143, 151104.4 ± 2.52105.1 ± 2.18
NNRTI, Chloride, Week 28, n=136, 150104.7 ± 2.41105.3 ± 2.31
NNRTI, Chloride, Week 32, n=137, 148104.7 ± 2.68105.1 ± 2.26
NNRTI, Chloride, Week 36, n=135, 147105.0 ± 2.28105.1 ± 2.30
NNRTI, Chloride, Week 40, n=138, 147104.7 ± 2.36105.0 ± 2.70
NNRTI, Chloride, Week 44, n=137, 148104.6 ± 2.17105.0 ± 2.32
NNRTI, Chloride, Week 48, n=131, 147104.6 ± 2.54104.5 ± 2.46
PI, Glucose, Baseline, n=51, 535.11 ± 0.8785.03 ± 0.505
PI, Glucose, Week 4, n=43, 435.06 ± 0.4815.29 ± 0.452
PI, Glucose, Week 8, n=25, 415.11 ± 0.4565.18 ± 0.462
PI, Glucose, Week 12, n=40, 435.21 ± 0.5335.25 ± 0.535
PI, Glucose, Week 16, n=39, 445.24 ± 0.8005.26 ± 0.614
PI, Glucose, Week 20, n=35, 425.11 ± 0.5805.29 ± 0.718
PI, Glucose, Week 24, n=38, 435.31 ± 0.5265.29 ± 0.747
PI, Glucose, Week 28, n=32, 435.16 ± 0.6515.12 ± 0.512
PI, Glucose, Week 32, n=36, 425.37 ± 0.7005.31 ± 0.643
PI, Glucose, Week 36, n=35, 425.13 ± 0.5255.23 ± 0.513
PI, Glucose, Week 40, n=34, 415.31 ± 0.4645.17 ± 0.555
PI, Glucose, Week 44, n=40, 405.13 ± 0.6815.20 ± 0.408
PI, Glucose, Week 48, n=39, 485.16 ± 0.6475.18 ± 0.661
INI, Glucose, Baseline, n=98, 965.06 ± 0.6385.25 ± 0.801
INI, Glucose, Week 4, n=55, 545.39 ± 0.7715.37 ± 1.043
INI, Glucose, Week 8, n=36, 585.16 ± 0.5845.49 ± 1.307
INI, Glucose, Week 12, n=53, 565.50 ± 1.3175.51 ± 1.414
INI, Glucose, Week 16, n=54, 535.41 ± 1.7275.25 ± 0.624
INI, Glucose, Week 20, n=52, 585.36 ± 0.6745.21 ± 0.793
INI, Glucose, Week 24, n=61, 625.34 ± 0.6605.36 ± 0.753
INI, Glucose, Week 28, n=53, 635.32 ± 0.8175.45 ± 0.940
INI, Glucose, Week 32, n=54, 565.57 ± 1.2605.52 ± 0.839
INI, Glucose, Week 36, n=53, 585.46 ± 0.6975.34 ± 1.142
INI, Glucose, Week 40, n=59, 635.53 ± 0.9315.46 ± 0.765
INI, Glucose, Week 44, n=54, 575.40 ± 1.0205.43 ± 0.637
INI, Glucose, Week 48, n=84, 915.16 ± 0.5495.24 ± 0.752
NNRTI, Glucose, Baseline, n=152, 1504.93 ± 0.6975.17 ± 1.201
NNRTI, Glucose, Week 4, n=118, 1295.11 ± 0.7985.48 ± 1.490
NNRTI, Glucose, Week 8, n=92, 1195.17 ± 1.2045.35 ± 1.030
NNRTI, Glucose, Week 12, n=113, 1225.04 ± 0.8565.30 ± 1.067
NNRTI, Glucose, Week 16, n=116, 1195.12 ± 0.9145.45 ± 1.683
NNRTI, Glucose, Week 20, n=107, 1215.16 ± 0.8025.48 ± 1.476
NNRTI, Glucose, Week 24, n=116, 1245.16 ± 0.9445.36 ± 0.914
NNRTI, Glucose, Week 28, n=105, 1205.08 ± 0.6355.40 ± 0.934
NNRTI, Glucose, Week 32, n=104, 1215.18 ± 1.0005.47 ± 1.316
NNRTI, Glucose, Week 36, n=103, 1205.07 ± 0.8565.49 ± 1.857
NNRTI, Glucose, Week 40, n=102, 1145.16 ± 0.7765.53 ± 1.558
NNRTI, Glucose, Week 44, n=99, 1165.15 ± 0.8775.53 ± 1.708
NNRTI, Glucose, Week 48, n=119, 1385.01 ± 0.6405.23 ± 1.160
PI, Phosphate, Baseline, n=51, 541.048 ± 0.15231.060 ± 0.1719
PI, Phosphate, Week 4, n=51, 531.116 ± 0.16481.069 ± 0.1647
PI, Phosphate, Week 8, n=34, 531.119 ± 0.18911.041 ± 0.1664
PI, Phosphate, Week 12, n=50, 521.073 ± 0.17881.064 ± 0.1872
PI, Phosphate, Week 16, n=48, 531.111 ± 0.20061.051 ± 0.1849
PI, Phosphate, Week 20, n=46, 531.119 ± 0.16891.076 ± 0.2187
PI, Phosphate, Week 24, n=47, 531.086 ± 0.16471.077 ± 0.1631
PI, Phosphate, Week 28, n=42, 531.085 ± 0.18031.076 ± 0.1970
PI, Phosphate, Week 32, n=45, 511.109 ± 0.18691.081 ± 0.1769
PI, Phosphate, Week 36, n=44, 501.084 ± 0.16591.058 ± 0.1830
PI, Phosphate, Week 40, n=42, 511.067 ± 0.20201.053 ± 0.1932
PI, Phosphate, Week 44, n=47, 511.084 ± 0.17851.063 ± 0.2227
PI, Phosphate, Week 48, n=43, 501.095 ± 0.16361.070 ± 0.1804
INI, Phosphate, Baseline, n=102, 991.045 ± 0.16871.063 ± 0.1700
INI, Phosphate, Week 4, n=99, 971.080 ± 0.17251.082 ± 0.1857
INI, Phosphate, Week 8, n=73, 981.086 ± 0.19011.071 ± 0.2001
INI, Phosphate, Week 12, n=99, 951.068 ± 0.19701.078 ± 0.1823
INI, Phosphate, Week 16, n=93, 961.063 ± 0.16231.061 ± 0.1702
INI, Phosphate, Week 20, n=93, 971.046 ± 0.17171.091 ± 0.1757
INI, Phosphate, Week 24, n=94, 951.066 ± 0.16611.052 ± 0.1921
INI, Phosphate, Week 28, n=89, 931.060 ± 0.16021.065 ± 0.1835
INI, Phosphate, Week 32, n=93, 951.045 ± 0.16491.045 ± 0.1569
INI, Phosphate, Week 36, n=94, 951.032 ± 0.15721.059 ± 0.1800
INI, Phosphate, Week 40, n=90, 951.054 ± 0.18381.062 ± 0.1731
INI, Phosphate, Week 44, n=91, 941.043 ± 0.18051.066 ± 0.2029
INI, Phosphate, Week 48, n=91, 951.072 ± 0.17211.066 ± 0.1918
NNRTI, Phosphate, Baseline, n=155, 1551.038 ± 0.19051.040 ± 0.1741
NNRTI, Phosphate, Week 4, n=151, 1531.128 ± 0.18671.056 ± 0.1764
NNRTI, Phosphate, Week 8, n=122, 1521.097 ± 0.19941.024 ± 0.1784
NNRTI, Phosphate, Week 12, n=146, 1521.091 ± 0.18381.051 ± 0.2002
NNRTI, Phosphate, Week 16, n=143, 1491.082 ± 0.18271.046 ± 0.1700
NNRTI, Phosphate, Week 20, n=138, 1521.076 ± 0.17631.037 ± 0.1806
NNRTI, Phosphate, Week 24, n=143, 1511.091 ± 0.19141.052 ± 0.1882
NNRTI, Phosphate, Week 28, n=136, 1501.076 ± 0.17641.038 ± 0.1585
NNRTI, Phosphate, Week 32, n=137, 1481.057 ± 0.17221.050 ± 0.1874
NNRTI, Phosphate, Week 36, n=135, 1471.055 ± 0.17901.039 ± 0.1793
NNRTI, Phosphate, Week 40, n=138, 1471.071 ± 0.16891.033 ± 0.1724
NNRTI, Phosphate, Week 44, n=137, 1481.076 ± 0.17951.040 ± 0.1693
NNRTI, Phosphate, Week 48, n=131, 1471.075 ± 0.19411.037 ± 0.1789
PI, Potassium, Baseline, n=51, 544.13 ± 0.2884.10 ± 0.308
PI, Potassium, Week 4, n=51, 534.25 ± 0.3554.31 ± 0.395
PI, Potassium, Week 8, n=34, 534.18 ± 0.2834.19 ± 0.331
PI, Potassium, Week 12, n=50, 524.25 ± 0.3354.31 ± 0.364
PI, Potassium, Week 16, n=48, 534.16 ± 0.3224.30 ± 0.359
PI, Potassium, Week 20, n=46, 534.18 ± 0.2914.29 ± 0.314
PI, Potassium, Week 24, n=47, 534.15 ± 0.3354.30 ± 0.379
PI, Potassium, Week 28, n=42, 534.21 ± 0.3424.26 ± 0.348
PI, Potassium, Week 32, n=45, 514.15 ± 0.3264.31 ± 0.367
PI, Potassium, Week 36, n=44, 504.25 ± 0.3454.26 ± 0.378
PI, Potassium, Week 40, n=42, 514.23 ± 0.2934.26 ± 0.363
PI, Potassium, Week 44, n=47, 514.24 ± 0.3484.32 ± 0.375
PI, Potassium, Week 48, n=43, 504.15 ± 0.2924.12 ± 0.320
INI, Potassium, Baseline, n=102, 994.17 ± 0.2454.18 ± 0.289
INI, Potassium, Week 4, n=99, 974.20 ± 0.3114.26 ± 0.359
INI, Potassium, Week 8, n=73, 984.14 ± 0.3064.24 ± 0.462
INI, Potassium, Week 12, n=99, 954.19 ± 0.3404.18 ± 0.291
INI, Potassium, Week 16, n=93, 964.15 ± 0.3174.19 ± 0.297
INI, Potassium, Week 20, n=93, 974.20 ± 0.2994.18 ± 0.289
INI, Potassium, Week 24, n=94, 954.19 ± 0.3044.21 ± 0.304
INI, Potassium,Week 28, n=89, 934.19 ± 0.4124.22 ± 0.341
INI, Potassium, Week 32, n=93, 954.20 ± 0.3584.19 ± 0.307
INI, Potassium, Week 36, n=94, 954.19 ± 0.3654.23 ± 0.332
INI, Potassium, Week 40, n=90, 954.18 ± 0.3324.19 ± 0.297
INI, Potassium, Week 44, n=91, 944.18 ± 0.3094.17 ± 0.314
INI, Potassium, Week 48, n=91, 954.15 ± 0.2664.16 ± 0.305
NNRTI, Potassium, Baseline, n=155, 1554.16 ± 0.3024.18 ± 0.331
NNRTI, Potassium, Week 4, n=151, 1534.21 ± 0.2874.28 ± 0.333
NNRTI, Potassium, Week 8, n=122, 1524.17 ± 0.2954.23 ± 0.366
NNRTI, Potassium, Week 12, n=146, 1524.18 ± 0.3224.26 ± 0.341
NNRTI, Potassium, Week 16, n=143, 1494.20 ± 0.3134.23 ± 0.320
NNRTI, Potassium,Week 20, n=138, 1524.20 ± 0.3264.21 ± 0.337
NNRTI, Potassium, Week 24, n=143, 1504.19 ± 0.2594.22 ± 0.341
NNRTI, Potassium, Week 28, n=136, 1504.18 ± 0.3014.25 ± 0.434
NNRTI, Potassium, Week 32, n=137, 1484.17 ± 0.3884.20 ± 0.349
NNRTI, Potassium, Week 36, n=135, 1474.17 ± 0.2894.22 ± 0.343
NNRTI, Potassium, Week 40, n=138, 1474.20 ± 0.2834.26 ± 0.321
NNRTI, Potassium, Week 44, n=137, 1484.23 ± 0.3244.24 ± 0.374
NNRTI, Potassium, Week 48, n=131, 1474.14 ± 0.2714.17 ± 0.352
PI, Sodium, Baseline, n=51, 54138.9 ± 2.15138.7 ± 2.10
PI, Sodium, Week 4, n=51, 53139.3 ± 1.64139.0 ± 2.08
PI, Sodium, Week 8, n=34, 53139.6 ± 2.10139.0 ± 1.95
PI, Sodium, Week 12, n=50, 52139.3 ± 1.76139.4 ± 2.03
PI, Sodium, Week 16, n=48, 53139.4 ± 2.18139.0 ± 1.75
PI, Sodium, Week 20, n=46, 53139.6 ± 1.71139.1 ± 1.97
PI, Sodium, Week 24, n=47, 53139.4 ± 2.08139.1 ± 2.07
PI, Sodium, Week 28, n=42, 53140.3 ± 1.59139.5 ± 2.49
PI, Sodium, Week 32, n=45, 51139.4 ± 2.14139.3 ± 2.28
PI, Sodium, Week 36, n=44, 50139.7 ± 1.63139.4 ± 2.32
PI, Sodium, Week 40, n=42, 51139.8 ± 1.94139.4 ± 1.93
PI, Sodium, Week 44, n=47, 51139.7 ± 1.78139.4 ± 2.09
PI, Sodium, Week 48, n=43, 50139.8 ± 1.86139.6 ± 1.90
INI, Sodium, Baseline, n=102, 99138.8 ± 1.62139.0 ± 1.67
INI, Sodium, Week 4, n=99, 97139.2 ± 1.58139.1 ± 1.72
INI, Sodium, Week 8, n=73, 98138.8 ± 2.00138.8 ± 1.79
INI, Sodium, Week 12, n=99, 95139.1 ± 1.97139.0 ± 1.88
INI, Sodium, Week 16, n=93, 96139.1 ± 1.87139.4 ± 1.89
INI, Sodium, Week 20, n=93, 97139.4 ± 1.92139.2 ± 1.67
INI, Sodium, Week 24, n=94, 95139.3 ± 1.86139.1 ± 1.91
INI, Sodium, Week 28, n=89, 93139.4 ± 1.65138.8 ± 1.67
INI, Sodium, Week 32, n=93, 95139.4 ± 1.63139.2 ± 1.68
INI, Sodium, Week 36, n=94, 95139.2 ± 1.84139.4 ± 1.99
INI, Sodium, Week 40, n=90, 95139.3 ± 2.01139.3 ± 1.83
INI, Sodium, Week 44, n=91, 94139.3 ± 1.67139.4 ± 1.88
INI, Sodium, Week 48, n=91, 95139.3 ± 1.98139.0 ± 1.76
NNRTI, Sodium, Baseline, n=155, 155139.1 ± 2.00139.2 ± 1.68
NNRTI, Sodium, Week 4, n=151, 153139.4 ± 1.79139.2 ± 1.90
NNRTI, Sodium, Week 8, n=122, 152139.1 ± 1.91139.2 ± 1.76
NNRTI, Sodium, Week 12, n=146, 152139.2 ± 1.78139.2 ± 1.77
NNRTI, Sodium, Week 16, n=143, 149139.0 ± 1.99139.0 ± 2.06
NNRTI, Sodium, Week 20, n=138, 152139.0 ± 1.87139.5 ± 1.83
NNRTI, Sodium, Week 24, n=143, 151139.2 ± 1.83139.4 ± 1.94
NNRTI, Sodium, Week 28, n=136, 150139.3 ± 1.84139.4 ± 1.99
NNRTI, Sodium, Week 32, n=137, 148139.2 ± 1.68139.7 ± 1.75
NNRTI, Sodium, Week 36, n=135, 147139.4 ± 1.80139.7 ± 2.19
NNRTI, Sodium, Week 40, n=138, 147139.4 ± 1.87139.7 ± 2.06
NNRTI, Sodium, Week 44, n=137, 148139.5 ± 1.88139.7 ± 1.92
NNRTI, Sodium, Week 48, n=131, 147139.4 ± 1.93139.5 ± 1.82
PI, Urea, Baseline, n=51, 544.97 ± 1.4094.89 ± 1.316
PI, Urea, Week 4, n=51, 534.99 ± 1.2104.91 ± 1.455
PI, Urea, Week 8, n=34, 535.10 ± 1.3534.88 ± 1.447
PI, Urea, Week 12, n=50, 525.03 ± 1.3684.85 ± 1.480
PI, Urea, Week 16, n=48, 535.20 ± 1.2955.09 ± 1.754
PI, Urea, Week 20, n=46, 535.18 ± 1.2165.07 ± 1.535
PI, Urea, Week 24, n=47, 535.44 ± 1.5875.00 ± 1.414
PI, Urea, Week 28, n=42, 535.21 ± 1.3584.90 ± 1.530
PI, Urea, Week 32, n=45, 515.13 ± 1.1355.09 ± 1.482
PI, Urea, Week 36, n=44, 504.99 ± 1.3104.78 ± 1.411
PI, Urea, Week 40, n=42, 515.35 ± 1.2275.30 ± 1.758
PI, Urea, Week 44, n=47, 515.38 ± 1.4835.10 ± 1.517
PI, Urea, Week 48, n=43, 505.22 ± 1.4695.11 ± 1.489
INI, Urea, Baseline, n=102, 995.76 ± 1.5285.61 ± 1.894
INI, Urea, Week 4, n=99, 975.63 ± 1.4715.77 ± 1.676
INI, Urea, Week 8, n=73, 985.80 ± 1.6175.60 ± 1.607
INI, Urea, Week 12, n=99, 955.81 ± 1.5365.83 ± 1.724
INI, Urea, Week 16, n=93, 965.76 ± 1.5775.70 ± 1.574
INI, Urea, Week 20, n=93, 975.75 ± 1.6405.76 ± 1.580
INI, Urea, Week 24, n=94, 955.84 ± 1.5785.72 ± 1.774
INI, Urea, Week 28, n=89, 935.76 ± 1.5935.65 ± 1.435
INI, Urea, Week 32, n=93, 955.67 ± 1.5375.63 ± 1.477
INI, Urea, Week 36, n=94, 955.67 ± 1.6705.53 ± 1.456
INI, Urea, Week 40, n=90, 955.81 ± 1.6695.66 ± 1.593
INI, Urea, Week 44, n=91, 945.59 ± 1.6075.46 ± 1.368
INI, Urea, Week 48, n=91, 955.83 ± 1.6545.50 ± 1.468
NNRTI, Urea, Baseline, n=155, 1554.96 ± 1.5195.10 ± 1.510
NNRTI, Urea, Week 4, n=151, 1535.08 ± 1.5565.09 ± 1.426
NNRTI, Urea, Week 8, n=122, 1525.09 ± 1.6755.10 ± 1.465
NNRTI, Urea, Week 12, n=146, 1525.20 ± 1.6845.13 ± 1.583
NNRTI, Urea, Week 16, n=143, 1495.03 ± 1.7685.34 ± 1.660
NNRTI, Urea, Week 20, n=138, 1525.18 ± 1.7095.15 ± 1.713
NNRTI, Urea, Week 24, n=143, 1515.29 ± 1.8785.26 ± 1.591
NNRTI, Urea, Week 28, n=136, 1505.20 ± 1.9315.10 ± 1.537
NNRTI, Urea, Week 32, n=137, 1485.38 ± 1.7965.14 ± 1.687
NNRTI, Urea, Week 36, n=135, 1475.07 ± 1.7195.13 ± 1.493
NNRTI, Urea, Week 40, n=138, 1475.30 ± 1.6165.07 ± 1.377
NNRTI, Urea, Week 44, n=137, 1485.23 ± 1.4895.18 ± 1.613
NNRTI, Urea, Week 48, n=131, 1475.32 ± 1.6715.06 ± 1.380
SecondaryAbsolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48

Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI).

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Millimoles per liter
Absolute Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
PI, Triglycerides, Baseline, n=46, 501.951 ± 1.88011.894 ± 1.4058
PI, Triglycerides, Week 48, n=40, 451.309 ± 0.76471.772 ± 1.1828
INI, Triglycerides, Baseline, n=82, 841.470 ± 1.01521.426 ± 0.8720
INI, Triglycerides, Week 48, n=72, 771.405 ± 0.90681.307 ± 0.7427
NNRTI, Triglycerides, Baseline, n=136, 1401.322 ± 0.79861.506 ± 1.4388
NNRTI, Triglycerides, Week 48, n=119, 1201.305 ± 0.87711.316 ± 0.7914
PI, Cholesterol, Baseline, n=46, 504.98 ± 0.9605.14 ± 1.152
PI, Cholesterol, Week 48, n=40, 455.07 ± 0.7755.16 ± 1.130
INI, Cholesterol, Baseline, n=82, 844.81 ± 1.0775.01 ± 1.080
INI, Cholesterol, Week 48, n=72, 774.90 ± 0.8814.87 ± 0.997
NNRTI, Cholesterol, Baseline, n=136, 1404.87 ± 0.9584.98 ± 1.007
NNRTI, Cholesterol, Week 48, n=119, 1204.93 ± 0.9044.91 ± 1.007
PI, HDL cholesterol, Baseline, n=46, 501.389 ± 0.49431.537 ± 0.6096
PI, HDL cholesterol, Week 48, n=40, 451.505 ± 0.54591.550 ± 0.5950
INI, HDL cholesterol, Baseline, n=82, 841.257 ± 0.34501.383 ± 0.3890
INI, HDL cholesterol, Week 48, n=72, 771.288 ± 0.36641.323 ± 0.3588
NNRTI, HDL cholesterol, Baseline, n=136, 1401.449 ± 0.47561.405 ± 0.4401
NNRTI, HDL cholesterol, Week 48, n=119, 1201.442 ± 0.44131.471 ± 0.4226
PI, LDL cholesterol, Baseline, n=43, 482.734 ± 0.78912.743 ± 0.7948
PI, LDL cholesterol, Week 48, n=37, 432.944 ± 0.71752.784 ± 0.8477
INI, LDL cholesterol, Basline, n=81, 832.881 ± 0.91962.946 ± 0.8614
INI, LDL cholesterol, Week 48, n=71, 762.975 ± 0.87872.939 ± 0.8591
NNRTI, LDL cholesterol, Baseline, n=134, 1372.834 ± 0.84422.901 ± 0.8714
NNRTI, LDL cholesterol, Week 48, n=116, 1192.900 ± 0.84152.834 ± 0.8763
SecondaryNumber of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants Discontinued or Withdrawn Due to AEs When Baseline Third Agent Treatment Class Was Used Over Time Including Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
PI22
INI60
NNRTI53
SecondaryPlasma Trough Concentration (Ctrough) for CAB LA Evaluable

Blood samples will be collected at indicated time points for pharmacokinetic (PK) analysis of CAB LA. PK population includes all participants who received CAB and / or RPV and underwent PK sampling during the study, and provided CAB and /or RPV plasma concentration data.

Time frame:
Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Geometric mean · Micrograms per milliliter
Plasma Trough Concentration (Ctrough) for CAB LA Evaluable
Micrograms per milliliterCAB LA
Pre-dose, Week 8, n=2521.2277 (1.1293 to 1.3346)
Pre-dose, Week 12, n=2611.6925 (1.6005 to 1.7897)
Pre-dose, Week 16, n=2481.9533 (1.8492 to 2.0632)
Pre-dose, Week 20, n=2332.1036 (1.9924 to 2.2209)
Pre-dose, Week 24, n=2342.2537 (2.1177 to 2.3984)
Pre-dose, Week 28, n=2322.4300 (2.3093 to 2.5569)
Pre-dose, Week 32, n=2192.4483 (2.3321 to 2.5703)
Pre-dose, Week 36, n=2092.4681 (2.3377 to 2.6057)
Pre-dose, Week 40, n=2092.5126 (2.3477 to 2.6890)
Pre-dose, Week 44, n=2212.7748 (2.6323 to 2.9250)
Pre-dose, Week 48, n=2172.8378 (2.6763 to 3.0090)
SecondaryCtrough for RPV LA Evaluable

Blood samples will be collected at indicated time points for PK analysis of RPV LA.

Time frame:
Pre-dose at Weeks 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Geometric mean · Nanograms per milliliter
Ctrough for RPV LA Evaluable
Nanograms per milliliterRPV LA
Pre-dose, Week 8, n=25138.58 (35.96 to 41.39)
Pre-dose, Week 12, n=26147.00 (44.50 to 49.64)
Pre-dose, Week 16, n=24753.87 (50.92 to 56.98)
Pre-dose, Week 20, n=23354.14 (51.13 to 57.34)
Pre-dose, Week 24, n=23161.26 (57.80 to 64.93)
Pre-dose, Week 28, n=23266.53 (62.87 to 70.40)
Pre-dose, Week 32, n=21870.93 (66.97 to 75.11)
Pre-dose, Week 36, n=20973.00 (68.54 to 77.75)
Pre-dose, Week 40, n=20876.24 (71.71 to 81.07)
Pre-dose, Week 44, n=22383.65 (78.94 to 88.63)
Pre-dose, Week 48, n=21690.28 (84.92 to 95.98)
SecondaryArea Under the Curve (AUC) for CAB LA

AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for CAB LA.

Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41
Reported as:
Geometric mean · Hours*microgram per milliliter
Area Under the Curve (AUC) for CAB LA
Hours*microgram per milliliterCAB LA
Area Under the Curve (AUC) for CAB LA2324.29 (2249.850 to 2401.187)
SecondaryAUC for RPV LA

AUC values are Bayesian PK parameter estimates obtained from a population PK meta-analysis of the data collected from studies 201585 and 201584 # NCT02938520. Blood samples from the current study 201585 were collected at indicated time points to analyze concentration in plasma for RPV LA.

Time frame:
Pre-dose at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48; 1 Week post-dose at Weeks 5 and 41
Reported as:
Geometric mean · Hours*nanogram per milliliter
AUC for RPV LA
Hours*nanogram per milliliterRPV LA
AUC for RPV LA67119.84 (64426.092 to 69926.208)
SecondaryMaximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41

Blood samples will be collected at indicated time points for PK analysis of CAB LA.

Time frame:
Week 41- 1 Week post dose
Reported as:
Geometric mean · Micrograms per milliliter
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 41
Micrograms per milliliterCAB LA
Maximum Concentration (Cmax) in Plasma for CAB LA Evaluable at Week 413.3862 (3.1804 to 3.6054)
SecondaryCmax in Plasma for RPV LA Evaluable at Week 41

Blood samples will be collected at indicated time points for PK analysis of RPV LA.

Time frame:
Week 41- 1 Week post dose
Reported as:
Geometric mean · Nanograms per milliliter
Cmax in Plasma for RPV LA Evaluable at Week 41
Nanograms per milliliterRPV LA
Cmax in Plasma for RPV LA Evaluable at Week 41110.36 (103.28 to 117.93)
SecondaryPercentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent

Percentage of participants with virologic failure endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \>=50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With a Virologic Failure Using Snapshot Algorithm by Baseline Third Agent
Percentage of participantsCAB LA+RPV LA (Q4W)Current ART
PI, n=51, 542.00
INI, n=102, 9902.0
NNRTI, n=155, 1552.60.6
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent

Percentage of participants with HIV-1 RNA \< 50copies/mL endpoint as per FDA snapshot algorithm at Week 48 was assessed based on the non-inferior antiviral activity of switching IM CAB LA+RPV LA every 4 weeks compared to continuation of current ART regimen over 48 weeks in HIV-1 infected ART-experienced participants. The HIV-RNA \<50 copies/mL per snapshot algorithm was determined using a Cochran-Mantel Haenszel test stratified by baseline third agent class: INI, NNRTI, or PI.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50copies/mL Using Snapshot Algorithm by Baseline Third Agent
Percentage of participantsCAB LA+RPV LA (Q4W)Current ART
PI, n=51, 549294
INI, n=102, 999496
NNRTI, n=155, 1559295
SecondaryNumber of Participants With Severity of Adverse Events by Baseline Third Agents

Severity of AEs were defined as per The Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table). Severity grades for AEs were as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (Potentially life-threatening) and Grade 5 were all deaths related to an AE.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Severity of Adverse Events by Baseline Third Agents
ParticipantsCAB LA+RPV LA (Q4W)Current ART
PI, Grade 12220
PI, Grade 22011
PI, Grade 344
PI, Grade 410
PI, Grade 501
INI, Grade 14040
INI, Grade 25023
INI, Grade 383
INI, Grade 412
INI, Grade 500
NNRTI, Grade 13955
NNRTI, Grade 28847
NNRTI, Grade 31512
NNRTI, Grade 462
NNRTI, Grade 500
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK

Blood samples were collected for the analysis of clinical chemistry parameters: ALT, ALP, AST and CK to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · International units per liter
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: ALT, ALP, AST and CK
International units per literCAB LA+RPV LA (Q4W)Current ART
PI, ALT, Week 4, n=51, 539.4 ± 17.931.1 ± 9.99
PI, ALT, Week 8, n=34, 537.9 ± 17.190.9 ± 7.20
PI, ALT, Week 12, n=50, 525.3 ± 17.311.4 ± 9.76
PI, ALT, Week 16, n=48, 536.5 ± 20.921.4 ± 8.75
PI, ALT, Week 20, n=46, 534.9 ± 18.060.3 ± 7.34
PI, ALT, Week 24, n=47, 534.1 ± 14.420.5 ± 7.30
PI, ALT, Week 28, n=42, 532.6 ± 11.470.8 ± 7.46
PI, ALT, Week 32, n=45, 513.5 ± 14.880.5 ± 7.36
PI, ALT, Week 36, n=44, 503.3 ± 13.552.0 ± 9.78
PI, ALT, Week 40, n=42, 515.4 ± 17.811.1 ± 10.52
PI, ALT, Week 44, n=47, 514.0 ± 15.830.9 ± 11.97
PI, ALT, Week 48, n=43, 502.9 ± 10.690.5 ± 8.04
INI, ALT, Week 4, n=99, 971.7 ± 15.150.7 ± 7.20
INI, ALT, Week 8, n=73, 983.3 ± 18.205.4 ± 50.20
INI, ALT, Week 12, n=99, 95-1.0 ± 12.481.7 ± 10.63
INI, ALT, Week 16, n=93, 96-1.8 ± 12.27-0.1 ± 8.58
INI, ALT, Week 20, n=93, 97-1.9 ± 13.60-0.5 ± 9.38
INI, ALT, Week 24, n=94, 950.6 ± 17.330.1 ± 9.95
INI, ALT, Week 28, n=89, 93-2.4 ± 9.70-0.4 ± 12.31
INI, ALT, Week 32, n=93, 95-1.8 ± 12.87-0.3 ± 7.79
INI, ALT, Week 36, n=94, 951.5 ± 35.82-0.4 ± 8.79
INI, ALT, Week 40, n=90, 955.0 ± 59.10-0.6 ± 9.62
INI, ALT, Week 44, n=91, 94-1.6 ± 13.90-0.4 ± 7.91
INI, ALT, Week 48, n=91, 95-0.2 ± 15.17-0.8 ± 7.41
NNRTI, ALT, Week 4, n=151, 153-2.6 ± 9.82-0.7 ± 10.80
NNRTI, ALT, Week 8, n=122, 152-2.9 ± 11.62-0.8 ± 12.06
NNRTI, ALT, Week 12, n=146, 1529.5 ± 160.61-0.8 ± 12.66
NNRTI, ALT, Week 16, n=143, 149-1.3 ± 26.21-1.6 ± 11.39
NNRTI, ALT, Week 20, n=138, 152-2.0 ± 28.04-2.0 ± 12.61
NNRTI, ALT, Week 24, n=143, 1512.6 ± 85.48-1.3 ± 11.85
NNRTI, ALT, Week 28, n=136, 150-4.5 ± 11.46-0.5 ± 14.03
NNRTI, ALT, Week 32, n=137, 148-3.8 ± 14.93-0.9 ± 14.33
NNRTI, ALT, Week 36, n=135, 147-3.8 ± 12.44-0.1 ± 12.48
NNRTI, ALT, Week 40, n=138, 147-3.8 ± 13.48-0.4 ± 13.47
NNRTI, ALT, Week 44, n=137, 148-4.7 ± 12.67-0.4 ± 14.67
NNRTI, ALT, Week 48, n=131, 147-4.6 ± 12.38-0.9 ± 12.75
PI, ALP, Week 4, n=51, 53-3.5 ± 11.63-2.9 ± 8.07
PI, ALP, Week 8, n=34, 53-2.1 ± 24.590.2 ± 11.37
PI, ALP, Week 12, n=50, 52-5.7 ± 14.400.9 ± 10.22
PI, ALP, Week 16, n=48, 53-7.3 ± 17.090.6 ± 8.68
PI, ALP, Week 20, n=46, 53-6.8 ± 16.710.1 ± 10.70
PI, ALP, Week 24, n=47, 53-7.5 ± 17.90-0.4 ± 7.67
PI, ALP, Week 28, n=42, 53-7.3 ± 17.233.0 ± 9.69
PI, ALP, Week 32, n=45, 51-9.3 ± 16.47-0.7 ± 8.50
PI, ALP, Week 36, n=44, 50-10.2 ± 18.520.6 ± 13.52
PI, ALP, Week 40, n=42, 51-8.7 ± 17.37-1.4 ± 8.79
PI, ALP, Week 44, n=47, 51-11.5 ± 17.49-0.9 ± 9.05
PI, ALP, Week 48, n=43, 50-8.0 ± 16.05-0.2 ± 9.08
INI, ALP, Week 4, n=99, 97-0.5 ± 10.59-0.9 ± 7.92
INI, ALP, Week 8, n=73, 98-1.8 ± 8.554.9 ± 33.17
INI, ALP, Week 12, n=99, 95-1.6 ± 8.573.5 ± 19.97
INI, ALP, Week 16, n=93, 96-1.7 ± 10.53-0.2 ± 10.93
INI, ALP, Week 20, n=93, 97-2.0 ± 10.23-0.4 ± 7.93
INI, ALP, Week 24, n=94, 95-1.4 ± 10.23-0.6 ± 8.25
INI, ALP, Week 28, n=89, 93-2.1 ± 10.83-0.8 ± 8.80
INI, ALP, Week 32, n=93, 95-1.6 ± 11.08-2.0 ± 8.23
INI, ALP, Week 36, n=94, 95-2.4 ± 12.03-2.2 ± 9.41
INI, ALP, Week 40, n=90, 95-0.9 ± 13.77-1.9 ± 9.33
INI, ALP, Week 44, n=91, 94-2.6 ± 13.69-0.4 ± 11.60
INI, ALP, Week 48, n=91, 95-1.9 ± 13.29-1.2 ± 10.26
NNRTI, ALP, Week 4, n=151, 153-10.4 ± 12.81-2.7 ± 9.60
NNRTI, ALP, Week 8, n=122, 152-10.9 ± 16.50-1.0 ± 10.77
NNRTI, ALP, Week 12, n=146, 152-13.0 ± 26.62-0.7 ± 11.04
NNRTI, ALP, Week 16, n=143, 149-15.7 ± 22.52-1.0 ± 10.54
NNRTI, ALP, Week 20, n=138, 152-14.9 ± 22.35-1.8 ± 13.77
NNRTI, ALP, Week 24, n=143, 151-14.5 ± 21.880.4 ± 12.75
NNRTI, ALP, Week 28, n=136, 150-16.2 ± 21.66-1.0 ± 13.18
NNRTI, ALP, Week 32, n=137, 148-15.8 ± 21.98-1.8 ± 13.63
NNRTI, ALP, Week 36, n=135, 147-16.1 ± 23.60-1.0 ± 11.86
NNRTI, ALP, Week 40, n=138, 147-17.2 ± 22.83-0.4 ± 13.19
NNRTI, ALP, Week 44, n=137, 148-17.3 ± 23.32-0.8 ± 13.20
NNRTI, ALP, Week 48, n=131, 147-18.0 ± 27.970.2 ± 14.69
PI, AST, Week 4, n=51, 533.8 ± 9.182.3 ± 16.78
PI, AST, Week 8, n=34, 535.1 ± 8.35-0.1 ± 4.60
PI, AST, Week 12, n=50, 522.7 ± 11.491.7 ± 7.21
PI, AST, Week 16, n=48, 533.9 ± 16.811.8 ± 10.69
PI, AST, Week 20, n=46, 534.1 ± 20.850.5 ± 4.29
PI, AST, Week 24, n=47, 531.5 ± 7.761.6 ± 9.93
PI, AST, Week 28, n=42, 532.9 ± 8.861.9 ± 7.45
PI, AST, Week 32, n=45, 513.1 ± 14.130.6 ± 4.93
PI, AST, Week 36, n=44, 501.7 ± 8.041.9 ± 6.24
PI, AST, Week 40, n=42, 515.7 ± 24.610.5 ± 6.05
PI, AST, Week 44, n=47, 511.7 ± 9.711.4 ± 11.60
PI, AST, Week 48, n=43, 501.7 ± 7.092.1 ± 8.74
INI, AST, Week 4, n=99, 970.0 ± 15.36-0.1 ± 6.29
INI, AST, Week 8, n=73, 983.3 ± 25.011.2 ± 21.48
INI, AST, Week 12, n=99, 95-1.3 ± 14.220.8 ± 7.35
INI, AST, Week 16, n=93, 96-2.1 ± 12.730.1 ± 10.96
INI, AST, Week 20, n=93, 97-1.7 ± 13.77-0.9 ± 12.67
INI, AST, Week 24, n=94, 95-0.4 ± 14.88-0.2 ± 10.40
INI, AST, Week 28, n=89, 93-1.4 ± 7.74-0.9 ± 13.48
INI, AST, Week 32, n=93, 95-2.1 ± 13.06-0.8 ± 10.01
INI, AST, Week 36, n=94, 95-0.7 ± 17.34-1.1 ± 11.70
INI, AST, Week 40, n=90, 951.0 ± 20.11-0.4 ± 13.96
INI, AST, Week 44, n=91, 941.0 ± 24.54-0.7 ± 10.69
INI, AST, Week 48, n=91, 950.4 ± 16.570.2 ± 11.91
NNRTI, AST, Week 4, n=151, 153-1.9 ± 11.09-0.5 ± 8.73
NNRTI, AST, Week 8, n=122, 152-1.3 ± 18.14-0.9 ± 8.31
NNRTI, AST, Week 12, n=146, 1524.7 ± 91.540.0 ± 10.08
NNRTI, AST, Week 16, n=143, 1490.3 ± 21.80-1.0 ± 8.37
NNRTI, AST, Week 20, n=138, 152-1.2 ± 17.47-0.7 ± 9.09
NNRTI, AST, Week 24, n=143, 150-0.1 ± 31.53-0.4 ± 8.87
NNRTI, AST, Week 28, n=136, 150-2.8 ± 9.020.4 ± 10.70
NNRTI, AST, Week 32, n=137, 148-2.0 ± 18.271.5 ± 16.84
NNRTI, AST, Week 36, n=135, 147-2.5 ± 10.330.2 ± 9.00
NNRTI, AST, Week 40, n=138, 147-2.7 ± 11.140.1 ± 9.40
NNRTI, AST, Week 44, n=137, 148-3.4 ± 10.380.1 ± 11.20
NNRTI, AST, Week 48, n=131, 147-2.9 ± 10.870.5 ± 10.60
PI, CK, Week 4, n=51, 538.6 ± 182.21133.5 ± 907.82
PI, CK, Week 8, n=34, 5367.9 ± 176.1423.5 ± 174.40
PI, CK, Week 12, n=50, 523.1 ± 162.7157.9 ± 406.52
PI, CK, Week 16, n=48, 5319.4 ± 253.8616.3 ± 66.34
PI, CK, Week 20, n=46, 53103.6 ± 696.546.8 ± 72.86
PI, CK, Week 24, n=47, 53-3.0 ± 181.0318.2 ± 86.69
PI, CK, Week 28, n=42, 5360.3 ± 299.8313.5 ± 93.14
PI, CK, Week 32, n=45, 51157.1 ± 988.651.5 ± 64.94
PI, CK, Week 36, n=44, 50-9.0 ± 191.2522.3 ± 62.09
PI, CK, Week 40, n=42, 51193.7 ± 1188.890.3 ± 48.24
PI, CK, Week 44, n=47, 51-6.3 ± 185.694.8 ± 62.91
PI, CK, Week 48, n=43, 50-1.0 ± 158.3372.9 ± 478.94
INI, CK, Week 4, n=99, 97-32.7 ± 717.86-17.9 ± 260.84
INI, CK, Week 8, n=73, 9895.6 ± 801.75-58.0 ± 577.11
INI, CK, Week 12, n=99, 95-16.1 ± 852.44-23.9 ± 304.61
INI, CK, Week 16, n=93, 96-59.5 ± 629.54-1.9 ± 686.38
INI, CK, Week 20, n=93, 97-55.7 ± 623.92-58.1 ± 622.84
INI, CK, Week 24, n=94, 95-63.1 ± 549.02-40.7 ± 588.24
INI, CK Week 28, n=89, 93-17.4 ± 224.35-27.4 ± 759.07
INI, CK, Week 32, n=93, 95-82.8 ± 587.51-42.1 ± 637.00
INI, CK, Week 36, n=94, 95-76.1 ± 602.03-60.9 ± 603.48
INI, CK, Week 40, n=90, 9540.3 ± 864.00-36.2 ± 609.80
INI, CK, Week 44, n=91, 94199.8 ± 2043.35-60.2 ± 576.84
INI, CK, Week 48, n=91, 9520.5 ± 861.55-25.0 ± 653.03
NNRTI, CK, Week 4, n=151, 15318.2 ± 502.1226.0 ± 214.58
NNRTI, CK, Week 8, n=122, 152108.2 ± 1339.52-3.6 ± 108.28
NNRTI, CK, Week 12, n=146, 15221.9 ± 440.8124.5 ± 222.26
NNRTI, CK, Week 16, n=143, 149139.9 ± 1121.087.0 ± 189.21
NNRTI, CK, Week 20, n=138, 15265.5 ± 656.111.6 ± 114.05
NNRTI, CK, Week 24, n=143, 15124.1 ± 606.4717.7 ± 167.38
NNRTI, CK, Week 28, n=136, 150-10.9 ± 169.2953.2 ± 462.07
NNRTI, CK, Week 32, n=137, 14831.3 ± 650.2794.0 ± 665.17
NNRTI, CK, Week 36, n=135, 14719.0 ± 440.5610.3 ± 135.08
NNRTI, CK, Week 40, n=138, 147-7.7 ± 237.0022.6 ± 195.23
NNRTI, CK, Week 44, n=137, 148-35.4 ± 183.1514.9 ± 173.39
NNRTI, CK, Week 48, n=131, 147-15.1 ± 212.5227.3 ± 272.59
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin

Blood samples were collected for the analysis of clinical chemistry parameter: albumin to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Grams per Liter
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Albumin
Grams per LiterCAB LA+RPV LA (Q4W)Current ART
PI, Week 4, n=51, 530.2 ± 2.21-0.2 ± 2.41
PI, Week 8, n=34, 530.7 ± 2.73-0.1 ± 2.74
PI, Week 12, n=50, 52-0.2 ± 2.67-0.3 ± 2.81
PI, Week 16, n=48, 53-0.2 ± 2.77-0.8 ± 2.72
PI, Week 20, n=46, 53-0.4 ± 2.35-0.8 ± 2.82
PI, Week 24, n=47, 53-0.6 ± 2.24-0.8 ± 2.40
PI, Week 28, n=42, 53-0.6 ± 2.26-1.4 ± 2.08
PI, Week 32, n=45, 51-0.7 ± 2.39-0.5 ± 2.42
PI, Week 36, n=44, 50-0.6 ± 2.44-0.9 ± 2.48
PI, Week 40, n=42, 51-0.1 ± 2.72-0.5 ± 2.37
PI, Week 44, n=47, 51-0.5 ± 2.15-0.5 ± 2.60
PI, Week 48, n=43, 50-0.3 ± 2.74-0.1 ± 2.44
INI, Week 4, n=99, 97-0.4 ± 2.56-0.9 ± 2.62
INI, Week 8, n=73, 98-0.5 ± 2.59-1.0 ± 2.89
INI, Week 12, n=99, 95-0.3 ± 2.92-0.5 ± 2.59
INI, Week 16, n=93, 96-0.5 ± 2.78-1.1 ± 2.80
INI, Week 20, n=93, 97-0.7 ± 2.71-0.7 ± 2.77
INI, Week 24, n=94, 95-0.8 ± 2.86-1.0 ± 2.74
INI, Week 28, n=89, 93-0.3 ± 2.55-1.1 ± 2.87
INI, Week 32, n=93, 95-0.2 ± 2.70-1.3 ± 2.77
INI, Week 36, n=94, 95-0.8 ± 2.67-1.1 ± 2.54
INI, Week 40, n=90, 95-0.3 ± 2.40-1.3 ± 2.84
INI, Week 44, n=91, 94-0.5 ± 2.77-1.0 ± 2.76
INI, Week 48, n=91, 95-0.1 ± 2.69-0.5 ± 2.69
NNRTI, Week 4, n=151, 153-0.8 ± 2.70-0.3 ± 2.42
NNRTI, Week 8, n=122, 152-0.4 ± 2.83-0.6 ± 2.53
NNRTI, Week 12, n=146, 152-0.8 ± 2.59-0.3 ± 2.61
NNRTI, Week 16, n=143, 149-0.8 ± 2.79-0.7 ± 2.63
NNRTI, Week 20, n=138, 152-0.9 ± 2.96-0.9 ± 2.33
NNRTI, Week 24, n=143, 151-0.7 ± 2.73-0.7 ± 2.57
NNRTI, Week 28, n=136, 150-0.9 ± 2.72-0.9 ± 2.34
NNRTI, Week 32, n=137, 148-0.9 ± 2.94-1.0 ± 2.45
NNRTI, Week 36, n=135, 147-1.0 ± 2.83-0.8 ± 2.79
NNRTI, Week 40, n=138, 147-0.7 ± 2.54-1.0 ± 2.52
NNRTI, Week 44, n=137, 148-0.3 ± 2.60-0.8 ± 2.22
NNRTI, Week 48, n=131, 147-0.6 ± 2.57-0.5 ± 2.49
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine

Blood samples were collected for the analysis of clinical chemistry parameter: bilirubin, direct bilirubin and creatinine to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Micromoles per liter
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Bilirubin, Direct Bilirubin and Creatinine
Micromoles per literCAB LA+RPV LA (Q4W)Current ART
PI, Bilirubin, Week 4, n=51, 53-9.0 ± 20.620.3 ± 6.95
PI, Bilirubin, Week 8, n=34, 53-6.6 ± 13.760.1 ± 5.76
PI, Bilirubin, Week 12, n=50, 52-10.2 ± 20.181.7 ± 7.11
PI, Bilirubin, Week 16, n=48, 53-10.0 ± 20.130.6 ± 6.42
PI, Bilirubin, Week 20, n=46, 53-9.2 ± 20.211.5 ± 12.45
PI, Bilirubin, Week 24, n=47, 53-9.6 ± 20.642.7 ± 11.87
PI, Bilirubin, Week 28, n=42, 53-10.0 ± 22.420.9 ± 7.70
PI, Bilirubin, Week 32, n=45, 51-8.9 ± 21.342.7 ± 8.64
PI, Bilirubin, Week 36, n=44, 50-10.5 ± 21.752.6 ± 7.35
PI, Bilirubin, Week 40, n=42, 51-11.0 ± 22.203.5 ± 12.74
PI, Bilirubin, Week 44, n=47, 51-9.6 ± 20.323.7 ± 9.10
PI, Bilirubin, Week 48, n=43, 50-10.7 ± 21.772.3 ± 5.23
INI, Bilirubin, Week 4, n=99, 970.2 ± 3.92-0.7 ± 3.93
INI, Bilirubin, Week 8, n=73, 980.4 ± 3.960.9 ± 12.43
INI, Bilirubin, Week 12, n=99, 950.6 ± 4.41-0.5 ± 4.69
INI, Bilirubin, Week 16, n=93, 960.6 ± 4.30-0.2 ± 4.35
INI, Bilirubin, Week 20, n=93, 970.9 ± 4.08-0.5 ± 4.32
INI, Bilirubin, Week 24, n=94, 940.2 ± 3.72-0.5 ± 3.88
INI, Bilirubin, Week 28, n=89, 931.1 ± 3.58-0.4 ± 4.85
INI, Bilirubin, Week 32, n=93, 950.7 ± 4.67-1.1 ± 4.54
INI, Bilirubin, Week 36, n=94, 950.5 ± 4.07-0.6 ± 4.62
INI, Bilirubin, Week 40, n=90, 950.6 ± 4.28-1.0 ± 4.26
INI, Bilirubin, Week 44, n=91, 940.9 ± 4.34-0.7 ± 4.72
INI, Bilirubin, Week 48, n=91, 951.1 ± 3.72-0.9 ± 3.96
NNRTI, Bilirubin, Week 4, n=151, 1531.4 ± 3.87-0.4 ± 2.85
NNRTI, Bilirubin, Week 8, n=122, 1521.4 ± 3.84-0.4 ± 2.43
NNRTI, Bilirubin, Week 12, n=146, 1522.0 ± 4.69-0.2 ± 3.01
NNRTI, Bilirubin, Week 16, n=143, 1493.3 ± 14.12-0.5 ± 2.66
NNRTI, Bilirubin, Week 20, n=138, 1522.1 ± 4.90-0.1 ± 2.81
NNRTI, Bilirubin, Week 24, n=143, 1511.8 ± 3.91-0.3 ± 2.84
NNRTI, Bilirubin, Week 28, n=136, 1502.4 ± 4.11-0.4 ± 3.04
NNRTI, Bilirubin, Week 32, n=137, 1482.2 ± 4.76-0.3 ± 2.57
NNRTI, Bilirubin, Week 36, n=135, 1471.8 ± 4.14-0.2 ± 2.61
NNRTI, Bilirubin, Week 40, n=138, 1472.2 ± 4.43-0.2 ± 2.61
NNRTI, Bilirubin, Week 44, n=137, 1482.0 ± 4.15-0.1 ± 2.72
NNRTI, Bilirubin, Week 48, n=131, 1472.2 ± 4.590.1 ± 2.98
PI, Direct bilirubin, Week 4, n=51, 53-1.2 ± 2.340.3 ± 1.40
PI, Direct bilirubin, Week 8, n=34, 53-0.9 ± 2.16-0.1 ± 1.44
PI, Direct bilirubin, Week 12, n=50, 52-1.6 ± 2.160.3 ± 1.39
PI, direct bilirubin, Week 16, n=48, 53-1.7 ± 2.120.0 ± 1.30
PI, Direct bilirubin, Week 20, n=46, 53-1.5 ± 2.270.0 ± 1.86
PI, Direct bilirubin, Week 24, n=47, 53-1.4 ± 2.270.2 ± 1.72
PI, Direct bilirubin, Week 28, n=42, 53-1.6 ± 2.43-0.3 ± 1.52
PI, Direct bilirubin, Week 32, n=45, 51-1.4 ± 2.480.2 ± 1.74
PI, Direct bilirubin, Week 36, n=44, 50-1.8 ± 2.290.2 ± 1.49
PI, Direct bilirubin, Week 40, n=42, 51-1.8 ± 2.290.2 ± 1.43
PI, Direct bilirubin, Week 44, n=47, 51-1.5 ± 2.220.3 ± 1.52
PI, Direct bilirubin, Week 48, n=43, 50-1.5 ± 2.350.2 ± 1.36
INI, Direct bilirubin, Week 4, n=99, 970.0 ± 1.110.0 ± 1.19
INI, Direct bilirubin, Week 8, n=73, 980.0 ± 1.130.7 ± 6.76
INI, Direct bilirubin, Week 12, n=99, 950.0 ± 1.140.0 ± 1.29
INI, Direct bilirubin, Week 16, n=93, 960.0 ± 1.14-0.3 ± 1.06
INI, Direct bilirubin, Week 20, n=93, 97-0.2 ± 0.96-0.2 ± 1.23
INI, Direct bilirubin, Week 24, n=94, 94-0.1 ± 1.07-0.3 ± 1.16
INI, Direct bilirubin, Week 28, n=89, 93-0.1 ± 0.97-0.2 ± 1.30
INI, Direct bilirubin, Week 32, n=93, 95-0.2 ± 1.24-0.4 ± 1.15
INI, Direct bilirubin, Week 36, n=94, 95-0.2 ± 1.33-0.3 ± 1.18
INI, Direct bilirubin, Week 40, n=90, 95-0.1 ± 1.10-0.4 ± 1.24
INI, Direct bilirubin. Week 44, n=91, 940.0 ± 1.14-0.3 ± 1.11
INI, Direct bilirubin, Week 48, n=91, 950.0 ± 1.01-0.1 ± 1.28
NNRTI, Direct bilirubin, Week 4, n=151, 1530.1 ± 1.140.1 ± 1.12
NNRTI, Direct bilirubin, Week 8, n=122, 1520.1 ± 1.240.0 ± 1.03
NNRTI, Direct bilirubin, Week 12, n=146, 1520.2 ± 1.380.0 ± 1.08
NNRTI, Direct bilirubin, Week 16, n=143, 1490.7 ± 6.82-0.1 ± 1.09
NNRTI, Direct bilirubin, Week 20, n=138, 1520.1 ± 1.32-0.2 ± 1.08
NNRTI, Direct bilirubin, Week 24, n=143, 1510.1 ± 1.34-0.1 ± 1.06
NNRTI, Direct bilirubin, Week 28, n=136, 1500.1 ± 1.29-0.2 ± 1.19
NNRTI, Direct bilirubin, Week 32, n=137, 1480.0 ± 1.31-0.2 ± 1.06
NNRTI, Direct bilirubin, Week 36, n=135, 1470.0 ± 1.47-0.2 ± 1.09
NNRTI, Direct bilirubin, Week 40, n=138, 1470.0 ± 1.55-0.2 ± 1.01
NNRTI, Direct bilirubin, Week 44, n=137, 1480.1 ± 1.28-0.1 ± 1.08
NNRTI, Direct bilirubin, Week 48, n=131, 1470.1 ± 1.270.0 ± 1.16
PI, Creatinine, Week 4, n=51, 531.46 ± 7.7262.16 ± 6.737
PI, Creatinine, Week 8, n=34, 530.87 ± 7.7771.17 ± 5.605
PI, Creatinine, Week 12, n=50, 52-1.66 ± 8.9713.01 ± 5.406
PI, Creatinine, Week 16, n=48, 53-0.90 ± 8.6582.88 ± 5.918
PI, Creatinine, Week 20, n=46, 531.63 ± 8.7095.00 ± 9.336
PI, Creatinine, Week 24, n=47, 530.48 ± 7.1432.47 ± 6.821
PI, Creatinine, Week 28, n=42, 533.06 ± 9.7413.05 ± 6.908
PI, Creatinine, Week 32, n=45, 512.29 ± 10.1243.79 ± 6.540
PI, Creatinine, Week 36, n=44, 502.20 ± 7.3472.36 ± 6.291
PI, Creatinine, Week 40, n=42, 511.10 ± 9.1553.46 ± 6.166
PI, Creatinine, Week 44, n=47, 513.01 ± 8.9812.73 ± 6.169
PI, Creatinine, Week 48, n=43, 504.41 ± 10.0091.86 ± 5.575
INI, Creatinine, Week 4, n=99, 95-1.61 ± 8.8481.64 ± 10.592
INI, Creatinine, Week 8, n=73, 98-3.93 ± 10.0301.56 ± 9.444
INI, Creatinine, Week 12, n=99, 95-2.47 ± 10.9733.03 ± 10.203
INI, Creatinine, Week 16, n=93, 96-3.93 ± 9.0000.36 ± 8.651
INI, Creatinine, Week 20, n=93, 97-3.73 ± 9.1010.86 ± 9.608
INI, Creatinine, Week 24, n=94, 94-4.25 ± 8.2810.87 ± 10.493
INI, Creatinine, Week 28, n=89, 93-3.54 ± 10.7130.92 ± 10.086
INI, Creatinine, Week 32, n=93, 95-3.48 ± 10.5910.86 ± 9.754
INI, Creatinine, Week 36, n=94, 95-4.31 ± 10.3601.34 ± 9.369
INI, Creatinine, Week 40, n=90, 95-3.08 ± 9.9131.66 ± 10.272
INI, Creatinine, Week 44, n=91, 94-3.33 ± 9.1650.98 ± 10.443
INI, Creatinine, Week 48, n=91, 95-2.99 ± 9.4420.47 ± 9.602
NNRTI, Creatinine, Week 4, n=151, 1532.86 ± 7.4561.77 ± 6.484
NNRTI, Creatinine, Week 8, n=122, 1520.86 ± 8.2631.05 ± 6.790
NNRTI, Creatinine, Week 12, n=146, 1521.47 ± 7.9280.44 ± 6.096
NNRTI, Creatinine, Week 16, n=143, 1491.67 ± 8.9341.98 ± 8.475
NNRTI, Creatinine, Week 20, n=138, 1523.04 ± 8.8361.27 ± 7.023
NNRTI, Creatinine, Week 24, n=143, 1514.42 ± 14.8191.28 ± 6.553
NNRTI, Creatinine, Week 28, n=136, 1503.61 ± 10.6271.50 ± 7.483
NNRTI, Creatinine, Week 32, n=137, 1482.26 ± 9.0332.01 ± 7.811
NNRTI, Creatinine, Week 36, n=135, 1472.98 ± 10.5961.54 ± 7.354
NNRTI, Creatinine, Week 40, n=138, 1473.39 ± 9.4960.99 ± 7.471
NNRTI, Creatinine, Week 44, n=137, 1483.24 ± 8.8921.21 ± 6.686
NNRTI, Creatinine, Week 48, n=131, 1473.84 ± 11.8600.69 ± 7.241
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance

Blood samples were collected for the analysis of clinical chemistry parameter: creatinine clearance to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). GFR will be estimated by the central laboratory using the CKD-EPI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Milliliters per minute per 1.73meter^2
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Creatinine Clearance
Milliliters per minute per 1.73meter^2CAB LA+RPV LA (Q4W)Current ART
PI, Week 4, n=51, 53-2.2 ± 9.77-2.8 ± 8.02
PI, Week 8, n=34, 53-1.1 ± 10.19-1.3 ± 6.58
PI, Week 12, n=50, 522.2 ± 11.04-3.7 ± 6.99
PI, Week 16, n=48, 530.9 ± 11.02-3.1 ± 7.63
PI, Week 20, n=46, 53-2.2 ± 10.80-5.0 ± 9.26
PI, Week 24, n=47, 53-1.0 ± 8.60-3.8 ± 8.51
PI, Week 28, n=42, 53-4.2 ± 11.82-4.0 ± 8.46
PI, Week 32, n=45, 51-3.2 ± 12.30-5.2 ± 7.56
PI, Week 36, n=44, 50-3.8 ± 8.68-3.6 ± 8.08
PI, Week 40, n=42, 51-2.4 ± 10.71-4.9 ± 7.25
PI, Week 44, n=47, 51-4.5 ± 10.63-4.2 ± 7.58
PI, Week 48, n=43, 50-5.6 ± 12.22-3.1 ± 6.54
INI, Week 4, n=99, 951.0 ± 9.51-2.0 ± 11.28
INI, Week 8, n=72, 983.9 ± 9.84-1.9 ± 9.28
INI, Week 12, n=99, 932.1 ± 11.32-3.1 ± 9.60
INI, Week 16, n=93, 963.6 ± 9.71-0.7 ± 8.59
INI, Week 20, n=93, 973.5 ± 9.77-1.7 ± 9.58
INI, Week 24, n=94, 943.9 ± 9.26-1.8 ± 10.38
INI, Week 28, n=89, 933.1 ± 11.02-1.6 ± 9.55
INI, Week 32, n=92, 953.0 ± 10.40-2.0 ± 9.69
INI, Week 36, n=94, 953.7 ± 11.19-2.3 ± 9.30
INI, Week 40, n=89, 952.7 ± 10.45-2.6 ± 10.14
INI, Week 44, n=91, 942.6 ± 9.88-1.6 ± 10.90
INI, Week 48, n=90, 943.0 ± 9.74-1.6 ± 9.73
NNRTI, Week 4, n=151, 153-3.4 ± 9.06-2.3 ± 8.10
NNRTI, Week 8, n=121, 152-1.1 ± 9.35-1.3 ± 7.72
NNRTI, Week 12, n=146, 152-1.7 ± 8.90-0.5 ± 7.03
NNRTI, Week 16, n=143, 148-1.8 ± 10.60-2.3 ± 9.06
NNRTI, Week 20, n=138, 152-3.7 ± 9.64-1.9 ± 7.41
NNRTI, Week 24, n=142, 151-4.3 ± 10.67-2.0 ± 7.67
NNRTI, Week 28, n=136, 150-4.3 ± 10.68-2.4 ± 8.67
NNRTI, Week 32, n=137, 148-3.3 ± 10.42-2.8 ± 8.80
NNRTI, Week 36, n=135, 147-3.8 ± 10.97-2.5 ± 8.16
NNRTI, Week 40, n=137, 147-4.4 ± 9.97-2.0 ± 8.90
NNRTI, Week 44, n=136, 148-4.4 ± 9.75-2.0 ± 7.45
NNRTI, Week 48, n=131, 147-5.2 ± 11.72-1.6 ± 8.25
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase

Blood samples were collected for the analysis of clinical chemistry parameter: lipase to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Units per liter
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48: Lipase
Units per literCAB LA+RPV LA (Q4W)Current ART
PI, Week 4, n=51, 53-2.2 ± 16.831.2 ± 19.34
PI, Week 8, n=34, 53-2.6 ± 6.712.5 ± 25.36
PI, Week 12, n=49, 52-1.4 ± 17.24-2.2 ± 15.95
PI, Week 16, n=47, 53-0.5 ± 18.711.4 ± 17.40
PI, Week 20, n=46, 53-2.5 ± 17.90-0.6 ± 17.49
PI, Week 24, n=47, 53-2.0 ± 16.61-2.7 ± 16.30
PI, Week 28, n=42, 53-0.7 ± 18.600.2 ± 16.18
PI, Week 32, n=45, 51-2.2 ± 19.272.5 ± 18.35
PI, Week 36, n=44, 50-0.8 ± 17.96-1.2 ± 18.18
PI, Week 40, n=42, 512.2 ± 26.77-1.8 ± 19.40
PI, Week 44, n=47, 51-1.2 ± 18.281.4 ± 17.94
PI, Week 48, n=43, 50-1.5 ± 19.38-1.3 ± 15.73
INI, Week 4, n=99, 978.1 ± 34.323.8 ± 30.44
INI, Week 8, n=72, 980.7 ± 9.79-0.5 ± 14.46
INI, Week 12, n=99, 934.3 ± 17.701.8 ± 21.29
INI, Week 16, n=93, 974.4 ± 22.420.6 ± 16.13
INI, Week 20, n=94, 972.5 ± 17.230.9 ± 17.07
INI, Week 24, n=94, 952.2 ± 15.172.2 ± 18.91
INI, Week 28, n=89, 945.6 ± 28.065.1 ± 24.20
INI, Week 32, n=92, 953.2 ± 18.685.4 ± 22.79
INI, Week 36, n=94, 955.2 ± 21.040.1 ± 13.82
INI, Week 40, n=89, 953.5 ± 11.711.7 ± 16.60
INI, Week 44, n=91, 944.3 ± 21.594.8 ± 23.54
INI, Week 48, n=90, 945.0 ± 24.953.9 ± 23.48
NNRTI, Week 4, n=151, 1535.7 ± 50.440.1 ± 20.35
NNRTI, Week 8, n=121, 1522.6 ± 25.041.5 ± 16.94
NNRTI, Week 12, n=146, 1523.0 ± 30.94-1.9 ± 17.59
NNRTI, Week 16, n=145, 1492.5 ± 27.826.1 ± 40.62
NNRTI, Week 20, n=138, 1520.9 ± 13.531.3 ± 37.14
NNRTI, Week 24, n=142, 1513.4 ± 24.815.4 ± 28.22
NNRTI, Week 28, n=136, 1500.8 ± 24.381.2 ± 15.79
NNRTI, Week 32, n=137, 1489.1 ± 78.961.9 ± 21.30
NNRTI, Week 36, n=135, 1476.9 ± 68.071.7 ± 19.14
NNRTI, Week 40, n=138, 1477.1 ± 43.530.5 ± 17.62
NNRTI, Week 44, n=136, 1481.6 ± 24.461.1 ± 20.52
NNRTI, Week 48, n=131, 1463.1 ± 32.540.9 ± 16.60
SecondaryChange From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48

Blood samples were collected for the analysis of clinical chemistry parameters: CO2, chloride, glucose, phosphate, potassium, sodium and urea to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Clinical Chemistry Parameters Using Baseline Third Agent Treatment Class Overtime Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
PI, CO2, Week 4, n=51, 531.3 ± 2.630.7 ± 2.34
PI, CO2, Week 8, n=34, 530.4 ± 2.360.3 ± 2.65
PI, CO2, Week 12, n=50, 520.7 ± 2.840.2 ± 2.23
PI, CO2, Week 16, n=48, 530.8 ± 2.600.2 ± 2.32
PI, CO2, Week 20, n=46, 530.9 ± 2.530.0 ± 2.26
PI, CO2, Week 24, n=47, 530.4 ± 2.230.1 ± 1.94
PI, CO2, Week 28, n=42, 530.6 ± 2.54-0.2 ± 2.37
PI, CO2, Week 32, n=45, 510.5 ± 2.35-0.2 ± 2.36
PI, CO2, Week 36, n=44, 500.5 ± 2.38-0.4 ± 1.98
PI, CO2, Week 40, n=42, 510.5 ± 2.100.3 ± 2.26
PI, CO2, Week 44, n=47, 510.7 ± 2.290.3 ± 2.18
PI, CO2, Week 48, n=43, 500.9 ± 2.69-0.1 ± 1.87
INI, CO2, Week 4, n=99, 971.0 ± 2.370.8 ± 2.21
INI, CO2, Week 8, n=73, 980.5 ± 2.290.6 ± 2.46
INI, CO2, Week 12, n=99, 950.4 ± 2.270.3 ± 2.31
INI, CO2, Week 16, n=93, 960.1 ± 2.560.6 ± 2.53
INI, CO2, Week 20, n=93, 970.1 ± 2.070.7 ± 2.25
INI, CO2, Week 24, n=94, 950.1 ± 2.320.2 ± 2.49
INI, CO2, Week 28, n=89, 93-0.3 ± 2.300.2 ± 2.41
INI, CO2, Week 32, n=93, 950.2 ± 2.330.1 ± 2.34
INI, CO2, Week 36, n=94, 950.0 ± 2.360.5 ± 2.58
INI, CO2, Week 40, n=90, 950.5 ± 2.430.3 ± 2.18
INI, CO2, Week 44, n=91, 940.5 ± 2.360.7 ± 2.45
INI, CO2, Week 48, n=91, 950.1 ± 2.120.3 ± 2.53
NNRTI, CO2, Week 4, n=151, 1530.9 ± 2.600.7 ± 2.18
NNRTI, CO2, Week 8, n=122, 1520.4 ± 2.320.8 ± 2.52
NNRTI, CO2, Week 12, n=146, 1520.5 ± 2.380.4 ± 2.51
NNRTI, CO2, Week 16, n=143, 1490.3 ± 2.250.5 ± 2.37
NNRTI, CO2, Week 20, n=138, 1520.1 ± 2.270.2 ± 2.35
NNRTI, CO2, Week 24, n=143, 1500.3 ± 2.630.3 ± 2.57
NNRTI, CO2, Week 28, n=136, 1500.1 ± 2.540.2 ± 2.40
NNRTI, CO2, Week 32, n=137, 148-0.2 ± 2.390.4 ± 2.27
NNRTI, CO2, Week 36, n=135, 1470.1 ± 2.380.5 ± 2.37
NNRTI, CO2, Week 40, n=138, 1470.4 ± 2.640.5 ± 2.38
NNRTI, CO2, Week 44, n=137, 1480.4 ± 2.350.5 ± 2.01
NNRTI, CO2, Week 48, n=131, 147-0.1 ± 2.470.3 ± 2.30
PI, Chloride, Week 4, n=51, 530.5 ± 1.800.5 ± 2.34
PI, Chloride, Week 8, n=34, 530.2 ± 2.590.7 ± 2.42
PI, Chloride, Week 12, n=50, 520.5 ± 2.390.8 ± 2.20
PI, Chloride, Week 16, n=48, 530.5 ± 2.461.0 ± 2.31
PI, Chloride, Week 20, n=46, 530.8 ± 2.200.7 ± 2.30
PI, Chloride, Week 24, n=47, 531.1 ± 2.071.3 ± 2.36
PI, Chloride, Week 28, n=42, 531.5 ± 2.191.2 ± 3.06
PI, Chloride, Week 32, n=45, 510.9 ± 2.430.9 ± 2.60
PI, Chloride, Week 36, n=44, 501.0 ± 2.281.0 ± 3.00
PI, Chloride, Week 40, n=42, 511.3 ± 2.351.1 ± 2.60
PI, Chloride, Week 44, n=47, 511.1 ± 2.211.1 ± 2.57
PI, Chloride, Week 48, n=43, 500.5 ± 2.100.9 ± 2.29
INI, Chloride, Week 4, n=99, 970.3 ± 2.020.5 ± 1.96
INI, Chloride, Week 8, n=73, 980.2 ± 2.020.1 ± 2.42
INI, Chloride, Week 12, n=99, 950.4 ± 2.530.5 ± 2.27
INI, Chloride, Week 16, n=93, 960.9 ± 2.450.7 ± 2.32
INI, Chloride, Week 20, n=93, 971.0 ± 2.440.2 ± 2.31
INI, Chloride, Week 24, n=94, 950.6 ± 2.460.5 ± 2.19
INI, Chloride, Week 28, n=89, 930.8 ± 1.920.3 ± 2.37
INI, Chloride, Week 32, n=93, 950.7 ± 2.390.7 ± 2.45
INI, Chloride, Week 36, n=94, 950.8 ± 2.200.5 ± 2.32
INI, Chloride, Week 40, n=90, 950.7 ± 2.240.4 ± 2.69
INI, Chloride, Week 44, n=91, 940.7 ± 2.380.5 ± 2.41
INI, Chloride, Week 48, n=91, 950.4 ± 2.37-0.3 ± 2.36
NNRTI, Chloride, Week 4, n=151, 1530.4 ± 2.150.6 ± 2.17
NNRTI, Chloride, Week 8, n=122, 1520.4 ± 2.050.7 ± 1.91
NNRTI, Chloride, Week 12, n=146, 1520.4 ± 2.120.5 ± 2.27
NNRTI, Chloride, Week 16, n=143, 1490.5 ± 2.370.8 ± 2.20
NNRTI, Chloride, Week 20, n=138, 1520.7 ± 2.271.1 ± 2.40
NNRTI, Chloride, Week 24, n=143, 1510.5 ± 2.601.1 ± 2.24
NNRTI, Chloride, Week 28, n=136, 1500.8 ± 2.381.3 ± 2.39
NNRTI, Chloride, Week 32, n=137, 1480.8 ± 2.441.1 ± 2.15
NNRTI, Chloride, Week 36, n=135, 1471.0 ± 2.151.1 ± 2.37
NNRTI, Chloride, Week 40, n=138, 1470.6 ± 2.201.0 ± 2.84
NNRTI, Chloride, Week 44, n=137, 1480.6 ± 2.071.0 ± 2.08
NNRTI, Chloride, Week 48, n=131, 1470.6 ± 2.450.5 ± 2.36
PI, Glucose, Week 4, n=43, 43-0.08 ± 0.9220.32 ± 0.401
PI, Glucose, Week 8, n=25, 410.17 ± 0.5130.22 ± 0.466
PI, Glucose, Week 12, n=40, 420.03 ± 0.9250.27 ± 0.494
PI, Glucose, Week 16, n=39, 430.11 ± 1.1630.28 ± 0.704
PI, Glucose, Week 20, n=35, 41-0.07 ± 1.0580.30 ± 0.799
PI, Glucose, Week 24, n=38, 420.11 ± 0.7050.32 ± 0.636
PI, Glucose, Week 28, n=32, 43-0.03 ± 1.3420.16 ± 0.441
PI, Glucose, Week 32, n=36, 410.23 ± 1.1480.29 ± 0.600
PI, Glucose, Week 36, n=35, 41-0.01 ± 1.0140.22 ± 0.483
PI, Glucose, Week 40, n=34, 400.11 ± 1.0350.18 ± 0.497
PI, Glucose, Week 44, n=40, 400.01 ± 1.0080.20 ± 0.278
PI, Glucose, Week 48, n=39, 48-0.01 ± 0.9770.11 ± 0.663
INI, Glucose, Week 4, n=55, 520.30 ± 0.6130.07 ± 0.774
INI, Glucose, Week 8, n=36, 570.12 ± 0.5950.21 ± 1.083
INI, Glucose, Week 12, n=52, 550.36 ± 0.9960.30 ± 1.357
INI, Glucose, Week 16, n=53, 520.35 ± 1.4370.13 ± 0.557
INI, Glucose, Week 20, n=51, 570.25 ± 0.515-0.06 ± 0.676
INI, Glucose, Week 24, n=59, 610.24 ± 0.5960.04 ± 0.652
INI, Glucose, Week 28, n=52, 620.17 ± 0.6810.33 ± 0.763
INI, Glucose, Week 32, n=53, 550.48 ± 1.0710.32 ± 0.876
INI, Glucose, Week 36, n=53, 570.34 ± 0.6420.19 ± 1.063
INI, Glucose, Week 40, n=59, 620.36 ± 0.9220.14 ± 0.566
INI, Glucose, Week 44, n=54, 570.33 ± 0.9710.16 ± 0.626
INI, Glucose, Week 48, n=81, 900.04 ± 0.577-0.03 ± 0.796
NNRTI, Glucose, Week 4, n=116, 1240.20 ± 0.6660.24 ± 1.055
NNRTI, Glucose, Week 8, n=90, 1160.27 ± 0.9870.23 ± 0.795
NNRTI, Glucose, Week 12, n=112, 1190.16 ± 0.7460.11 ± 0.887
NNRTI, Glucose, Week 16, n=115, 1160.22 ± 0.7670.33 ± 1.347
NNRTI, Glucose, Week 20, n=106, 1180.25 ± 0.6360.28 ± 1.104
NNRTI, Glucose, Week 24, n=115, 1210.27 ± 0.7630.16 ± 1.037
NNRTI, Glucose, Week 28, n=104, 1200.23 ± 0.5960.30 ± 1.077
NNRTI, Glucose, Week 32, n=103, 1170.32 ± 0.8110.24 ± 1.062
NNRTI, Glucose, Week 36, n=102, 1170.17 ± 0.7890.31 ± 1.217
NNRTI, Glucose, Week 40, n=100, 1110.27 ± 0.6920.33 ± 1.118
NNRTI, Glucose, Week 44, n=99, 1160.26 ± 0.7930.35 ± 1.121
NNRTI, Glucose, Week 48, n=118, 1360.06 ± 0.6590.02 ± 1.074
PI, Phosphate, Week 4, n=51, 530.068 ± 0.15130.009 ± 0.1682
PI, Phosphate, Week 8, n=34, 530.076 ± 0.2023-0.019 ± 0.1752
PI, Phosphate, Week 12, n=50, 520.025 ± 0.17940.007 ± 0.1524
PI, Phosphate, Week 16, n=48, 530.056 ± 0.2028-0.008 ± 0.1610
PI, Phosphate, Week 20, n=46, 530.069 ± 0.18640.017 ± 0.1924
PI, Phosphate, Week 24, n=47, 530.037 ± 0.19710.018 ± 0.1735
PI, Phosphate, Week 28, n=42, 530.035 ± 0.21400.017 ± 0.1971
PI, Phosphate, Week 32, n=45, 510.053 ± 0.21910.032 ± 0.1545
PI, Phosphate, Week 36, n=44, 500.032 ± 0.1818-0.001 ± 0.1828
PI, Phosphate, Week 40, n=42, 510.027 ± 0.23920.001 ± 0.1657
PI, Phosphate, Week 44, n=47, 510.033 ± 0.21070.011 ± 0.1736
PI, Phosphate, Week 48, n=43, 500.048 ± 0.19940.017 ± 0.1387
INI, Phosphate, Week 4, n=99, 970.036 ± 0.15180.017 ± 0.1588
INI, Phosphate, Week 8, n=73, 980.056 ± 0.15320.010 ± 0.1676
INI, Phosphate, Week 12, n=99, 950.024 ± 0.21080.017 ± 0.1808
INI, Phosphate, Week 16, n=93, 960.031 ± 0.18950.001 ± 0.1708
INI, Phosphate, Week 20, n=93, 970.012 ± 0.17640.025 ± 0.1823
INI, Phosphate, Week 24, n=94, 950.031 ± 0.1501-0.011 ± 0.1785
INI, Phosphate, Week 28, n=89, 930.032 ± 0.16280.006 ± 0.1806
INI, Phosphate, Week 32, n=93, 950.012 ± 0.1751-0.017 ± 0.1827
INI, Phosphate, Week 36, n=94, 95-0.002 ± 0.1496-0.001 ± 0.1979
INI, Phosphate, Week 40, n=90, 950.018 ± 0.1766-0.002 ± 0.1721
INI, Phosphate, Week 44, n=91, 940.005 ± 0.16950.005 ± 0.1977
INI, Phosphate, Week 48, n=91, 950.028 ± 0.16840.002 ± 0.2072
NNRTI, Phosphate, Week 4, n=151, 1530.085 ± 0.17850.016 ± 0.1580
NNRTI, Phosphate, Week 8, n=122, 1520.061 ± 0.2002-0.012 ± 0.1515
NNRTI, Phosphate, Week 12, n=146, 1520.057 ± 0.19460.012 ± 0.1780
NNRTI, Phosphate, Week 16, n=143, 1490.043 ± 0.20880.008 ± 0.1613
NNRTI, Phosphate, Week 20, n=138, 1520.039 ± 0.1935-0.002 ± 0.1823
NNRTI, Phosphate, Week 24, n=143, 1510.050 ± 0.22200.012 ± 0.1923
NNRTI, Phosphate, Week 28, n=136, 1500.040 ± 0.1850-0.003 ± 0.1789
NNRTI, Phosphate, Week 32, n=137, 1480.018 ± 0.20560.011 ± 0.2020
NNRTI, Phosphate, Week 36, n=135, 1470.014 ± 0.2069-0.002 ± 0.1794
NNRTI, Phosphate, Week 40, n=138, 1470.026 ± 0.2095-0.006 ± 0.1783
NNRTI, Phosphate, Week 44, n=137, 1480.041 ± 0.21120.000 ± 0.1735
NNRTI, Phosphate, Week 48, n=131, 1470.034 ± 0.2220-0.001 ± 0.1619
PI, Potassium, Week 4, n=51, 530.12 ± 0.3690.20 ± 0.447
PI, Potassium, Week 8, n=34, 530.05 ± 0.2450.08 ± 0.307
PI, Potassium, Week 12, n=50, 520.12 ± 0.3530.19 ± 0.388
PI, Potassium, Week 16, n=48, 530.02 ± 0.3430.19 ± 0.398
PI, Potassium, Week 20, n=46, 530.05 ± 0.3380.18 ± 0.420
PI, Potassium, Week 24, n=47, 530.01 ± 0.3540.19 ± 0.384
PI, Potassium, Week 28, n=42, 530.09 ± 0.3380.15 ± 0.342
PI, Potassium, Week 32, n=45, 510.02 ± 0.3560.19 ± 0.408
PI, Potassium, Week 36, n=44, 500.12 ± 0.3630.14 ± 0.371
PI, Potassium, Week 40, n=42, 510.09 ± 0.3480.15 ± 0.394
PI, Potassium, Week 44, n=47, 510.10 ± 0.4090.21 ± 0.433
PI, Potassium, Week 48, n=43, 500.02 ± 0.3590.01 ± 0.409
INI, Potassium, Week 4, n=99, 970.03 ± 0.3080.08 ± 0.335
INI, Potassium, Week 8, n=73, 98-0.02 ± 0.2820.06 ± 0.483
INI, Potassium, Week 12, n=99, 950.02 ± 0.3160.01 ± 0.329
INI, Potassium, Week 16, n=93, 96-0.01 ± 0.2860.01 ± 0.319
INI, Potassium, Week 20, n=93, 970.03 ± 0.3330.00 ± 0.313
INI, Potassium, Week 24, n=94, 950.02 ± 0.3040.04 ± 0.315
INI, Potassium,Week 28, n=89, 930.02 ± 0.4220.03 ± 0.372
INI, Potassium, Week 32, n=93, 950.02 ± 0.3220.01 ± 0.289
INI, Potassium, Week 36, n=94, 950.01 ± 0.3450.05 ± 0.349
INI, Potassium, Week 40, n=90, 950.01 ± 0.2880.01 ± 0.329
INI, Potassium, Week 44, n=91, 940.01 ± 0.2650.00 ± 0.327
INI, Potassium, Week 48, n=91, 95-0.03 ± 0.249-0.01 ± 0.292
NNRTI, Potassium, Week 4, n=151, 1530.05 ± 0.3540.10 ± 0.368
NNRTI, Potassium, Week 8, n=122, 1520.02 ± 0.3420.05 ± 0.355
NNRTI, Potassium, Week 12, n=146, 1520.02 ± 0.3510.08 ± 0.353
NNRTI, Potassium, Week 16, n=143, 1490.03 ± 0.3730.05 ± 0.320
NNRTI, Potassium,Week 20, n=138, 1520.04 ± 0.3580.03 ± 0.355
NNRTI, Potassium, Week 24, n=143, 1500.04 ± 0.3290.04 ± 0.324
NNRTI, Potassium, Week 28, n=136, 1500.03 ± 0.3640.08 ± 0.412
NNRTI, Potassium, Week 32, n=137, 1480.01 ± 0.4420.02 ± 0.348
NNRTI, Potassium, Week 36, n=135, 1470.02 ± 0.3590.05 ± 0.360
NNRTI, Potassium, Week 40, n=138, 1470.05 ± 0.3750.08 ± 0.342
NNRTI, Potassium, Week 44, n=137, 1480.08 ± 0.3640.07 ± 0.366
NNRTI, Potassium, Week 48, n=131, 147-0.02 ± 0.3110.00 ± 0.329
PI, Sodium, Week 4, n=51, 530.4 ± 1.930.3 ± 2.11
PI, Sodium, Week 8, n=34, 530.9 ± 2.210.3 ± 2.25
PI, Sodium, Week 12, n=50, 520.5 ± 2.090.7 ± 1.97
PI, Sodium, Week 16, n=48, 530.5 ± 2.300.3 ± 2.24
PI, Sodium, Week 20, n=46, 530.6 ± 2.150.4 ± 2.12
PI, Sodium, Week 24, n=47, 530.5 ± 2.330.4 ± 2.30
PI, Sodium, Week 28, n=42, 531.3 ± 2.060.8 ± 2.75
PI, Sodium, Week 32, n=45, 510.5 ± 2.470.5 ± 2.26
PI, Sodium, Week 36, n=44, 500.8 ± 2.210.6 ± 2.63
PI, Sodium, Week 40, n=42, 510.8 ± 2.200.7 ± 2.03
PI, Sodium, Week 44, n=47, 510.8 ± 2.100.7 ± 2.49
PI, Sodium, Week 48, n=43, 500.9 ± 1.980.8 ± 1.95
INI, Sodium, Week 4, n=99, 970.3 ± 1.620.0 ± 1.97
INI, Sodium, Week 8, n=73, 980.1 ± 1.98-0.3 ± 1.87
INI, Sodium, Week 12, n=99, 950.3 ± 2.110.0 ± 1.69
INI, Sodium, Week 16, n=93, 960.3 ± 1.950.4 ± 1.97
INI, Sodium, Week 20, n=93, 970.5 ± 1.940.1 ± 1.86
INI, Sodium, Week 24, n=94, 950.5 ± 1.790.0 ± 1.73
INI, Sodium, Week 28, n=89, 930.5 ± 1.74-0.3 ± 1.93
INI, Sodium, Week 32, n=93, 950.5 ± 1.870.2 ± 1.75
INI, Sodium, Week 36, n=94, 950.4 ± 1.860.3 ± 1.88
INI, Sodium, Week 40, n=90, 950.5 ± 1.910.2 ± 2.01
INI, Sodium, Week 44, n=91, 940.5 ± 1.770.3 ± 1.93
INI, Sodium, Week 48, n=91, 950.4 ± 2.00-0.1 ± 1.85
NNRTI, Sodium, Week 4, n=151, 1530.2 ± 1.950.1 ± 1.98
NNRTI, Sodium, Week 8, n=122, 1520.2 ± 1.910.0 ± 1.82
NNRTI, Sodium, Week 12, n=146, 1520.1 ± 2.040.1 ± 2.01
NNRTI, Sodium, Week 16, n=143, 149-0.1 ± 2.28-0.2 ± 2.04
NNRTI, Sodium, Week 20, n=138, 152-0.1 ± 2.140.3 ± 1.95
NNRTI, Sodium, Week 24, n=143, 1510.1 ± 2.140.3 ± 1.95
NNRTI, Sodium, Week 28, n=136, 1500.3 ± 2.290.2 ± 2.18
NNRTI, Sodium, Week 32, n=137, 1480.1 ± 2.010.5 ± 1.84
NNRTI, Sodium, Week 36, n=135, 1470.4 ± 2.050.5 ± 2.22
NNRTI, Sodium, Week 40, n=138, 1470.3 ± 2.040.5 ± 2.12
NNRTI, Sodium, Week 44, n=137, 1480.5 ± 2.170.5 ± 1.96
NNRTI, Sodium, Week 48, n=131, 1470.3 ± 2.390.4 ± 1.97
PI, Urea, Week 4, n=51, 530.02 ± 1.4490.01 ± 1.124
PI, Urea, Week 8, n=34, 530.21 ± 1.142-0.02 ± 1.205
PI, Urea, Week 12, n=50, 520.04 ± 1.446-0.01 ± 1.312
PI, Urea, Week 16, n=48, 530.25 ± 1.3090.20 ± 1.377
PI, Urea, Week 20, n=46, 530.18 ± 1.4250.17 ± 1.275
PI, Urea, Week 24, n=47, 530.41 ± 1.2480.10 ± 1.182
PI, Urea, Week 28, n=42, 530.18 ± 1.3520.00 ± 1.236
PI, Urea, Week 32, n=45, 510.12 ± 1.5670.16 ± 1.210
PI, Urea, Week 36, n=44, 500.01 ± 1.449-0.13 ± 1.190
PI, Urea, Week 40, n=42, 510.17 ± 1.2910.33 ± 1.714
PI, Urea, Week 44, n=47, 510.36 ± 1.2580.13 ± 1.276
PI, Urea, Week 48, n=43, 500.10 ± 1.3030.13 ± 1.305
INI, Urea, Week 4, n=99, 97-0.14 ± 1.4770.19 ± 1.635
INI, Urea, Week 8, n=73, 98-0.14 ± 1.7990.01 ± 1.601
INI, Urea, Week 12, n=99, 950.05 ± 1.5540.21 ± 1.481
INI, Urea, Week 16, n=93, 960.01 ± 1.4020.05 ± 1.375
INI, Urea, Week 20, n=93, 970.01 ± 1.5310.15 ± 1.495
INI, Urea, Week 24, n=94, 950.04 ± 1.3670.12 ± 1.441
INI, Urea, Week 28, n=89, 930.01 ± 1.570-0.02 ± 1.579
INI, Urea, Week 32, n=93, 95-0.09 ± 1.5920.01 ± 1.522
INI, Urea, Week 36, n=94, 95-0.10 ± 1.514-0.05 ± 1.478
INI, Urea, Week 40, n=90, 950.01 ± 1.5190.12 ± 1.469
INI, Urea, Week 44, n=91, 94-0.16 ± 1.583-0.19 ± 1.721
INI, Urea, Week 48, n=91, 950.11 ± 1.633-0.05 ± 1.304
NNRTI, Urea, Week 4, n=151, 1530.10 ± 1.2650.04 ± 1.185
NNRTI, Urea, Week 8, n=122, 1520.16 ± 1.2860.01 ± 1.252
NNRTI, Urea, Week 12, n=146, 1520.26 ± 1.2900.06 ± 1.344
NNRTI, Urea, Week 16, n=143, 1490.07 ± 1.4070.28 ± 1.609
NNRTI, Urea, Week 20, n=138, 1520.25 ± 1.2960.07 ± 1.507
NNRTI, Urea, Week 24, n=143, 1510.33 ± 1.4990.18 ± 1.276
NNRTI, Urea, Week 28, n=136, 1500.22 ± 1.5490.02 ± 1.422
NNRTI, Urea, Week 32, n=137, 1480.41 ± 1.4100.06 ± 1.416
NNRTI, Urea, Week 36, n=135, 1470.19 ± 1.3390.04 ± 1.392
NNRTI, Urea, Week 40, n=138, 1470.32 ± 1.347-0.01 ± 1.339
NNRTI, Urea, Week 44, n=137, 1480.25 ± 1.3460.10 ± 1.344
NNRTI, Urea, Week 48, n=131, 1470.37 ± 1.389-0.02 ± 1.325
SecondaryChange From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48

Blood samples were collected for the analysis of fasting lipid panel: triglycerides, total cholesterol, HDL cholesterol and LDL cholesterol to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Week 48
Reported as:
Mean · Millimoles per liter
Change From Baseline Values for Fasting Lipid Panel Using Baseline Third Agent Treatment Class Overtime Including Week 48
Millimoles per literCAB LA+RPV LA (Q4W)Current ART
PI, Triglycerides, Week 48, n=40, 45-0.733 ± 1.56120.060 ± 0.9960
INI, Triglycerides, Week 48, n=72, 77-0.078 ± 0.4964-0.117 ± 0.8052
NNRTI, Triglycerides, Week 48, n=119, 120-0.015 ± 0.6121-0.014 ± 0.6761
PI, Cholesterol, Week 48, n=40, 45-0.06 ± 0.6290.06 ± 0.744
INI, Cholesterol, Week 48, n=72, 770.18 ± 0.614-0.12 ± 0.674
NNRTI, Cholesterol, Week 48, n=119, 1200.06 ± 0.743-0.02 ± 0.626
PI, HDL cholesterol, Week 48, n=40, 450.130 ± 0.22720.001 ± 0.3429
INI, HDL cholesterol, Week 48, n=72, 770.074 ± 0.2339-0.038 ± 0.2308
NNRTI, HDL cholesterol, Week 48, n=119, 120-0.011 ± 0.29360.028 ± 0.2577
PI, LDL cholesterol, Week 48, n=37, 430.075 ± 0.57740.043 ± 0.5545
INI, LDL cholesterol, Week 48, n=71, 760.144 ± 0.4840-0.015 ± 0.5333
NNRTI, LDL cholesterol, Week 48, n=116, 1190.078 ± 0.6885-0.040 ± 0.5246
SecondaryNumber of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48

Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Genotypic Resistance data for the following drugs: DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented.

Time frame:
At the time of CVF
Reported as:
Count of participants · Participants
Number of Participants With Genotypic Resistance Using Baseline Third Agent Through Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
PI, INI, DTG, resistant, n=1, 000
PI, INI, DTG, resistance possible, n=1, 000
PI, INI, DTG, sensitive, n=1, 010
PI, INI, EVG, resistant, n=1, 000
PI, INI, EVG, resistance possible, n=1, 000
PI, INI, EVG, sensitive, n=1, 010
PI, INI, RAL, resistant, n=1, 000
PI, INI, RAL, resistance possible, n=1, 000
PI, INI, RAL, sensitive, n=1, 010
PI, NNRTI, DLV, resistant, n=1, 000
PI, NNRTI, DLV, resistance possible, n=1, 000
PI, NNRTI, DLV, sensitive, n=1, 010
PI, NNRTI, EFV, resistant, n=1, 000
PI, NNRTI, EFV, resistance possible, n=1, 000
PI, NNRTI, EFV, sensitive, n=1, 010
PI, NNRTI, ETR, resistant, n=1, 000
PI, NNRTI, ETR, resistance possible, n=1, 000
PI, NNRTI, ETR, sensitive, n=1, 010
PI, NNRTI, NVP, resistant, n=1, 000
PI, NNRTI, NVP, resistance possible, n=1, 000
PI, NNRTI, NVP, sensitive, n=1, 010
PI, NNRTI, RPV, resistant, n=1, 010
PI, NNRTI, RPV, resistance possible, n=1, 000
PI, NNRTI, RPV, sensitive, n=1, 000
PI, NRTI, 3TC, resistant, n=1, 000
PI, NNRTI, 3TC, resistance possible, n=1, 000
PI, NRTI, 3TC, sensitive, n=1, 010
PI, NRTI, ABC, resistant, n=1, 000
PI, NRTI, ABC, resistance possible, n=1, 000
PI, NRTI, ABC, sensitive, n=1, 010
PI, NRTI, FTC, resistant, n=1, 000
PI, NRTI, FTC, resistance possible, n=1, 000
PI, NRTI, FTC, sensitive, n=1, 010
PI, NRTI, TDF, resistant, n=1, 000
PI, NRTI, TDF, resistance possible, n=1, 000
PI, NRTI, TDF, sensitive, n=1, 010
PI, NRTI, ZDV, resistant, n=1, 000
PI, NRTI, ZDV, resistance possible, n=1, 000
PI, NRTI, ZDV, sensitive, n=1, 010
PI, NRTI, d4T, resistant, n=1, 000
PI, NRTI, d4T, resistance possible, n=1, 000
PI, NRTI, d4T, sensitive, n=1, 010
PI, NRTI, ddI, resistant, n=1, 000
PI, NRTI, ddI, resistance possible, n=1, 000
PI, NRTI, ddI, sensitive, n=1, 010
PI, PI, ATV, resistant, n=1, 000
PI, PI, ATV, resistance possible, n=1, 000
PI, PI, ATV, sensitive, n=1, 010
PI, PI, ATV/r, resistant, n=1, 000
PI, PI, ATV/r, resistance possible, n=1, 000
PI, PI, ATV/r, sensitive, n=1, 010
PI, PI, DRV/r, resistant, n=1, 000
PI, PI, DRV/r, resistance possible, n=1, 000
PI, PI, DRV/r, sensitive, n=1, 010
PI, PI, FPV/r, resistant, n=1, 000
PI, PI, FPV/r, resistance possible, n=1, 000
PI, PI, FPV/r, sensitive, n=1, 010
PI, PI, IDV/r, resistant, n=1, 000
PI, PI, IDV/r, resistance possible, n=1, 000
PI, PI, IDV/r, sensitive, n=1, 010
PI, PI, LPV/r, resistant, n=1, 000
PI, PI, LPV/r, resistance possible, n=1, 000
PI, PI, LPV/r, sensitive, n=1, 010
PI, PI, NFV, resistant, n=1, 000
PI, PI, NFV, resistance possible, n=1, 000
PI, PI, NFV, sensitive, n=1, 010
PI, PI, RTV, resistant, n=1, 000
PI, PI, RTV, resistance possible, n=1, 000
PI, PI, RTV, sensitive, n=1, 010
PI, PI, SQV/r, resistant, n=1, 000
PI, PI, SQV/r, resistance possible, n=1, 000
PI, PI, SQV/r, sensitive, n=1, 010
PI, PI, TPV/r, resistant, n=1, 000
PI, PI, TPV/r, resistance possible, n=1, 000
PI, PI, TPV/r, sensitive, n=1, 010
INI, INI, DTG, resistant, n=0, 300
INI, INI, DTG, resistance possible, n=0, 300
INI, INI, DTG, sensitive, n=0, 303
INI, INI, EVG, resistant, n=0, 300
INI, INI, EVG, resistance possible, n=0, 300
INI, INI, EVG, sensitive, n=0, 303
INI, INI, RAL, resistant, n=0, 300
INI, INI, RAL, resistance possible, n=0, 300
INI, INI, RAL, sensitive, n=0, 303
INI, NNRTI, DLV, resistant, n=0, 300
INI, INI, DLV, resistance possible, n=0, 300
INI, NNRTI, DLV, sensitive, n=0, 303
INI, NNRTI, EFV, resistant, n=0, 300
INI, INI, EFV, resistance possible, n=0, 300
INI, NNRTI, EFV, sensitive, n=0, 303
INI, NNRTI, ETR, resistant,, n=0, 300
INI, NNRTI, ETR, resistance possible, n=0, 300
INI, NNRTI, ETR, sensitive, n=0, 303
INI, NNRTI, NVP, resistant, n=0, 300
INI, NNRTI, NVP, resistance possible, n=0, 300
INI, NNRTI, NVP, sensitive, n=0, 303
INI, NNRTI, RPV, resistant, n=0, 301
INI, NNRTI, RPV, resistance possible, n=0, 300
INI, NNRTI, RPV, sensitive, n=0, 302
INI, NRTI, 3TC, resistant, n=0, 301
INI, NNRTI, 3TC, resistance possible, n=0, 300
INI, NRTI, 3TC, sensitive, n=0, 302
INI, NRTI, ABC, resistant, n=0, 300
INI, NRTI, ABC, resistance possible,, n=0, 300
INI, NRTI, ABC, sensitive, n=0, 303
INI, NRTI, FTC, resistant, n=0, 301
INI, NRTI, FTC, resistance possible, n=0, 300
INI, NRTI, FTC, sensitive, n=0, 302
INI, NRTI, TDF, resistant, n=0, 300
INI, NRTI, TDF, resistance possible, n=0, 300
INI, NRTI, TDF, sensitive, n=0, 303
INI, NRTI, ZDV, resistant, n=0, 300
INI, NRTI, ZDV, resistance possible, n=0, 300
INI, NRTI, ZDV, sensitive, n=0, 303
INI, NRTI, d4T, resistant, n=0, 300
INI, NRTI, d4T, resistance possible, n=0, 300
INI, NRTI, d4T, sensitive, n=0, 303
INI, NRTI, ddI, resistant, n=0, 300
INI, NRTI, ddI, resistance possible, n=0, 301
INI, NRTI, ddI, sensitive, n=0, 302
INI, PI, ATV, resistant, n=0, 300
INI, PI, ATV, resistance possible, n=0, 300
INI, PI, ATV, sensitive, n=0, 303
INI, PI, ATV/r, n=0, 300
INI, PI, ATV/r, resistance possible, n=0, 300
INI, PI, ATV/r, sensitive, n=0, 303
INI, PI, DRV/r, resistant, n=0, 300
INI, PI, DRV/r, resistance possible, n=0, 300
INI, PI, DRV/r, sensitive, n=0, 303
INI, PI, FPV/r, resistant, n=0, 300
INI, PI, FPV/r, resistance possible, n=0, 300
INI, PI, FPV/r, sensitive, n=0, 303
INI, PI, IDV/r, resistant, n=0, 300
INI, PI, IDV/r, resistance possible, n=0, 300
INI, PI, IDV/r, sensitive, n=0, 303
INI, PI, LPV/r, resistant, n=0, 300
INI, PI, LPV/r, resistance possible, n=0, 300
INI, PI, LPV/r, sensitive, n=0, 303
INI, PI, NFV, resistant, n=0, 300
INI, PI, NFV, resistance possible, n=0, 300
INI, PI, NFV, sensitive, n=0, 303
INI, PI, RTV, resistant, n=0, 300
INI, PI, RTV, resistance possible, n=0, 300
INI, PI, RTV, sensitive, n=0, 303
INI, PI, SQV/r, resistant, n=0, 300
INI, PI, SQV/r, resistance possible, n=0, 300
INI, PI, SQV/r, sensitive, n=0, 303
INI, PI, TPV/r, resistant, n=0, 300
INI, PI, TPV/r, resistance possible, n=0, 300
INI, PI, TPV/r, sensitive, n=0, 303
NNRTI, INI, DTG, resistant, n=2, 100
NNRTI, INI, DTG, resistance possible, n=2, 100
NNRTI, INI, DTG, sensitive, n=2, 121
NNRTI, INI, EVG, resistant, n=2, 110
NNRTI, INI, EVG, resistance possible, n=2, 100
NNRTI, INI, EVG, sensitive, n=2, 111
NNRTI, INI, RAL, resistant, n=2, 110
NNRTI, INI, RAL, resistance possible, n=2, 100
NNRTI, INI, RAL, sensitive, n=2, 111
NNRTI, NNRTI, DLV, resistant, n=2, 100
NNRTI, INI, DLV, resistance possible, n=2, 100
NNRTI, NNRTI, DLV, sensitive, n=2, 121
NNRTI, NNRTI, EFV, resistant, n=2, 111
NNRTI, INI, EFV, resistance possible, n=2, 100
NNRTI, NNRTI, EFV, sensitive, n=2, 110
NNRTI, NNRTI, ETR, resistant, n=2, 100
NNRTI, NNRTI, ETR, resistance possible,n=2, 120
NNRTI, NNRTI, ETR, sensitive, n=2, 101
NNRTI, NNRTI, NVP, resistant, n=2, 111
NNRTI, NNRTI, NVP, resistance possible, n=2, 100
NNRTI, NNRTI, NVP, sensitive, n=2, 110
NNRTI, NNRTI, RPV, resistant, n=2, 120
NNRTI, NNRTI, RPV, resistance possible, n=2, 100
NNRTI, NNRTI, RPV, sensitive, n=2, 101
NNRTI, NRTI, 3TC, resistant, n=2, 101
NNRTI, NNRTI, 3TC, resistance possible, n=2, 100
NNRTI, NRTI, 3TC, sensitive, n=2, 120
NNRTI, NRTI, ABC, resistant, n=2, 100
NNRTI, NRTI, ABC, resistance possible, n=2, 100
NNRTI, NRTI, ABC, sensitive, n=2, 121
NNRTI, NRTI, FTC, resistant, n=2, 101
NNRTI, NRTI, FTC, resistance possible, n=2, 100
NNRTI, NRTI, FTC, sensitive, n=2, 120
NNRTI, NRTI, TDF, resistant, n=2, 100
NNRTI, NRTI, TDF, resistance possible, n=2, 100
NNRTI, NRTI, TDF, sensitive, n=2, 121
NNRTI, NRTI, ZDV, resistant, n=2, 100
NNRTI, NRTI, ZDV, resistance possible, n=2, 100
NNRTI, NRTI, ZDV, sensitive, n=2, 121
NNRTI, NRTI, d4T, resistant, n=2, 100
NNRTI, NRTI, d4T, resistance possible, n=2, 100
NNRTI, NRTI, d4T, sensitive, n=2, 121
NNRTI, NRTI, ddI, resistant, n=2, 100
NNRTI, NRTI, ddI, resistance possible, n=2, 101
NNRTI, NRTI, ddI, sensitive, n=2, 120
NNRTI, PI, ATV, resistant, n=2, 110
NNRTI, PI, ATV, resistance possible, n=2, 100
NNRTI, PI, ATV, sensitive, n=2, 111
NNRTI, PI, ATV/r, resistant, n=2, 100
NNRTI, PI, ATV/r, resistance possible, n=2, 110
NNRTI, PI, ATV/r, sensitive, n=2, 111
NNRTI, PI, DRV/r, resistant, n=2, 100
NNRTI, PI, DRV/r, resistance possible, n=2, 100
NNRTI, PI, DRV/r, sensitive, n=2, 121
NNRTI, PI, FPV/r, resistant, n=2, 100
NNRTI, PI, FPV/r, resistance possible, n=2, 100
NNRTI, PI, FPV/r, sensitive, n=2, 121
NNRTI, PI, IDV/r, resistant, n=2, 100
NNRTI, PI, IDV/r, resistance possible, n=2, 100
NNRTI, PI, IDV/r, sensitive, n=2, 121
NNRTI, PI, LPV/r, resistant, n=2, 100
NNRTI, PI, LPV/r, resistance possible, n=2, 100
NNRTI, PI, LPV/r, sensitive, n=2, 121
NNRTI, PI, NFV, resistant, n=2, 110
NNRTI, PI, NFV, resistance possible, n=2, 100
NNRTI, PI, NFV, sensitive, n=2, 111
NNRTI, PI, RTV, resistant, n=2, 100
NNRTI, PI, RTV, resistance possible, n=2, 100
NNRTI, PI, RTV, sensitive, n=2, 121
NNRTI, PI, SQV/r, resistant, n=2, 100
NNRTI, PI, SQV/r, resistance possible, n=2, 100
NNRTI, PI, SQV/r, sensitive, n=2, 121
NNRTI, PI, TPV/r, resistant, n=2, 100
NNRTI, PI, TPV/r, resistance possible, n=2, 100
NNRTI, PI, TPV/r, sensitive, n=2, 121
SecondaryNumber of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48

Plasma samples were collected from participants who met confirmed virologic withdrawal criteria to assess the impact of Baseline third agent treatment class (PI, NNRTI and INI). Phenotypic Resistance data for the following drugs: CAB, DTG, EVG, RAL, DLV, EFV, ETR, NVP, RPV, 3TC, ABC, FTC, TDF, ZDV, d4T, ddI, ATV, DRV, FPV, IDV, LPV, NFV, RTV, SQV and TPV in participants meeting CVF criteria has been presented. Phenotypic resistance, partially sensitive, and Sensitive were defined based on FC value from Monogram as: resistance (FC\>clinical higher cutoff/biologic cutoff), partially sensitive (FC \<=clinical higher cutoff and \> clinical lower cutoff), sensitive (FC \<= clinical lower cutoff/biologic cutoff).

Time frame:
At the time of CVF
Reported as:
Count of participants · Participants
Number of Participants With Phenotypic Resistance Using Baseline Third Agent Through Week 48
ParticipantsCAB LA+RPV LA (Q4W)Current ART
PI, INI, CAB, resistant , n=1, 000
PI, INI, CAB, sensitive, n=1, 010
PI, INI, DTG, resistant, n=1, 000
PI, INI, DTG, partially sensitive, n=1, 000
PI, INI, DTG, sensitive, n=1, 010
PI, INI, EVG, resistant, n=1, 000
PI, INI, EVG, sensitive, n=1, 010
PI, INI, RAL, resistant, n=1, 000
PI, INI, RAL, sensitive, n=1, 010
PI, NNRTI, DLV, resistant, n=1, 000
PI, NNRTI, DLV, sensitive, n=1, 010
PI, NNRTI, EFV, resistant, n=1, 000
PI, NNRTI, EFV, sensitive, n=1, 010
PI, NNRTI, ETR, resistant, n=1, 000
PI, NNRTI, ETR, partially sensitive, n=1, 000
PI, NNRTI, ETR, sensitive, n=1, 010
PI, NNRTI, NVP, resistant, n=1, 000
PI, NNRTI, NVP, sensitive, n=1, 010
PI, NNRTI, RPV, resistant, n=1, 010
PI, NNRTI, RPV, sensitive, n=1, 000
PI, NRTI, 3TC, resistant, n=1, 000
PI, NRTI, 3TC, sensitive, n=1, 010
PI, NRTI, ABC, resistant, n=1, 000
PI, NRTI, ABC, partially sensitive, n=1, 000
PI, NRTI, ABC, sensitive, n=1, 010
PI, NRTI, FTC, resistant, n=1, 000
PI, NRTI, FTC, sensitive, n=1, 010
PI, NRTI, TDF, resistant, n=1, 000
PI, NRTI, TDF, partially sensitive, n=1, 000
PI, NRTI, TDF, sensitive, n=1, 010
PI, NRTI, ZDV, resistant, n=1, 000
PI, NRTI, ZDV, sensitive, n=1, 010
PI, NRTI, d4T, resistant, n=1, 000
PI, NRTI, d4T, sensitive, n=1, 010
PI, NRTI, ddI, resistant, n=1, 000
PI, NRTI, ddI, partially sensitive, n=1, 000
PI, NRTI, ddI, sensitive, n=1, 010
PI, PI, ATV, resistant, n=1, 000
PI, PI, ATV, sensitive, n=1, 010
PI, PI, DRV, resistant, n=1, 000
PI, PI, DRV, partially sensitive, n=1, 000
PI, PI, DRV, sensitive, n=1, 010
PI, PI, FPV, resistant, n=1, 000
PI, PI, FPV, partially sensitive, n=1, 000
PI, PI, FPV, sensitive, n=1, 010
PI, PI, IDV, resistant, n=1, 000
PI, PI, IDV, sensitive, n=1, 010
PI, PI, LPV, resistant, n=1, 000
PI, PI, LPV, partially sensitive, n=1, 000
PI, PI, LPV, sensitive, n=1, 010
PI, PI, NFV, resistant, n=1, 000
PI, PI, NFV, sensitive, n=1, 010
PI, PI, RTV, resistant, n=1, 000
PI, PI, RTV, sensitive, n=1, 010
PI, PI, SQV, resistant, n=1, 000
PI, PI, SQV, partially sensitive, n=1, 000
PI, PI, SQV, sensitive, n=1, 010
PI, PI, TPV, resistant, n=1, 000
PI, PI, TPV, partially sensitive, n=1, 000
PI, PI, TPV, sensitive, n=1, 010
INI, INI, CAB, resistant , n=0, 300
INI, INI, CAB, sensitive, n=0, 303
INI, INI, DTG, resistant, n=0, 300
INI, INI, DTG, partially sensitive, n=0, 300
INI, INI, DTG, sensitive, n=0, 303
INI, INI, EVG, resistant, n=0, 300
INI, INI, EVG, sensitive, n=0, 303
INI, INI, RAL, resistant, n=0, 300
INI, INI, RAL, sensitive, n=0, 303
INI, NNRTI, DLV, resistant, n=0, 300
INI, NNRTI, DLV, sensitive, n=0, 303
INI, NNRTI, EFV, resistant, n=0, 300
INI, NNRTI, EFV, sensitive, n=0, 303
INI, NNRTI, ETR, resistant, n=0, 300
INI, NNRTI, ETR, partially sensitive, n=0, 300
INI, NNRTI, ETR, sensitive, n=0, 303
INI, NNRTI, NVP, resistant, n=0, 300
INI, NNRTI, NVP, sensitive, n=0, 303
INI, NNRTI, RPV, resistant, n=0, 300
INI, NNRTI, RPV, sensitive, n=0, 303
INI, NRTI, 3TC, resistant, n=0, 301
INI, NRTI, 3TC, sensitive, n=0, 302
INI, NRTI, ABC, resistant, n=0, 300
INI, NRTI, ABC, partially sensitive, n=0, 300
INI, NRTI, ABC, sensitive, n=0, 303
INI, NRTI, FTC, resistant, n=0, 301
INI, NRTI, FTC, sensitive, n=0, 302
INI, NRTI, TDF, resistant, n=0, 300
INI, NRTI, TDF, partially sensitive, n=0, 300
INI, NRTI, TDF, sensitive, n=0, 303
INI, NRTI, ZDV, resistant, n=0, 300
INI, NRTI, ZDV, sensitive, n=0, 303
INI, NRTI, d4T, resistant, n=0, 300
INI, NRTI, d4T, sensitive, n=0, 303
INI, NRTI, ddI, resistant, n=0, 300
INI, NRTI, ddI, partially sensitive, n=0, 300
INI, NRTI, ddI, sensitive, n=0, 303
INI, PI, ATV, resistant, n=0, 300
INI, PI, ATV, sensitive, n=0, 303
INI, PI, DRV, resistant, n=0, 300
INI, PI, DRV, partially sensitive, n=0, 300
INI, PI, DRV, sensitive, n=0, 303
INI, PI, FPV, resistant, n=0, 300
INI, PI, FPV, partially sensitive, n=0, 300
INI, PI, FPV, sensitive, n=0, 303
INI, PI, IDV, resistant, n=0, 300
INI, PI, IDV, sensitive, n=0, 303
INI, PI, LPV, resistant, n=0, 300
INI, PI, LPV, partially sensitive, n=0, 300
INI, PI, LPV, sensitive, n=0, 303
INI, PI, NFV, resistant, n=0, 300
INI, PI, NFV, sensitive, n=0, 303
INI, PI, RTV, resistant, n=0, 300
INI, PI, RTV, sensitive, n=0, 303
INI, PI, SQV, resistant, n=0, 300
INI, PI, SQV, partially sensitive, n=0, 300
INI, PI, SQV, sensitive, n=0, 303
INI, PI, TPV, resistant, n=0, 300
INI, PI, TPV, partially sensitive, n=0, 300
INI, PI, TPV, sensitive, n=0, 303
NNRTI, INI, CAB, resistant , n=2, 110
NNRTI, INI, CAB, sensitive, n=2, 111
NNRTI, INI, DTG, resistant, n=2, 100
NNRTI, INI, DTG, partially sensitive, n=2, 100
NNRTI, INI, DTG, sensitive, n=2, 121
NNRTI, INI, EVG, resistant, n=2, 110
NNRTI, INI, EVG, sensitive, n=2, 111
NNRTI, INI, RAL, resistant, n=2, 110
NNRTI, INI, RAL, sensitive, n=2, 111
NNRTI, NNRTI, DLV, resistant, n=2, 020
NNRTI, NNRTI, DLV, sensitive, n=2, 000
NNRTI, NNRTI, EFV, resistant, n=2, 020
NNRTI, NNRTI, EFV, sensitive, n=2, 000
NNRTI, NNRTI, ETR, resistant, n=2, 000
NNRTI, NNRTI, ETR, partially sensitive, n=2, 020
NNRTI, NNRTI, ETR, sensitive, n=2, 000
NNRTI, NNRTI, NVP, resistant, n=2, 020
NNRTI, NNRTI, NVP, sensitive, n=2, 000
NNRTI, NNRTI, RPV, resistant, n=2, 020
NNRTI, NNRTI, RPV, sensitive, n=2, 000
NNRTI, NRTI, 3TC, resistant, n=2, 000
NNRTI, NRTI, 3TC, sensitive, n=2, 020
NNRTI, NRTI, ABC, resistant, n=2, 000
NNRTI, NRTI, ABC, partially sensitive, n=2, 000
NNRTI, NRTI, ABC, sensitive, n=2, 020
NNRTI, NRTI, FTC, resistant, n=2, 000
NNRTI, NRTI, FTC, sensitive, n=2, 020
NNRTI, NRTI, TDF, resistant, n=2, 000
NNRTI, NRTI, TDF, partially sensitive, n=2, 000
NNRTI, NRTI, TDF, sensitive, n=2, 020
NNRTI, NRTI, ZDV, resistant, n=2, 010
NNRTI, NRTI, ZDV, sensitive, n=2, 010
NNRTI, NRTI, d4T, resistant, n=2, 000
NNRTI, NRTI, d4T, sensitive, n=2, 020
NNRTI, NRTI, ddI, resistant, n=2, 000
NNRTI, NRTI, ddI, partially sensitive, n=2, 000
NNRTI, NRTI, ddI, sensitive, n=2, 020
NNRTI, PI, ATV, resistant, n=2, 000
NNRTI, PI, ATV, sensitive, n=2, 020
NNRTI, PI, DRV, resistant, n=2, 000
NNRTI, PI, DRV, partially sensitive, n=2, 000
NNRTI, PI, DRV, sensitive, n=2, 020
NNRTI, PI, FPV, resistant, n=2, 000
NNRTI, PI, FPV, partially sensitive, n=2, 000
NNRTI, PI, FPV, sensitive, n=2, 020
NNRTI, PI, IDV, resistant, n=2, 000
NNRTI, PI, IDV, sensitive, n=2, 020
NNRTI, PI, LPV, resistant, n=2, 000
NNRTI, PI, LPV, partially sensitive, n=2, 000
NNRTI, PI, LPV, sensitive, n=2, 020
NNRTI, PI, NFV, resistant, n=2, 000
NNRTI, PI, NFV, sensitive, n=2, 020
NNRTI, PI, RTV, resistant, n=2, 000
NNRTI, PI, RTV, sensitive, n=2, 020
NNRTI, PI, SQV, resistant, n=2,000
NNRTI, PI, SQV, partially sensitive, n=2, 000
NNRTI, PI, SQV, sensitive, n=2, 020
NNRTI, PI, TPV, resistant, n=2, 000
NNRTI, PI, TPV, partially sensitive, n=2, 000
NNRTI, PI, TPV, sensitive, n=2, 020
SecondaryChange From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm

The PIN questionnaire explores the bother of pain at the injection site and injection site reactions (ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCFwas used as primary method of analysis

Time frame:
Week 5 and at Weeks 41 and 48
Reported as:
Mean · Scores on the scale
Change From Week 5 in Dimension Scores Using Percerption of Injection Questionnaire (PIN)-Last Observation Carried Forward (LOCF) in Q4W Arm
Scores on the scaleCAB LA+RPV LA (Q4W)
Bother of ISRs, Week 41-0.21 ± 0.532
Bother of ISRs, Week 48-0.21 ± 0.524
Leg movement, Week 41-0.52 ± 0.903
Leg movement, Week 48-0.59 ± 0.950
Sleep, Week 41-0.56 ± 0.877
Sleep, Week 48-0.56 ± 0.937
Acceptance, Week 41-0.49 ± 1.094
Acceptance, Week 48-0.54 ± 1.080
SecondaryPercentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm

The PIN questionnaire explores the bother of pain at the injection site and injection site reactions(ISR), anxiety before and after injection, willingness to receive an HIV injectable treatment the following visit and satisfaction with the mode of treatment administration of individuals receiving injection and perceptions of individuals associated with receiving injections.This measure contains 21 items that measure pain at injection site, local site reactions, impact on functioning and willingness to pursue injectable treatment outside of a clinical trial.Scores range from 1 to 5, and questions are phrased in such a way as to ensure that 1 always equated with the most favourable perception of vaccination, and 5 the most unfavourable.Dimension scores include bother from ISR, leg movement, sleep and acceptability.The score of a domain is calculated as the mean of all items with the domain.Higher scores represent worse perception of injection. LOCF was used as primary method of analysis

Time frame:
Weeks 5, 41 and 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Extremely or Very Acceptable Pain and Local Reaction: Acceptability Score on PIN Questionnaire in Q4W Arm
Percentage of participantsCAB LA+RPV LA (Q4W)
Local reaction, Week 5, total, n=296141
Local reaction,Week 5, very acceptable, n=29677
Local reaction, Week 5, moderate, n=29654
Local reaction, Week 5, little, n=29615
Local reaction, Week 5, not at all, n=2969
Pain, Week 5, total, n=29686
Pain, Week 5, very acceptable, n=296103
Pain, Week 5, moderate, n=29659
Pain, Week 5, little, n=29629
Pain, Week 5, not at all, n=29619
Local reaction, Week 41, total, n=300188
Local reaction, Week 41, very acceptable, n=30077
Local reaction, Week 41, moderate, n=30024
Local reaction, Week 41, little, n=3006
Local reaction, Week 41, not at all, n=3005
Pain, Week 41, total, n=300166
Pain, Week 41, very acceptable, n=30085
Pain, Week 41, moderate, n=30031
Pain, Week 41, little, n=30012
Pain, Week 41, not at all, n=3006
Local reaction, week 48, total, n=303202
Local reaction, Week 48, very acceptable, n=30369
Local reaction, Week 48, moderate, n=30321
Local reaction, Week 48, little, n=3038
Local reaction, Week 48, not at all, n=3033
Pain, Week 48, total, n=303168
Pain, Week 48, very acceptable, n=30395
Pain, Week 48, moderate, n=30326
Pain, Week 48, little, n=30311
Pain, Week 48, not at all, n=3033
SecondaryChange From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire

The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for LISAT is calculated on a 0-100 scale using the formula: LISAT 100=\[100 divided by (20 minus 4)\]\*(LISAT minus 4). A response of 5 in LISAT score shows satisfaction all of the time and 1 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% confidence interval (CI).Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline (Day 1) and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Life Satisfaction (LISAT) Using HIV/AIDs-targeted Quality of Life (HATQoL) Questionnaire
Scores on a scaleCAB LA+RPV LA (Q4W)Current ART
Week 24, n=292, 2911.0 (-0.6 to 2.6)1.1 (-0.5 to 2.7)
Week 48, n=292, 2971.1 (-0.6 to 2.8)0.1 (-1.6 to 1.7)
Statistical analysis
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.944 · Adjusted difference: -0.1 · 95% CI -2.4 to 2.2Treatment comparison at Week 24 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.385 · Adjusted difference: 1.0 · 95% CI -1.3 to 3.4Treatment comparison at Week 48 for the groups CAB LA+ RPV LA and current ART is presented.
SecondaryChange From Baseline in HIV Medication, MEDWO Using HATQoL

The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for MEDWO is calculated on a 0-100 scale using the formula: MEDWO 100=\[100 divided by (20 minus 5)\]\*(MEDWO minus 5). A response of 1 in MEDWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in HIV Medication, MEDWO Using HATQoL
Scores on a scaleCAB LA+RPV LA (Q4W)Current ART
Week 24, n=292, 2904.2 (2.7 to 5.8)-0.7 (-2.2 to 0.9)
Week 48, n=292, 2964.0 (2.3 to 5.7)-2.4 (-4.1 to -0.8)
Statistical analysis
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = <0.001 · Adjusted difference: 4.9 · 95% CI 2.8 to 7.1Treatment comparison at Week 24 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = <0.001 · Adjusted difference: 6.4 · 95% CI 4.0 to 8.8Treatment comparison at Week 48 for the groups CAB LA+ RPV LA and current ART is presented.
SecondaryChange From Baseline in DISWO Using HATQoL

The HATQoL questionnaire was used to assess the health related QoL (HRQoL). It comprises of three dimensions: LISAT, medication worries (MEDWO) and disclosure worries (DISWO). The total imputed value score for DISWO is calculated on a 0-100 scale using the formula: DISWO 100=\[100 divided by (20 minus 5)\]\*(DISWO minus 5). A response of 1 in DISWO score shows less medication worries all of the time and 5 as none of the time. The higher the score, the greater satisfaction to life and the less worry. The transformed dimension score for each domain was summarized and analyzed. LOCF was used as primary method of analysis. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in DISWO Using HATQoL
Scores on a scaleCAB LA+RPV LA (Q4W)Current ART
Week 24, n=291, 2908.3 (5.6 to 11.0)3.0 (0.3 to 5.8)
Week 48, n=291, 2964.6 (1.7 to 7.6)2.6 (-0.3 to 5.6)
Statistical analysis
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.008 · Adjusted difference: 5.3 · 95% CI 1.4 to 9.1Treatment comparison at Week 24 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.347 · Adjusted difference: 2.0 · 95% CI -2.2 to 6.2
SecondaryChange From Baseline in Health Status Using 12-item Short Form Survey (SF-12)

The SF-12 questionnaire consists of 7 questions which measures the degree of general health status and mental health distress. Each question is scored 0-5, except for question 2 scored 0-3. The HRQoL using SF-12 for the total score, physical component summary (PCS) and the mental component summary (MCS) were assessed for the two treatment groups. Missing Total or the component scores was imputed using LOCF. The PCS/MCS are calculated using computer software purchased from QualityMetric (http://www.qualitymetric.com). The higher the score, the better will be the health status. Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and at Weeks 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Health Status Using 12-item Short Form Survey (SF-12)
Scores on a scaleCAB LA+RPV LA (Q4W)Current ART
Total score, Week 24, n=291, 2890.0 (-0.3 to 0.4)-0.2 (-0.5 to 0.1)
Total score, Week 48, n=293, 296-0.0 (-0.4 to 0.3)0.0 (-0.3 to 0.4)
MCS, Week 24, n=289, 2860.288 (-0.579 to 1.155)-0.388 (-1.259 to 0.484)
MCS, Week 48, n=291, 2930.260 (-0.638 to 1.158)-0.375 (-1.270 to 0.520)
PCS, Week 24, n=286, 2880.650 (0.087 to 1.213)-0.047 (-0.608 to 0.514)
PCS, Week 48, n=288, 2950.758 (0.184 to 1.332)0.062 (-0.505 to 0.629)
Statistical analysis
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.344 · Adjusted difference: 0.2 · 95% CI -0.2 to 0.7Treatment comparison of SF-12 total scores at Week 24 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.785 · Adjusted difference: -0.1 · 95% CI -0.6 to 0.4Treatment comparison of SF-12 total scores at Week 48 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.282 · Adjusted difference: 0.676 · 95% CI -0.557 to 1.909Treatment comparison of SF-12 MCS at Week 24 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.327 · Adjusted difference: 0.635 · 95% CI -0.637 to 1.907Treatment comparison of SF-12 MCS at Week 48 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.086 · Adjusted difference: 0.697 · 95% CI -0.100 to 1.494Treatment comparison of SF-12 PCS at Week 24 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = 0.092 · Adjusted difference: 0.696 · 95% CI -0.113 to 1.505Treatment comparison of SF-12 PCS at Week 48 for the groups CAB LA+ RPV LA and current ART is presented.
SecondaryChange From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44

The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants

Time frame:
Baseline and at Weeks 4b, 24 and 44
Reported as:
Mean · Scores on a scale
Change From Baseline in Total Treatment Satisfaction Using HIV Treatment Satisfaction Questionnaire (HIVTSQs) at Weeks 4b, 24 and 44
Scores on a scaleCAB LA+RPV LA (Q4W)Current ART
Week 4b, n=295, 03.99 ± 8.982—
Week 24, n=300, 2886.39 ± 10.3281.08 ± 8.510
Week 44, n=300, 2946.02 ± 10.8080.54 ± 9.877
SecondaryChange in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm

The HIVTSQ for total treatment satisfaction score is computed with 1-11 items. These 1-11 items are summed to produce a score with a possible range of -33 to 33. The item 12 in the scale will be calculated as an individual score.The higher the score, the greater the improvement in satisfaction with treatment; the lower the score, the greater the deterioration in satisfaction with treatment.A score of 0 represents no change. A maximum of 5 items can be missing, the missing scores will be imputed with the mean of the completed item scores. If 6 or more items are missing, then the overall treatment satisfaction scale score should not be computed and will remain missing.LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value. Data has been presented with respect to actual treatment received to the participants

Time frame:
Week 48
Reported as:
Mean · Scores on a scale
Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm
Scores on a scaleCAB LA+RPV LA (Q4W)
Change in Treatment Satisfaction Over Time Using HIVTSQ Change (HIVTSQc) at Week 48 in Q4W Arm29.05 ± 6.978
SecondaryChange From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire

The ACCEPT questionnaire is a generic medication acceptance measure assessing how participants weigh advantages and disadvantages of long-term medication.The questionnaire consists of 25 items that capture six dimensions.3 questions that focus on general acceptance of study medication will be analyzed.Items on the scale are rated as 1-5 scores:1:totally disagree,2:somewhat disagree,3:somewhat agree, 4:totally agree and 5:I don't know.Total score of the dimension is calculated as the mean of the recoded items of the dimension and then linearly transformed to be on a scale from 0 to 100:score:Total Score=(mean of the recoded items in the dimension minus1)divided by2\*100.LOCF was used as primary method of analysis.Measure type was considered as mean for adjusted mean and dispersion measure as 95% CI.Baseline value is defined as the latest pre-treatment assessment with a non-missing value.Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value

Time frame:
Baseline and at Weeks 8, 24 and 48
Reported as:
Mean · Scores on a scale
Change From Baseline in Treatment Acceptance at Weeks 8, 24 and 48 Using "General Acceptance" Dimension of the Chronic Treatment Acceptance (ACCEPT) Questionnaire
Scores on a scaleCAB LA+RPV LA (Q4W)Current ART
Week 8, n=302, 2878.9 (6.3 to 11.6)1.0 (-1.7 to 3.8)
Week 24, 303, 29512.3 (9.9 to 14.8)5.5 (3.0 to 8.0)
Week 48, n=302, 29813.7 (11.2 to 16.3)3.0 (0.4 to 5.6)
Statistical analysis
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = <0.001 · Adjusted difference: 7.9 · 95% CI 4.1 to 11.7Treatment comparison at Week 8 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = <0.001 · Adjusted difference: 6.9 · 95% CI 3.3 to 10.4Treatment comparison Week 24 for the groups CAB LA+ RPV LA and current ART is presented.
  • CAB LA+RPV LA (Q4W) vs Current ART · ANCOVA · p = <0.001 · Adjusted difference: 10.7 · 95% CI 7.1 to 14.4Treatment comparison at Week 48 for the groups CAB LA+ RPV LA and current ART is presented.
SecondaryChange From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm

The NRS questionnaire is used to assess the tolerability of injections in CAB LA+RPV LA arm only. The questionnaire consists of one single question and will assess maximum level of pain experienced with the most recent injections ranking from no pain (0) to extreme pain (10). Missing scores was imputed using LOCF.

Time frame:
Weeks 4b, 5, 40 and 41
Reported as:
Mean · Scores on a scale
Change From 4b in Tolerability of Injection at Week 5, 40 and 41 Using Numeric Rating Scale (NRS) Within CAB LA+RPV LA Arm
Scores on a scaleCAB LA+RPV LA (Q4W)
Week 52.0 ± 2.94
Week 400.5 ± 2.79
Week 410.4 ± 2.83
SecondaryChange From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44

HIVTSQc is a 12 item questionnaire. The individual treatment change item scores on HIVTSQc scale are rated as +3 ('much more satisfied', 'much more convenient', 'much more flexible',etc.) to -3 ('much less satisfied', 'much less convenient', 'much less flexible', etc.). The higher the score, the greater the improvement in satisfaction with each aspect of treatment and the lower the score, the greater the deterioration in satisfaction with each aspect of treatment. LOCF was used as primary method of analysis. Baseline value is defined as the latest pre-treatment assessment with a non-missing value. Change from Baseline value is calculated as the value at the post-dose visit minus the Baseline value.

Time frame:
Baseline and Weeks 4b, 24 and 44
Reported as:
Mean · Scores on a scale
Change From Baseline in Individual Item Scores of HIVTSQc at Weeks 4b, 24 and 44
Scores on a scaleCAB LA+RPV LA (Q4W)Current ART
Item 1; Week 4b; n=294, 00.3 ± 1.42—
Item 1; Week 24; n=300, 2870.4 ± 1.46-0.1 ± 1.04
Item 1; Week 44; n=300, 2930.5 ± 1.42-0.1 ± 1.21
Item 2; Week 4b; n=295, 00.0 ± 0.60—
Item 2; Week 24; n=300, 2870.1 ± 0.700.0 ± 0.68
Item 2; Week 44; n=300, 2930.1 ± 0.84-0.1 ± 0.82
Item 3; Week 4b; n=295, 00.4 ± 1.35—
Item 3; Week 24; n=300, 2880.3 ± 1.470.1 ± 1.12
Item 3; Week 44; n=300, 2940.3 ± 1.450.0 ± 1.26
Item 4; Week 4b; n=295, 00.3 ± 1.21—
Item 4; Week 24; n=300, 2880.5 ± 1.29-0.0 ± 1.16
Item 4; Week 44; n=300, 2940.4 ± 1.30-0.1 ± 1.22
Item 5; Week 4b; n=295, 00.5 ± 1.24—
Item 5; Week 24; n=300, 2880.8 ± 1.320.1 ± 1.31
Item 5; Week 44; n=300, 2940.8 ± 1.420.0 ± 1.37
Item 6; Week 4b; n=294, 00.5 ± 1.63—
Item 6; Week 24; n=299, 2880.8 ± 1.770.2 ± 1.79
Item 6; Week 44; n=299, 2930.9 ± 1.720.2 ± 1.78
Item 7; Week 4b; n=295, 00.2 ± 0.90—
Item 7; Week 24; n=300, 2880.2 ± 0.940.1 ± 1.00
Item 7; Week 44; n=300, 2940.2 ± 0.990.2 ± 1.08
Item 8; Week 4b; n=294, 00.3 ± 1.21—
Item 8; Week 24; n=299, 2880.7 ± 1.270.1 ± 1.20
Item 8; Week 44; n=299, 2940.6 ± 1.310.0 ± 1.27
Item 9; Week 4b; n=294, 00.4 ± 1.22—
Item 9; Week 24; n=299, 2880.6 ± 1.270.1 ± 1.20
Item 9; Week 44; n=299, 2940.5 ± 1.320.0 ± 1.25
Item 10; Week 4b; n=293, 00.8 ± 1.44—
Item 10; Week 24; n=298, 2871.2 ± 1.560.3 ± 1.38
Item 10; Week 44; n=298, 2931.1 ± 1.640.2 ± 1.60
Item 11; Week 4b; n=292, 00.4 ± 1.23—
Item 11; Week 24; n=297, 2870.7 ± 1.310.1 ± 1.28
Item 11; Week 44; n=297, 2930.6 ± 1.450.1 ± 1.38
Item 12; Week 4b; n=293, 00.3 ± 1.41—
Item 12; Week 24; n=298, 2870.0 ± 1.520.1 ± 1.14
Item 12; Week 44; n=298, 2930.0 ± 1.580.2 ± 1.17
Other pre-specifiedNumber of Participants With Different Demographic Parameters for Inter-subject Variability

Blood samples were planned to be collected at indicated time points for PK analysis of CAB LA and RPV LA. Demographic parameters including, but not limited to, age, sex, race, body weight, body mass index, and relevant laboratory parameters were planned to be evaluated as potential predictors of inter subject variability for pharmacokinetic parameters.

Time frame:
Upto Week 48

No measurements were reported for this outcome.

Adverse events

Collected over Up to Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAB LA+RPV LA (Q4W)0/308 (0%)13/308 (4.2%)263/308 (85.4%)
Current ART1/308 (0.3%)14/308 (4.5%)117/308 (38%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventCAB LA+RPV LA (Q4W)Current ART
ColitisGastrointestinal disorders0/3082/308
Hepatitis AInfections and infestations1/3081/308
Acute hepatitis BInfections and infestations1/3080/308
Anal abscessInfections and infestations0/3081/308
AppendicitisInfections and infestations0/3081/308
Gastroenteritis Escherichia coliInfections and infestations1/3080/308
Liver abscessInfections and infestations1/3080/308
PneumoniaInfections and infestations0/3081/308
Pyelonephritis acuteInfections and infestations1/3080/308
Viral infectionInfections and infestations1/3080/308
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCAB LA+RPV LA (Q4W)Current ART
Injection site painGeneral disorders231/3080/308
NasopharyngitisInfections and infestations52/30842/308
Injection site noduleGeneral disorders37/3080/308
HeadacheNervous system disorders34/30817/308
Upper respiratory tract infectionInfections and infestations32/30825/308
Injection site indurationGeneral disorders30/3080/308
Injection site swellingGeneral disorders23/3080/308
FatigueGeneral disorders22/3086/308
DiarrhoeaGastrointestinal disorders22/30815/308
PyrexiaGeneral disorders21/3089/308

Baseline characteristics

Age, Continuous
Age, Continuous(Years)CAB LA+RPV LA (Q4W)Current ARTTotal
Mean41.6 ± 9.9943.2 ± 11.4342.4 ± 10.76
Sex: Female, Male
Sex: Female, Male(Participants)CAB LA+RPV LA (Q4W)Current ARTTotal
Female99104203
Male209204413
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)CAB LA+RPV LA (Q4W)Current ARTTotal
American Indian (AI) or Alaska Native (AN)8816
Asian-Central South Asian Heritage101
Asian-Japanese/East/South-East Asian Heritage211334
Black or African American6277139
Native Hawaiian or other Pacific Islander011
White214207421
AI or AN & Black/African American011
AI or AN & Black/African American & White112
Black/African American or White101
09

Study locations

113 sites
  • GSK Investigational Site
    Birmingham, Alabama 35294, United States
  • GSK Investigational Site
    Phoenix, Arizona 85015, United States
  • GSK Investigational Site
    Bakersfield, California 93301, United States
  • GSK Investigational Site
    Long Beach, California 90813, United States
  • GSK Investigational Site
    Los Angeles, California 90036, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Palm Springs, California 92264, United States
  • GSK Investigational Site
    San Francisco, California 94109, United States
  • GSK Investigational Site
    San Francisco, California 94110, United States
  • GSK Investigational Site
    Denver, Colorado 80246-1438, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20007, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20009, United States
  • GSK Investigational Site
    Washington D.C., District of Columbia 20037-3201, United States
  • GSK Investigational Site
    Fort Lauderdale, Florida 33316, United States
  • GSK Investigational Site
    Ft. Pierce, Florida 34982, United States
  • GSK Investigational Site
    Sarasota, Florida 34237-3116, United States
  • GSK Investigational Site
    Vero Beach, Florida 32960, United States
  • GSK Investigational Site
    Macon, Georgia 31201, United States
  • GSK Investigational Site
    Chicago, Illinois 60611-2826, United States
  • GSK Investigational Site
    Boston, Massachusetts 02129, United States
  • GSK Investigational Site
    Detroit, Michigan 48202, United States
  • GSK Investigational Site
    St Louis, Missouri 63110-1035, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198-8106, United States
  • GSK Investigational Site
    Buffalo, New York 14201, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    New York, New York 10029, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599-7064, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28209, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45267-0405, United States
  • GSK Investigational Site
    Allentown, Pennsylvania 18102, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15212, United States
  • GSK Investigational Site
    Austin, Texas 78705-3326, United States
  • GSK Investigational Site
    Dallas, Texas 75246-2004, United States
  • GSK Investigational Site
    Houston, Texas 77098, United States
  • GSK Investigational Site
    Annandale, Virginia 22003, United States
  • GSK Investigational Site
    Lynchburg, Virginia 24501, United States
  • GSK Investigational Site
    Buenos Aires, 1141, Argentina
  • GSK Investigational Site
    Buenos Aires, 1427, Argentina
  • GSK Investigational Site
    Ciudad Autonoma Buenos Aires, C1405CKC, Argentina
  • GSK Investigational Site
    Rosario, 2000, Argentina
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Prahran, Victoria 3181, Australia
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1K2, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Montreal, Quebec H4A 3J1, Canada
  • GSK Investigational Site
    Québec, Quebec G1V 4G2, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4P 0W5, Canada
  • GSK Investigational Site
    Montpellier, 34295, France
  • GSK Investigational Site
    Paris, 75018, France
  • GSK Investigational Site
    Paris, 75475, France
  • GSK Investigational Site
    Paris, 75571, France
  • GSK Investigational Site
    Paris, 75651, France
  • GSK Investigational Site
    Saint-Denis, 93205, France
  • GSK Investigational Site
    Toulouse, 31059, France
  • GSK Investigational Site
    Tourcoing, 59208, France
  • GSK Investigational Site
    Frankfurt am Main, Hesse 60590, Germany
  • GSK Investigational Site
    Hanover, Lower Saxony 30625, Germany
  • GSK Investigational Site
    Essen, North Rhine-Westphalia 45122, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Bonn, 53127, Germany
  • GSK Investigational Site
    Frankfurt, 60596, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Hamburg, 20246, Germany
  • GSK Investigational Site
    München, 80335, Germany
  • GSK Investigational Site
    Milan, MI 20157, Italy
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Guadajalara, 44280, Mexico
  • GSK Investigational Site
    Kazan', 420061, Russia
  • GSK Investigational Site
    Kemerovo, 650056, Russia
  • GSK Investigational Site
    Krasnodar, 350015, Russia
  • GSK Investigational Site
    Lipetsk, 398043, Russia
  • GSK Investigational Site
    Moscow, 105275, Russia
  • GSK Investigational Site
    Oryol, 302040, Russia
  • GSK Investigational Site
    Saint Petersburg, 190103, Russia
  • GSK Investigational Site
    Saint Petersburg, 193167, Russia
  • GSK Investigational Site
    Saint Petersburg, 196645, Russia
  • GSK Investigational Site
    Saratov, 410009, Russia
  • GSK Investigational Site
    Smolensk, 214006, Russia
  • GSK Investigational Site
    Toliyatti, 445846, Russia
  • GSK Investigational Site
    Yekaterinburg, 620102, Russia
  • GSK Investigational Site
    Bloemfontein, Free State 9301, South Africa
  • GSK Investigational Site
    Middelburg, Mpumalanga 1055, South Africa
  • GSK Investigational Site
    Cape Town, 7925, South Africa
  • GSK Investigational Site
    Durban, 4001, South Africa
  • GSK Investigational Site
    Durban, 4052, South Africa
  • GSK Investigational Site
    Johannesburg, 2113, South Africa
  • GSK Investigational Site
    Pretorai, 0087, South Africa
  • GSK Investigational Site
    Winnie Mandela, 9400, South Africa
  • GSK Investigational Site
    Daegu, 41944, South Korea
  • GSK Investigational Site
    Daejeon, 35015, South Korea
  • GSK Investigational Site
    Pusan, 49241, South Korea
  • GSK Investigational Site
    Seoul, 03722, South Korea
  • GSK Investigational Site
    Seoul, 06591, South Korea
  • GSK Investigational Site
    Badalona, Barcelona 08916, Spain
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Barcelona, 08036, Spain

Showing the first 100 of 113 sites across 13 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, Shon A, Benn P, Huang JO, Harrington CM, Hove K, Ford SL, Talarico CL, Chounta V, Crauwels H, Van Solingen-Ristea R, Vanveggel S, Margolis DA, Smith KY, Vandermeulen K, Spreen WR. Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022 Feb 1;36(2):185-194. doi: 10.1097/QAD.0000000000003025. PubMed 34261093 ↗
  • Elliot ER, Polli JW, Patel P, Garside L, Grove R, Barnett V, Roberts J, Byrapuneni S, Crauwels H, Ford SL, Van Solingen-Ristea R, Birmingham E, D'Amico R, Baugh B, van Wyk J. Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials. J Infect Dis. 2024 Jul 25;230(1):e34-e42. doi: 10.1093/infdis/jiad580. PubMed 39052748 ↗
  • Chounta V, Byrnes HF, Henry-Szatkowski M, Browning D, Donatti C, Lambert J. Psychometric Validation of the Perception of Injection (PIN) Questionnaire Using Data From Two Phase III, Open-Label, Active-Controlled, Non-Inferiority Studies in People Living With HIV. Adv Ther. 2023 Dec;40(12):5300-5314. doi: 10.1007/s12325-023-02656-1. Epub 2023 Sep 30. PubMed 37776478 ↗
  • Moreno S, Rivero A, Ventayol P, Falco V, Torralba M, Schroeder M, Neches V, Vallejo-Aparicio LA, Mackenzie I, Turner M, Harrison C. Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain. Infect Dis Ther. 2023 Aug;12(8):2039-2055. doi: 10.1007/s40121-023-00840-y. Epub 2023 Jul 14. PubMed 37452174 ↗
  • Chounta V, Snedecor SJ, Wu S, Van de Velde N. Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection. BMC Infect Dis. 2022 May 4;22(1):428. doi: 10.1186/s12879-022-07243-3. PubMed 35508986 ↗
  • Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masia M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. PubMed 33136751 ↗
  • Swindells S, Andrade-Villanueva JF, Richmond GJ, Rizzardini G, Baumgarten A, Masia M, Latiff G, Pokrovsky V, Bredeek F, Smith G, Cahn P, Kim YS, Ford SL, Talarico CL, Patel P, Chounta V, Crauwels H, Parys W, Vanveggel S, Mrus J, Huang J, Harrington CM, Hudson KJ, Margolis DA, Smith KY, Williams PE, Spreen WR. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. N Engl J Med. 2020 Mar 19;382(12):1112-1123. doi: 10.1056/NEJMoa1904398. Epub 2020 Mar 4. PubMed 32130809 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study is available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below).

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2016 to primary completion in May 2018, 19 months.

Results were first posted in Jun 2019, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 19 months is below that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2016
First posted
Nov 1, 2016
StartActual
Oct 28, 2016
Primary completionActual
May 29, 2018
CompletionEst.
Dec 31, 2029
Results first posted
Jun 13, 2019
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 7 sites removed
Show 7 added (3 Germany, 2 South Africa, 1 Italy, 1 Spain)
  • GSK Investigational Site · Frankfurt am Main, Germany
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Milan, Italy
  • GSK Investigational Site · Bloemfontein, South Africa
  • GSK Investigational Site · Middelburg, South Africa
  • GSK Investigational Site · Badalona, Spain
Show 7 removed
  • GSK Investigational Site · Essen, Germany
  • GSK Investigational Site · Frankfurt, Germany
  • GSK Investigational Site · Hanover, Germany
  • GSK Investigational Site · Milan, Italy
  • GSK Investigational Site · Bloemfontein, South Africa
  • GSK Investigational Site · Middelburg, South Africa
  • GSK Investigational Site · Badalona, Spain
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    7 sites added, 7 sites removed
    Show 7 added (3 Germany, 2 South Africa, 1 Italy, 1 Spain)
    • GSK Investigational Site · Frankfurt am Main, Germany
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Milan, Italy
    • GSK Investigational Site · Bloemfontein, South Africa
    • GSK Investigational Site · Middelburg, South Africa
    • GSK Investigational Site · Badalona, Spain
    Show 7 removed
    • GSK Investigational Site · Essen, Germany
    • GSK Investigational Site · Frankfurt, Germany
    • GSK Investigational Site · Hanover, Germany
    • GSK Investigational Site · Milan, Italy
    • GSK Investigational Site · Bloemfontein, South Africa
    • GSK Investigational Site · Middelburg, South Africa
    • GSK Investigational Site · Badalona, Spain
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

12

Registry details

Key details

Study ID
NCT02951052
Lead sponsor
ViiV Healthcare
Responsible party
Sponsor
First posted
Nov 1, 2016
Start date
Oct 28, 2016
Primary completion
May 29, 2018
Completion
Dec 31, 2029 (estimated)
Results posted
Jun 13, 2019
Last update
Nov 10, 2026

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabotegravir

Start the discussion